Pharmacological and mechanical interventions for labour induction in outpatient settings by Vogel, Joshua P et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacological and mechanical interventions for labour
induction in outpatient settings
Citation for published version:
Vogel, JP, Osoti, AO, Kelly, AJ, Livio, S, Norman, JE & Alfirevic, Z 2017, 'Pharmacological and mechanical
interventions for labour induction in outpatient settings', Cochrane Database of Systematic Reviews, vol. 9,
pp. CD007701. https://doi.org/10.1002/14651858.CD007701.pub3
Digital Object Identifier (DOI):
10.1002/14651858.CD007701.pub3
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Cochrane Database of Systematic Reviews
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Cochrane Database of Systematic Reviews
Pharmacological andmechanical interventions for labour
induction in outpatient settings (Review)
Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, Alfirevic Z
Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, Alfirevic Z.
Pharmacological andmechanical interventions for labour induction in outpatient settings.
Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD007701.
DOI: 10.1002/14651858.CD007701.pub3.
www.cochranelibrary.com
Pharmacological andmechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
28ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
33DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
89DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 1 Additional
induction agents required. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Analysis 1.2. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 2 Epidural. . 97
Analysis 1.3. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 3 Uterine
hyperstimulation (FHR changes unclear). . . . . . . . . . . . . . . . . . . . . . . . . 98
Analysis 1.4. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 4 Caesarean
section. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Analysis 1.5. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 5 Apgar score < 7 at
5 minutes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
Analysis 1.6. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 6 NICU
admission. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Analysis 1.7. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 7
Chorioamnionitis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Analysis 1.8. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 8 Indicator of
’progress’ in labour - Cervix unchanged at follow up (not pre-specified). . . . . . . . . . . . . . . 102
Analysis 1.9. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 9 ’Spontaneous
labour’ within 48 hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 1.10. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 10 Indicator of
’progress’ in labour - Admitted to hospital for labour. . . . . . . . . . . . . . . . . . . . . 104
Analysis 1.11. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 11 Time to birth -
Gestational age at birth (weeks). . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Analysis 1.12. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 12 Time to birth -
Gestational age on admission (days). . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Analysis 2.1. Comparison 2 Intracervical PGE versus placebo, Outcome 1 Additional induction agent required (induction
with oxytocin or other means). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Analysis 2.2. Comparison 2 Intracervical PGE versus placebo, Outcome 2 Additional induction agents required (further
prostaglandin required). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Analysis 2.3. Comparison 2 Intracervical PGE versus placebo, Outcome 3 Uterine rupture. . . . . . . . . . 107
Analysis 2.4. Comparison 2 Intracervical PGE versus placebo, Outcome 4 Birth not achieved in 48 to 72 hours. . . 107
Analysis 2.5. Comparison 2 Intracervical PGE versus placebo, Outcome 5 Oxytocin augmentation. . . . . . . 108
Analysis 2.6. Comparison 2 Intracervical PGE versus placebo, Outcome 6 Uterine hyperstimulation (with FHR
changes). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Analysis 2.7. Comparison 2 Intracervical PGE versus placebo, Outcome 7 Assisted (instrumental) vaginal birth. . . 109
iPharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.8. Comparison 2 Intracervical PGE versus placebo, Outcome 8 Caesarean section. . . . . . . . . 110
Analysis 2.9. Comparison 2 Intracervical PGE versus placebo, Outcome 9 Apgar score < 7 at 5 minutes. . . . . . 111
Analysis 2.10. Comparison 2 Intracervical PGE versus placebo, Outcome 10 NICU admission. . . . . . . . . 112
Analysis 2.11. Comparison 2 Intracervical PGE versus placebo, Outcome 11 Postpartum haemorrhage (> 500 mL). . 112
Analysis 2.12. Comparison 2 Intracervical PGE versus placebo, Outcome 12 Chorioamnionitis. . . . . . . . 113
Analysis 2.13. Comparison 2 Intracervical PGE versus placebo, Outcome 13 Endometritis. . . . . . . . . . 114
Analysis 2.14. Comparison 2 Intracervical PGE versus placebo, Outcome 14 Side effects - Maternal side effects. . . 114
Analysis 2.15. Comparison 2 Intracervical PGE versus placebo, Outcome 15 Time to birth - Interval from intervention to
birth (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Analysis 2.16. Comparison 2 Intracervical PGE versus placebo, Outcome 16 Time to birth - Gestational age at birth
(weeks). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Analysis 2.17. Comparison 2 Intracervical PGE versus placebo, Outcome 17 Indicator of ’progress’ in labour - Induction
for gestational age > 42 weeks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Analysis 2.18. Comparison 2 Intracervical PGE versus placebo, Outcome 18 Time to birth - Birth within 48 hours of
treatment (all births). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Analysis 3.1. Comparison 3 Vaginal misoprostol versus placebo, Outcome 1 Serious neonatal morbidity or death. . 117
Analysis 3.2. Comparison 3 Vaginal misoprostol versus placebo, Outcome 2 Epidural. . . . . . . . . . . . 118
Analysis 3.3. Comparison 3 Vaginal misoprostol versus placebo, Outcome 3 Uterine hyperstimulation (with FHR
changes). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
Analysis 3.4. Comparison 3 Vaginal misoprostol versus placebo, Outcome 4 Uterine hyperstimulation (without FHR
changes). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Analysis 3.5. Comparison 3 Vaginal misoprostol versus placebo, Outcome 5 Assisted (instrumental) vaginal birth. . 120
Analysis 3.6. Comparison 3 Vaginal misoprostol versus placebo, Outcome 6 Caesarean section. . . . . . . . . 121
Analysis 3.7. Comparison 3 Vaginal misoprostol versus placebo, Outcome 7 Apgar score < 7 at 5 minutes. . . . . 122
Analysis 3.8. Comparison 3 Vaginal misoprostol versus placebo, Outcome 8 NICU admission. . . . . . . . . 123
Analysis 3.9. Comparison 3 Vaginal misoprostol versus placebo, Outcome 9 Perinatal death. . . . . . . . . . 123
Analysis 3.10. Comparison 3 Vaginal misoprostol versus placebo, Outcome 10 Neonatal infection. . . . . . . . 124
Analysis 3.11. Comparison 3 Vaginal misoprostol versus placebo, Outcome 11 Indicator of ’progress’ in labour - Oxytocin
dose used (mU). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
Analysis 3.12. Comparison 3 Vaginal misoprostol versus placebo, Outcome 12 Indicator of ’progress’ in labour - Number
of medication dose. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
Analysis 3.13. Comparison 3 Vaginal misoprostol versus placebo, Outcome 13 Indicator of ’progress’ in labour - Number
of women requiring dosing on day 2. . . . . . . . . . . . . . . . . . . . . . . . . . . 126
Analysis 3.14. Comparison 3 Vaginal misoprostol versus placebo, Outcome 14 Indicator of ’progress’ in labour - Number
of women requiring induction on day 3. . . . . . . . . . . . . . . . . . . . . . . . . 126
Analysis 3.15. Comparison 3 Vaginal misoprostol versus placebo, Outcome 15 Indicator of ’progress’ in labour - Days to
admission (all) (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Analysis 3.16. Comparison 3 Vaginal misoprostol versus placebo, Outcome 16 Indicator of ’progress’ in labour - Days to
admission (subgroups by parity) (days). . . . . . . . . . . . . . . . . . . . . . . . . . 128
Analysis 3.17. Comparison 3 Vaginal misoprostol versus placebo, Outcome 17 Indicator of ’progress’ in labour - Gestational
age at labour (weeks). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
Analysis 3.18. Comparison 3 Vaginal misoprostol versus placebo, Outcome 18 Indicator of ’progress’ in labour - Days to
admission (parous) (weeks). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
Analysis 3.19. Comparison 3 Vaginal misoprostol versus placebo, Outcome 19 Indicator of ’progress’ in labour - Days to
PROM (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
Analysis 3.20. Comparison 3 Vaginal misoprostol versus placebo, Outcome 20 Time to birth - Interval from intervention
to vaginal birth (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
Analysis 3.21. Comparison 3 Vaginal misoprostol versus placebo, Outcome 21 Time to birth - Days to birth (all) (days). 131
Analysis 3.22. Comparison 3 Vaginal misoprostol versus placebo, Outcome 22 Time to birth - Days to birth (subgroups by
parity) (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
Analysis 4.1. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 1 Additional induction agents required
(oxytocin). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
Analysis 4.2. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 2 Uterine hyperstimulation. . . . . 133
iiPharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 3 Caesarean section. . . . . . . 134
Analysis 4.4. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 4 NICU admission. . . . . . . 134
Analysis 4.5. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 5 Interval from treatment to birth (in days,
all births). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Analysis 5.1. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 1 Uterine hyperstimulation (with or
without FHR changes). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Analysis 5.2. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 2 Caesarean section. . . . . 136
Analysis 5.3. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 3 Apgar score < 7 after 5 minutes. 136
Analysis 5.4. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 4 Admission to NICU. . . . 137
Analysis 5.5. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 5 Indicator of ’progress’ in labour -
Interval from administration to admission (hours). . . . . . . . . . . . . . . . . . . . . . 137
Analysis 5.6. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 6 Indicator of ’progress’ in labour -
Labour or SROM during ripening. . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Analysis 5.7. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 7 Time to birth - Birth within 24
hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Analysis 5.8. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 8 Time to birth - Birth within 48
hours (cumulative). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
Analysis 6.1. Comparison 6 Oral misoprostol versus placebo, Outcome 1 Vaginal delivery not achieved within 24 hours. 139
Analysis 6.2. Comparison 6 Oral misoprostol versus placebo, Outcome 2 Additional induction agents required. . . 140
Analysis 6.3. Comparison 6 Oral misoprostol versus placebo, Outcome 3 Oxytocin augmentation. . . . . . . . 140
Analysis 6.4. Comparison 6 Oral misoprostol versus placebo, Outcome 4 Uterine hyperstimulation (with FHR changes). 141
Analysis 6.5. Comparison 6 Oral misoprostol versus placebo, Outcome 5 Uterine hyperstimulation (FHR changes
unclear). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Analysis 6.6. Comparison 6 Oral misoprostol versus placebo, Outcome 6 Instrumental vaginal birth. . . . . . . 142
Analysis 6.7. Comparison 6 Oral misoprostol versus placebo, Outcome 7 Caesarean section. . . . . . . . . . 142
Analysis 6.8. Comparison 6 Oral misoprostol versus placebo, Outcome 8 Apgar score < 7 at 5 minutes. . . . . . 143
Analysis 6.9. Comparison 6 Oral misoprostol versus placebo, Outcome 9 Neonatal intensive care unit admission. . 143
Analysis 6.10. Comparison 6 Oral misoprostol versus placebo, Outcome 10 Postpartum haemorrhage. . . . . . 144
Analysis 6.11. Comparison 6 Oral misoprostol versus placebo, Outcome 11 Chorioamnionitis. . . . . . . . . 144
Analysis 6.12. Comparison 6 Oral misoprostol versus placebo, Outcome 12 Endometritis. . . . . . . . . . 145
Analysis 6.13. Comparison 6 Oral misoprostol versus placebo, Outcome 13 Indicator of ’progress’ in labour - Time from
first dose to active labor (hours). . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Analysis 6.14. Comparison 6 Oral misoprostol versus placebo, Outcome 14 Time to birth - First dose to birth (hours). 146
Analysis 6.15. Comparison 6 Oral misoprostol versus placebo, Outcome 15 Indicator of ’progress’ in labour - Total doses
of medication. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Analysis 7.1. Comparison 7 Mifepristone versus placebo, Outcome 1 Additional induction agents required. . . . 147
Analysis 7.2. Comparison 7 Mifepristone versus placebo, Outcome 2 Serious neonatal morbidity or death. . . . . 147
Analysis 7.3. Comparison 7 Mifepristone versus placebo, Outcome 3 Oxytocin augmentation. . . . . . . . . 148
Analysis 7.4. Comparison 7 Mifepristone versus placebo, Outcome 4 Epidural. . . . . . . . . . . . . . 149
Analysis 7.5. Comparison 7 Mifepristone versus placebo, Outcome 5 Assisted (instrumental) vaginal birth. . . . . 149
Analysis 7.6. Comparison 7 Mifepristone versus placebo, Outcome 6 Caesarean section. . . . . . . . . . . 150
Analysis 7.7. Comparison 7 Mifepristone versus placebo, Outcome 7 Apgar score < 7 at 5 minutes. . . . . . . 151
Analysis 7.8. Comparison 7 Mifepristone versus placebo, Outcome 8 NICU admission. . . . . . . . . . . 151
Analysis 7.9. Comparison 7 Mifepristone versus placebo, Outcome 9 Perinatal death. . . . . . . . . . . . 152
Analysis 7.10. Comparison 7 Mifepristone versus placebo, Outcome 10 Uterine scar separation. . . . . . . . 152
Analysis 7.11. Comparison 7 Mifepristone versus placebo, Outcome 11 Chorioamnionitis. . . . . . . . . . 153
Analysis 7.12. Comparison 7 Mifepristone versus placebo, Outcome 12 Indicator of ’progress’ in labour - Labour or ripe
cervix in 48 hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
Analysis 7.13. Comparison 7Mifepristone versus placebo, Outcome 13 Indicator of ’progress’ in labour - Cervix unchanged
after 24/48 hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Analysis 7.14. Comparison 7 Mifepristone versus placebo, Outcome 14 Indicator of ’progress’ in labour - Spontaneous
labour within 72 hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
iiiPharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.15. Comparison 7 Mifepristone versus placebo, Outcome 15 Indicator of ’progress’ in labour - Spontaneous
labour within 48 hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
Analysis 7.16. Comparison 7 Mifepristone versus placebo, Outcome 16 Indicator of ’progress’ in labour - Oxytocin
requirements (IU). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
Analysis 7.17. Comparison 7 Mifepristone versus placebo, Outcome 17 Indicator of ’progress’ in labour - Interval between
day 1 and start of labour (hours). . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
Analysis 8.1. Comparison 8 Oestrogens versus placebo, Outcome 1 Oxytocin augmentation. . . . . . . . . . 157
Analysis 8.2. Comparison 8 Oestrogens versus placebo, Outcome 2 Assisted (instrumental) vaginal birth. . . . . 157
Analysis 8.3. Comparison 8 Oestrogens versus placebo, Outcome 3 Caesarean section. . . . . . . . . . . . 158
Analysis 8.4. Comparison 8 Oestrogens versus placebo, Outcome 4 NICU admission. . . . . . . . . . . . 158
Analysis 8.5. Comparison 8 Oestrogens versus placebo, Outcome 5 Chorioamnionitis. . . . . . . . . . . . 159
Analysis 8.6. Comparison 8 Oestrogens versus placebo, Outcome 6 Endometritis. . . . . . . . . . . . . 159
Analysis 9.1. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 1 Vaginal birth not achieved
in 24/48 hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Analysis 9.2. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 2 Additional induction agents
required. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Analysis 9.3. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 3 Maternal satisfaction. 161
Analysis 9.4. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 4 Maternal satisfaction. 163
Analysis 9.5. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 5 Perinatal death. . . 164
Analysis 9.6. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 6 Neonatal trauma (long
bone fracture, collarbone fracture, basal skull fracture, brachial plexus palsy, facial nerve palsy, phrenic nerve palsy, or
subdural haemorrhage). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
Analysis 9.7. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 7 Neonatal convulsions in
the first 24 hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
Analysis 9.8. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 8 Tracheal ventilation > 24
hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
Analysis 9.9. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 9 Neonatal ICU admission
for 5 or more days. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
Analysis 9.10. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 10 Neonatal transfer. 167
Analysis 9.11. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 11 Maternal death. . 168
Analysis 9.12. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 12 Severe postpartum
haemorrhage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
Analysis 9.13. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 13 Deep vein thrombosis. 169
Analysis 9.14. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 14 Oxytocin
augmentation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169
Analysis 9.15. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 15 Epidural. . . . 170
Analysis 9.16. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 16 Uterine hyperstimulation
(with FHR changes). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
Analysis 9.17. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 17 Uterine hyperstimulation
(FHR changes unclear). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
Analysis 9.18. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 18 Assisted (instrumental)
vaginal birth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
Analysis 9.19. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 19 Caesarean section. 173
Analysis 9.20. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 20 Apgar score < 7 at 5
minutes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
Analysis 9.21. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 21 NICU (or SCBU)
admission. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
Analysis 9.22. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 22 Postpartum haemorrhage
(> 500 mL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
Analysis 9.23. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 23 Neonatal infection. 177
Analysis 9.24. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 24 Side effects - Maternal
side effect - nausea. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
ivPharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.25. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 25 Side effects - Maternal
side effect - headache. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
Analysis 9.26. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 26 Side effects - Maternal
side effects - severe headache. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
Analysis 9.27. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 27 Indicator of ’progress’ in
labour - Admitted in established labour within 24 hours. . . . . . . . . . . . . . . . . . . . 179
Analysis 9.28. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 28 Indicator of ’progress’ in
labour - Bishop score > 6 or active labour at 36 hours. . . . . . . . . . . . . . . . . . . . . 180
Analysis 9.29. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 29 Time to birth - Time in
hours from admission to birth (all women). . . . . . . . . . . . . . . . . . . . . . . . 180
Analysis 9.30. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 30 Indicator of ’progress’ in
labour - Bishop score on admission after treatment. . . . . . . . . . . . . . . . . . . . . . 181
Analysis 9.31. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 31 Indicator of ’progress’ in
labour - Change in Bishop score. . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
Analysis 9.32. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 32 Time to birth - Interval
from onset of labour to birth (hours). . . . . . . . . . . . . . . . . . . . . . . . . . 182
Analysis 9.33. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 33 Indicator of ’progress’ in
labour - Cervix unchanged after 48 hours. . . . . . . . . . . . . . . . . . . . . . . . . 183
Analysis 9.34. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 34 Time to birth - Interval
from admission to vaginal birth (hours). . . . . . . . . . . . . . . . . . . . . . . . . . 183
Analysis 9.35. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 35 Total cost of care package
(GBP). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
Analysis 10.1. Comparison 10 Acupuncture versus routine care, Outcome 1 Additional induction agents required. . 184
Analysis 10.2. Comparison 10 Acupuncture versus routine care, Outcome 2 Caesarean section. . . . . . . . . 185
Analysis 11.1. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 1 Maternal satisfaction -
I look back positively on the treatment I received. . . . . . . . . . . . . . . . . . . . . . 185
Analysis 11.2. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 2 Maternal satisfaction -
In retrospect, I would have preferred another treatment than received. . . . . . . . . . . . . . . 186
Analysis 11.3. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 3 Augmentation,
induction or both. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
Analysis 11.4. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 4 Epidural, opioids or
both for pain relief. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
Analysis 11.5. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 5 Instrumental vaginal
birth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
Analysis 11.6. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 6 Caesarean section. 188
Analysis 11.7. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 7 Apgar < 7 at 5
minutes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
Analysis 11.8. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 8 Neonatal intensive
care unit admission. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
Analysis 11.9. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 9 Duration of birth
(hours). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
189ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
194WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
194CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
194DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
194SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
195DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
195INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
vPharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Pharmacological and mechanical interventions for labour
induction in outpatient settings
Joshua P Vogel1, Alfred O Osoti2, Anthony J Kelly3, Stefania Livio4 , Jane E Norman5, Zarko Alfirevic6
1UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Re-
production (HRP), Department of ReproductiveHealth and Research,WorldHealthOrganization, Geneva, Switzerland. 2Department
of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya. 3Department of Obstetrics and Gynaecology, Brighton and
Sussex University Hospitals NHS Trust, Brighton, UK. 4Department of Obstetrics and Gynaecology, University of Milan, Children’s
Hospital “V. Buzzi”, Milano, Italy. 5MRC Centre for Reproductive Health, University of Edinburgh Queen’s Medical Research Centre,
Edinburgh, UK. 6Department of Women’s and Children’s Health, The University of Liverpool, Liverpool, UK
Contact address: Zarko Alfirevic, Department of Women’s and Children’s Health, The University of Liverpool, First Floor, Liverpool
Women’s NHS Foundation Trust, Crown Street, Liverpool, L8 7SS, UK. zarko@liverpool.ac.uk.
Editorial group: Cochrane Pregnancy and Childbirth Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 9, 2017.
Citation: Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, Alfirevic Z. Pharmacological and mechanical interventions for
labour induction in outpatient settings. Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD007701. DOI:
10.1002/14651858.CD007701.pub3.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Induction of labour is carried out for a variety of indications and using a range of methods. For women at low risk of pregnancy
complications, some methods of induction of labour or cervical ripening may be suitable for use in outpatient settings.
Objectives
To examine pharmacological and mechanical interventions to induce labour or ripen the cervix in outpatient settings in terms of
effectiveness, maternal satisfaction, healthcare costs and, where information is available, safety.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 November 2016) and reference lists of retrieved
studies.
Selection criteria
We included randomised controlled trials examining outpatient cervical ripening or induction of labour with pharmacological agents
or mechanical methods. Cluster trials were eligible for inclusion.
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. We
assessed evidence using the GRADE approach.
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Main results
This updated review included 34 studies of 11 different methods for labour induction with 5003 randomised women, where women
received treatment at home or were sent home after initial treatment and monitoring in hospital.
Studies examined vaginal and intracervical prostaglandin E (PGE ), vaginal and oral misoprostol, isosorbide mononitrate, mifepris-
tone, oestrogens, amniotomy and acupuncture, compared with placebo, no treatment, or routine care. Trials generally recruited healthy
women with a term pregnancy. The risk of bias was mostly low or unclear, however, in 16 trials blinding was unclear or not attempted.
In general, limited data were available on the review’s main and additional outcomes. Evidence was graded low to moderate quality.
1. Vaginal PGE versus expectant management or placebo (5 studies)
Fewer women in the vaginal PGE group needed additional induction agents to induce labour, however, confidence intervals were
wide (risk ratio (RR) 0.52, 95% confidence interval (CI) 0.27 to 0.99; 150 women; 2 trials). There were no clear differences between
groups in uterine hyperstimulation (with or without fetal heart rate (FHR) changes) (RR 3.76, 95% CI 0.64 to 22.24; 244 women;
4 studies; low-quality evidence), caesarean section (RR 0.80, 95% CI 0.49 to 1.31; 288 women; 4 studies; low-quality evidence), or
admission to a neonatal intensive care unit (NICU) (RR 0.32, 95% CI 0.10 to 1.03; 230 infants; 3 studies; low-quality evidence).
There was no information on vaginal birth within 24, 48 or 72 hours, length of hospital stay, use of emergency services or maternal or
caregiver satisfaction. Serious maternal and neonatal morbidity or deaths were not reported.
2. Intracervical PGE versus expectant management or placebo (7 studies)
There was no clear difference between women receiving intracervical PGE and no treatment or placebo in terms of need for additional
induction agents (RR 0.98, 95% CI 0.74 to 1.32; 445 women; 3 studies), vaginal birth not achieved within 48 to 72 hours (RR 0.83,
95% CI 0.68 to 1.02; 43 women; 1 study; low-quality evidence), uterine hyperstimulation (with FHR changes) (RR 2.66, 95% CI
0.63 to 11.25; 488 women; 4 studies; low-quality evidence), caesarean section (RR 0.90, 95% CI 0.72 to 1.12; 674 women; 7 studies;
moderate-quality evidence), or babies admitted to NICU (RR 1.61, 95% CI 0.43 to 6.05; 215 infants; 3 studies; low-quality evidence).
There were no uterine ruptures in either the PGE group or placebo group.
There was no information on vaginal birth not achieved within 24 hours, length of hospital stay, use of emergency services, mother or
caregiver satisfaction, or serious morbidity or neonatal morbidity or perinatal death.
3. Vaginal misoprostol versus placebo (4 studies)
One small study reported on the rate of perinatal death with no clear differences between groups; there were no deaths in the treatment
group compared with one stillbirth (reason not reported) in the control group (RR 0.34, 95% CI 0.01 to 8.14; 77 infants; 1 study;
low-quality evidence).
There was no clear difference between groups in rates of uterine hyperstimulation with FHR changes (RR 1.97, 95% CI 0.43 to 9.00;
265 women; 3 studies; low-quality evidence), caesarean section (RR 0.94, 95% CI 0.61 to 1.46; 325 women; 4 studies; low-quality
evidence), and babies admitted to NICU (RR 0.89, 95% CI 0.54 to 1.47; 325 infants; 4 studies; low-quality evidence).
There was no information on vaginal birth not achieved within 24, 48 or 72 hours, additional induction agents required, length of
hospital stay, use of emergency services, mother or caregiver satisfaction, serious maternal, and other neonatal, morbidity or death.
No substantive differences were found for other comparisons. One small study found that women who received oral misoprostol were
more likely to give birth within 24 hours (RR 0.65, 95% CI 0.48 to 0.86; 87 women; 1 study) and were less likely to require additional
induction agents (RR 0.60, 95% CI 0.37 to 0.97; 127 women; 2 studies). Women who received mifepristone were also less likely to
require additional induction agents (average RR 0.59, 95% CI 0.37 to 0.95; 311 women; 4 studies; I² = 74%); however, this result
should be interpreted with caution due to high heterogeneity. One trial each of acupuncture and outpatient amniotomy were included,
but few review outcomes were reported.
Authors’ conclusions
Induction of labour in outpatient settings appears feasible and important adverse events seem rare, however, in general there is insufficient
evidence to detect differences. There was no strong evidence that agents used to induce labour in outpatient settings had an impact
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(positive or negative) on maternal or neonatal health. There was some evidence that compared to placebo or no treatment, induction
agents administered on an outpatient basis reduced the need for further interventions to induce labour, and shortened the interval from
intervention to birth.
We do not have sufficient evidence to know which induction methods are preferred by women, the interventions that are most effective
and safe to use in outpatient settings, or their cost effectiveness. Further studies where various women-friendly outpatient protocols
are compared head-to-head are required. As part of such work, women should be consulted on what sort of management they would
prefer.
P L A I N L A N G U A G E S U M M A R Y
Medications and mechanical interventions for induction of labour in outpatient settings
What is the issue?
Induction of labour (starting labour artificially) is often needed for medical reasons, such as when women have passed their due dates.
Different induction methods can be used, such as medications (like prostaglandin E , misoprostol or isosorbide mononitrate) or
breaking membranes. Inductions are usually carried out in hospital; some methods may be suitable for use with women treated as
outpatients, and allowed to go home to wait for labour to progress. We examined the feasibility, effectiveness and safety of outpatient
induction, as well as women’s satisfaction and healthcare costs.
Why is this important?
Pregnant women who have reached their due date can be assessed in hospital as outpatients, given the induction treatment followed by
monitoring for a short time, and then sent home. Alternatively, they are given the drug or treatment to take at home. Women may be
more comfortable waiting for labour to start at home, and outpatient care may be less costly for health services.
What evidence did we find?
This is an updated review that includes six new studies. We included 34 randomised controlled trials involving 5003 pregnant women
(search date: November 2016). The women were healthy and at low risk of complications. They were given induction, a fake treatment
(placebo) or no treatment. Limited information was available on the outcomes that were of interest, and risk of bias was generally low
or unclear. The quality of evidence was judged to be low-quality, with a few moderate-quality findings.
Women at term who were induced as outpatients may be less likely to need further induction, compared to women given placebo
or no treatment. Medications like vaginal PGE , mifepristone and oral misoprostol appear to be effective. No clear differences were
reported for excessive activity of the uterus (hyperstimulation), caesarean section or need for neonatal intensive care.
There were too few women in these trials to determine differences in rare events, such as infant deaths or serious illnesses of mothers
or babies. The trials did not report on use of emergency services to return to hospital. Some medications caused side effects (such as
headaches). Overall, there was little information on costs of different methods.
What does this mean?
For healthy, low-risk pregnant women at term, outpatient induction and enabling women to return home to wait for labour to start
appears to be feasible. Outpatient induction treatments may reduce both need for further drugs and time from treatment to birth.
It does not appear to increase the likelihood of needing other interventions in labour. However, there is insufficient evidence to say
definitively whether outpatient induction is safe. Future research should focus on which methods women prefer, and are most effective
and safe.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vaginal PGE compared to placebo or expectant management for the induction of labour in outpatient settings
Patient or population: women requiring term labour induct ion
Setting: outpat ient clinics and hospitals in the USA
Intervention: vaginal PGE
Comparison: placebo or expectant management
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo
or expectant manage-
ment
Risk with intravaginal
PGE gel
Vaginal birth not
achieved within 24 h
Study populat ion - (0 study) - No included trial re-
ported this outcome.
see comment see comment
Vaginal birth not
achieved in 48 to 72 h
Study populat ion - (0 study) - No included trial re-
ported this outcome.
see comment see comment
Uterine hyperst imula-
t ion (fetal heart rate
changes unclear)
Study populat ion RR 3.76
(0.64 to 22.24)
244
(4 RCTs)
⊕⊕©©
LOW 1
There were no events in
the control group and
so it was not possible
to calculate the ant ici-
pated absolute ef fectssee comment see comment
Caesarean sect ion Study populat ion RR 0.80
(0.49 to 1.31)
288
(4 RCTs)
⊕⊕©©
LOW 2
196 per 1000 157 per 1000
(96 to 257)
Serious neonatal mor-
bidity or death
Study populat ion - (0 study) - No included trial re-
ported this outcome.
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see comment see comment
Serious maternal mor-
bidity or death
Study populat ion - (0 studies) - No included trial re-
ported this outcome.
see comment see comment
Neonatal intensive care
unit admission
Study populat ion RR 0.32
(0.10 to 1.03)
230
(3 RCTs)
⊕⊕©©
LOW 1
93 per 1000 30 per 1000
(9 to 96)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Wide conf idence interval crossing the line of no ef fect, few events and small sample size (-2).
2 Wide conf idence interval crossing the line of no ef fect and small sample size (-2).
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B A C K G R O U N D
Introduction
This Cochrane Review was first published in 2010 and updated
in 2017. The review complements existing reviews on labour in-
duction examining effectiveness and safety.
Description of the condition
The number of women whose labours are induced has risen over
the past two decades. Rates in the USA and the UK now exceed
20% of all births (Glantz 2003; Kirby 2004; NHS 2014-15).
There is considerable variation in reported induction rates, and the
reasons for this variability are often not clear. In some units in the
USA, up to half of all births follow induction of labour (Rayburn
2002). Fewer data are available on induction rates in facilities in
low- and middle-income countries; however, the World Health
Organization (WHO) Global Survey of Maternal and Perinatal
Health of facility obstetric practices in 22 countries reported in-
duction rates of 11.4% in eight Latin American countries, 4.4%
in seven African countries, and 12.1% in nine Asian countries
(Guerra 2009; Vogel 2013).
It has not been definitively shown that increased use of induc-
tion has been associated with improvements in maternal, fetal or
neonatal outcomes; women who are induced also tend to be less
satisfied with their experience of childbirth (Shetty 2005). In this
context, and with increasing pressure on healthcare resources, it is
particularly important to address questions about how to provide
induction of labour safely and effectively, in settings and ways that
are acceptable to women, and in the most cost-effective way pos-
sible.
Description of the intervention
A number of pharmacological and mechanical methods of cervi-
cal ripening and induction of labour are available, and these have
been the focus of a series of Cochrane Reviews that share generic
protocols (Hofmeyr 2009). On the basis of these Cochrane Re-
views, WHO currently recommends oral misoprostol (25 µg, 2
hourly) and vaginal low-dose misoprostol (25 µg, 6 hourly) for
induction of labour (misoprostol is not recommended for women
with a previous caesarean section) (WHO2011). If prostaglandins
are not available, WHO recommends intravenous oxytocin alone
for induction. Balloon catheter is recommended for induction,
but amniotomy alone is not. The combination of balloon catheter
plus oxytocin is recommended as an alternative method of induc-
tion of labour when prostaglandins (including misoprostol) are
not available or are contra-indicated. Importantly, the WHO rec-
ommendations stipulate the need to assess maternal and fetal well-
being during induction.
In these reviews, the safety and effectiveness of different methods
and agents have been examined, but less attention was paid to
the setting in which cervical ripening and induction of labour
take place. In this review, we brought together some of the studies
included in previous reviews, focusing specifically on those studies
where labour induction or cervical ripening was carried out in
outpatient settings. For most methods of induction, the number
of trials carried out in outpatient settings is likely to be small,
making it difficult to definitively establish benefits and harms.
The purpose of this review was to examine issues such as benefits
and harms, health service utilisation, feasibility and women’s views
about their care. For some interventions, there may be sufficient
data to address questions of effectiveness and safety. In this way,
this review complements others in the suite rather than simply
duplicating findings.
A related review included trials in which the same methods of
ripening or induction were compared in outpatient and hospital
settings (Kelly 2013).
Induction of labour is carried out for a variety of indications and
using a range of pharmacological, mechanical and other meth-
ods. The main indication for induction of labour is prolonged
pregnancy, and there is evidence from a related Cochrane Review
(Gülmezoglu 2012) that for pregnancies which have continued
beyond 41 weeks, induction of labour may reduce perinatal mor-
tality. Other inductions are carried out on an individual basis.
Most inductions of labour are carried out in inpatient settings.
Outpatient procedures may not be safe for women with some risk
factors, and some methods may only be feasible and safe in hos-
pital, or in settings with specialised staff and facilities available.
For example, outpatient induction is unlikely to be suitable for
women with serious medical conditions or complications in the
current pregnancy (Sawai 1995). Some women may be unsuitable
for home care simply because they live at an unacceptable travel-
ling distance from emergency care facilities.
How the intervention might work
Ideally, the agents or methods used for cervical ripening at home
would achieve changes in the cervix similar to the normal physio-
logical changes which promote the ’spontaneous’ onset of labour,
but without causing uterine contractions (Sawai 1995). Most
methods for cervical ripening or induction of labour do have some
undesirable side effects, including, on occasions, excessive uterine
activity. The consequences of excessive uterine activity as a result
of iatrogenic uterine hyperstimulation can be life-threatening for
the mother and fetus.
Sometimes drugs to induce labour can only be administered by
intravenous infusion or by repeated injections, or using specialist
procedures that cannot easily be carried out in an outpatient set-
ting. Drugs that can be taken orally, or procedures that are simple
to perform, and require only limited monitoring, may lend them-
selvesmore readily for use in an outpatient setting. At least theoret-
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ically, outpatient induction may offer a number of advantages to
women, clinical staff and providers of health services. Outpatient
induction may be more convenient for and preferred by women;
it may reduce hospital bed occupancy, and therefore, be associated
with lower healthcare costs.
A number of papers have set out indications for outpatient cervical
ripening or induction such as post-dates pregnancy in women
who are otherwise well, and where there have been no signs of
fetal distress. Several outpatient induction protocols have been
described in observational studies suggesting that such inductions
are feasible, safe and acceptable to women (Elliott 1992; McGill
2007; Neale 2002).
Why it is important to do this review
For some methods, and for selected groups of women, induction
of labour is already being carried out in outpatient settings. This
Cochrane Review brings together evidence from available trials
in outpatient settings to assess benefits and harms of outpatient
induction, as well as preferences of women and providers, and the
feasibility of their use in outpatient settings. To achieve this, we
pooled data from trials examining the same methods to address
questions of safety.
In the context of this review, the issue of safety is of great impor-
tance. At the same time, it is unlikely that safety could be ade-
quately addressed in studies of randomised cohorts. Severe mater-
nal and neonatal mortality and morbidity are likely to be very rare
events in the low-risk population included in studies of outpatient
induction. Information on adverse events and the relative safety of
outpatient methods is most likely to emerge where there have been
several large studies and where the same methods have been di-
rectly compared in different settings. Information on rare adverse
events takes time to accumulate, but by systematically recording
information on adverse events in all the studies included in the
review, we may shed some light on this question.
We did not include studies where the same method of cervical
ripening or induction of labour was compared in outpatient versus
inpatient settings: this has been addressed in a related Cochrane
Review (Kelly 2013).
O B J E C T I V E S
To examine pharmacological and mechanical interventions to in-
duce labour or ripen the cervix in outpatient settings in terms
of effectiveness, maternal satisfaction, healthcare costs and, where
information is available, safety.
This Cochrane Review complements existing Cochrane Reviews
on labour induction examining effectiveness and safety.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised trials which compared
different methods of cervical ripening or induction of labour car-
ried out in outpatient settings were eligible for inclusion. All trials
included random allocation to intervention and control groups.
We did not include quasi-randomised trials. We included studies
reported in abstracts and brief reports provided that sufficient in-
formation was available to allow us to assess eligibility and risk of
bias; where such information was not provided we attempted to
contact trial authors. We planned to include cluster-randomised
trials if they were otherwise eligible. We did not include cross-over
studies because we did not consider they were appropriate in this
topic area.
Types of participants
Pregnant women (with a viable fetus) at or near team (greater than
35 weeks) in an outpatient setting. Specifically, women in whom
induction of labour is being considered, but where expectantman-
agement is acceptable.
Types of interventions
We included studies examining outpatient cervical ripening or
induction of labour with pharmacological agents or mechanical
methods. We included studies where different methods of in-
duction of labour in outpatient settings were compared; where a
method was compared with a placebo; where a method was com-
pared with expectant management or routine care; or where dif-
ferent doses of the same drug were compared. ’Outpatient’ was
defined by the trialists and included any cervical ripening or in-
duction of labour intervention (with the exception of membrane
sweeping) that can be carried out at home or within commu-
nity healthcare settings. It also includes a package of care initially
provided in hospital (fetal monitoring, drug administration) after
which the woman is allowed home until later review or admission
in labour. We did not include interventions where women remain
in hospital throughout (even if they were in ’day-care’ settings, or
in other parts of the hospital, but not formally admitted as inpa-
tients) because a purpose of this review was to examine outcomes
where women do not have immediate access to emergency care
facilities. Trials comparing inpatient versus outpatient induction
of labour were considered in Kelly 2013.
7Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of outcome measures
Clinically relevant outcomes for trials ofmethods of cervical ripen-
ing and labour induction have been pre-specified by two authors
of labour induction reviews (Justus Hofmeyr and Zarko Alfirevic)
(Hofmeyr 2009). We have used most of these outcomes (relevant
to both inpatient and outpatient settings) in this review.
In addition, we attempted to use relevant outcome measures to
quantify any cost effectiveness benefits of outpatient ripening.
Main outcomes
1. Vaginal birth not achieved within 24 hours.
2. Additional induction agents required.
3. Length of hospital stay.
4. Use of emergency services.
5. Maternal satisfaction
6. Caregiver satisfaction
7. Serious neonatal morbidity or perinatal death (composite
outcome will include, for example, seizures, birth asphyxia
defined by trialists, neonatal encephalopathy, disability in
childhood).
8. Serious maternal morbidity or death (composite outcome
will include, for example, uterine rupture, admission to intensive
care unit, septicaemia).
Additional outcomes of interest
Additional outcomes of interest related to measures of effective-
ness, complications and satisfaction
Measures of effectiveness
1. Vaginal birth not achieved within 48 and 72 hours.
2. Randomisation to birth interval.
3. Oxytocin augmentation.
4. Pain relief requirements (epidural, opioids).
Complications
1. Uterine hyperstimulation (with fetal heart rate (FHR)
changes).
2. Uterine hyperstimulation (without FHR changes).
3. Instrumental vaginal birth.
4. Caesarean section.
5. Apgar score < 7 at 5 minutes.
6. Neonatal intensive care unit admission.
7. Perinatal death.
8. Postpartum haemorrhage (as defined by the trial authors).
9. Serious maternal complications (considered as separate
outcomes, e.g. intensive care unit admission, septicaemia, uterine
rupture).
10. Serious neonatal complications (considered as separate
outcomes).
In the absence of formal economic evaluation, we had planned
to estimate potential cost savings and the impact of interventions
used within an outpatient setting. These estimates could involve
using some measures of effectiveness and complications in com-
bination with estimates of healthcare provision.
We also included some additional outcomes that may serve as
proxy measures of progress towards labour or birth.
• Indicators of progress in labour such as: preterm rupture of
membranes, diagnosis of active/spontaneous labour, self-referral
back to hospital, Bishop scores at fixed time points post-
randomisation.
• Failed induction (as defined by trialists, but excluding the
use of oxytocin for augmentation in women already in
established labour).
• Time to birth including the interval from randomisation to
birth; interval to admission along with length of labour.
• Side effects or adverse outcomes (not specified above)
related or possibly related to the intervention.
Detailed definitions for outcomes
• Perinatal and maternal morbidity and mortality are
composite outcomes. This is not an ideal solution because some
components are clearly less severe than others. It is possible for
one intervention to cause more deaths but less severe morbidity.
However, in the context of labour induction at term, this is
unlikely. All these events are rare, and a modest change in their
incidence will be easier to detect if composite outcomes are
presented. The incidence of individual components are explored
as additional outcomes (see above).
• ’Uterine rupture’ includes all clinically significant ruptures
of unscarred or scarred uteri. Trivial scar dehiscence noted
incidentally at the time of surgery is excluded.
• The terminology of uterine hyperstimulation is problematic
(Curtis 1987). In the reviews, the term ’uterine hyperstimulation’
is defined as uterine tachysystole (more than 5 contractions per
10 minutes for at least 20 minutes) and uterine hypersystole/
hypertonus (a contraction lasting at least 2 minutes).
• ’Uterine hyperstimulation with FHR changes’ is usually
defined as uterine hyperstimulation syndrome (tachysystole or
hypersystole with FHR changes such as persistent decelerations,
tachycardia or decreased short-term variability). However, due to
varied reporting, there is the possibility of subjective bias in the
interpretation of these outcomes. Also, it is not always clear from
trials if these outcomes are reported in a mutually exclusive
manner. More importantly, continuous monitoring is unlikely in
an outpatient setting. Therefore, there is a high risk of biased
reporting of uterine hyperstimulation (with or without FHR
changes). It is possible that bias will favour the outpatient setting
(i.e. by failure to recognise mild forms of hyperstimulation
without continuous monitoring). On the other hand, clinicians
who favour inpatient induction may, in the absence of
continuous monitoring, label any maternal description of
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painful, frequent uterine contractions as hyperstimulation.
Therefore, in the absence of blinding, hyperstimulation and
other ’soft’ outcomes should be interpreted with extreme caution.
While we sought data on all of the outcomes listed above, we doc-
umented only those with data in the analysis tables. We included
outcomes in the analysis if reasonable measures were taken tomin-
imise observer bias, and data were available according to original
treatment allocation.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (30 November 2016).
The Register is a database containing over 23,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ‘Specialized Register ’ sec-
tion from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set which has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification).
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Dowswell 2010.
For this update, the following methods were used to assess the 10
reports that were identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors independently assessed all the potential stud-
ies identified as a result of the search strategy for inclusion. We
resolved any disagreement through discussion or, if required, we
consulted a third review author.
Data extraction and management
We designed a form to extract data. For eligible studies, two re-
view authors extracted the data using the agreed form.We resolved
discrepancies through discussion or, if required, we consulted the
third review author. Data were entered into Review Manager soft-
ware (RevMan 2014) and checked for accuracy.
When information regarding any of the above was unclear, we
planned to contact authors of the original reports to provide fur-
ther details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in theCochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). Any disagreement
was resolved by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
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(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we planned to re-include missing data in the
analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we planned to
assess the likely magnitude and direction of the bias and whether
we considered it is likely to impact on the findings. In future
updates, we will explore the impact of the level of bias through
undertaking sensitivity analyses (see Sensitivity analysis).
Assessment of the quality of the evidence using the
GRADE approach
For this update the quality of the evidence was assessed using the
GRADE approach as outlined in the GRADE handbook to assess
the quality of the body of evidence relating to the following out-
comes for the main comparisons (vaginal PGE versus placebo
or expectant management; intracervical PGE versus placebo or
expectant management; vaginal misoprostol versus placebo or ex-
pectant management):
1. Vaginal birth not achieved within 24 hours.
2. Vaginal birth not achieved within 48 and 72 hours.
3. Uterine hyperstimulation with FHR changes.
4. Caesarean section.
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5. Serious neonatal morbidity or perinatal death (composite
outcome will include, for example, seizures, birth asphyxia
defined by trialists, neonatal encephalopathy, disability in
childhood).
6. Serious maternal morbidity or death (composite outcome
will include, for example, uterine rupture, admission to intensive
care unit, septicaemia).
7. Neonatal intensive care unit admission.
GRADEproGuidelineDevelopmentTool was used to import data
from Review Manager 5.3 (RevMan 2014) to create ’Summary of
findings’ tables. A summary of the intervention effect and a mea-
sure of quality for each of the above outcomes was produced us-
ing the GRADE approach. The GRADE approach uses five con-
siderations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of the body
of evidence for each outcome. The evidence can be downgraded
from ’high quality’ by one level for serious (or by 2 levels for very
serious) limitations, depending on assessments for risk of bias, in-
directness of evidence, serious inconsistency, imprecision of effect
estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
We presented results as summary risk ratio with 95% confidence
intervals for dichotomous data.
Continuous data
We used the mean difference if outcomes were measured in the
same way between trials for continuous data. We used the stan-
dardised mean difference to combine trials that measured the same
outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
If future searches identify eligible cluster-randomised trials, we will
include these in the analyses along with individually randomised
trials. We will adjust their sample sizes or standard errors using the
methods described in the Handbook (Section 16.3.4 or 16.3.6 as
appropriate) using an estimate of the intracluster correlation co-
efficient (ICC) derived from the trial (if possible), from a similar
trial or from a study of a similar population. If we use ICCs from
other sources, we will report this and conduct sensitivity analyses
to investigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually-randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomisation unit is
considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
We decided to exclude cross-over trials as we did not think this
design was appropriate in this topic area.
Other unit of analysis issues
Trials with multiple arms
Two trials had multiple intervention arms - Larmon 2002 and
Magann 1998. Larmon 2002 was a three-arm trial comparing
intracervical PGE , oestrogen and placebo and is included in
more than one comparison. In Magann 1998, one intervention
was not eligible for inclusion so data for this were not included. If
we identify furthermultiple-armed trials in future searches, wewill
divide the control group in the analysis to avoid double counting,
and follow the methods set out in the Handbook (Higgins 2011).
Dealing with missing data
Levels of attrition were noted for included studies. In future up-
dates, if more eligible studies are included, the impact of including
studies with high levels of missing data in the overall assessment
of treatment effect will be explored by using sensitivity analysis.
For all outcomes, analyses were carried out, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised to each group in the analyses. The denominator
for each outcome in each trial was the number randomised minus
any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if I² was greater than 30% and either Tau² was greater than
zero, or there was a low P value (< 0.10) in the Chi² test for het-
erogeneity. If we identified substantial heterogeneity (> 30%), we
planned to explore the source in pre-specified subgroup analysis.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate the source.
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Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
meta-analysis to produce an overall summary if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary will be treated as the average range of
possible treatment effects and we will discuss the clinical implica-
tions of treatment effects differing between trials. If the average
treatment effect is not clinically meaningful, we will not combine
trials. If we used random-effects analyses, the results were pre-
sented as the average treatment effect with 95% confidence inter-
vals, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated the
source using subgroup analyses. We considered whether an overall
summary was meaningful, and if it was, we used random-effects
analysis to produce the effect.
If sufficient data were available, we planned to carry out the fol-
lowing subgroup analyses.
1. Nulliparous versus multiparous.
2. Induction indication.
We planned to use only the primary outcomes in subgroup anal-
ysis.
We also planned to assess subgroup differences by interaction tests
available in RevMan (RevMan 2014), and to report the results of
subgroup analyses quoting the Chi² statistic and P value, and the
interaction test I² value. However, insufficient data were available
to permit any subgroup analyses.
Sensitivity analysis
We planned to carry out sensitivity analyses to explore the effect of
trial quality assessed by concealment of allocation, high attrition
rates, or both, with poor quality studies being excluded from the
analyses in order to assess whether this makes any difference to the
overall result. Gaffaney 2009 and Rijnders 2011 were assessed as
being at high risk of attrition bias. However, insufficient data were
available to permit any sensitivity analyses.
R E S U L T S
Description of studies
Results of the search
The previous version of this review identified 72 reports, repre-
senting 55 separate studies (some trials were reported inmore than
one published paper) (Dowswell 2010). A total of 28 studies were
included in the review, 25 were excluded and two awaiting classi-
fication (Ascher-Walsh 2000; Thakur 2005) (Figure 1).
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Figure 1. Study flow diagram.
13Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For this update, the search identified an additional 10 reports. We
also reassessed two studies that were awaiting further classifica-
tion in Dowswell 2010. A total of six new studies were included
(Agarwal 2012; Attanayake 2014; Gaffaney 2009; Ghanaie 2013;
Rijnders 2011; Schmitz 2014), one excluded (Rezk 2014;), and
one new study is awaiting classification (Mostaghel 2009). One
report was included as an additional report of a study already in-
cluded in the review (Bollapragada 2006a). Both studies previously
awaiting classification (Ascher-Walsh 2000;Thakur 2005) remain;
and ISRCTN47736435 (previously excluded) was included as an
additional report of Rijnders 2011. See Characteristics of studies
awaiting classification tables.
Included studies
We included 34 studies that involved a total of 5003 women (
Characteristics of included studies).
The studies included a variety of different comparisons.
• Vaginal prostaglandin (PGE ) versus expectant
management or placebo (5 studies) (Hage 1993; Newman 1997;
O’Brien 1995; Sawai 1991; Sawai 1994).
• Intracervical prostaglandin (PgE ) versus expectant
management or placebo (7 studies) (Buttino 1990; Gittens
1996; Larmon 2002; Lien 1998; Magann 1998; McKenna 1999;
Rayburn 1999).
• Vaginal misoprostol versus placebo (4 studies) (Incerpi
2001; McKenna 2004; Oboro 2005; Stitely 2000).
• Vaginal misoprostol 25 µg versus 50 µg (1 study) (Kipikasa
2005).
• Intracervical prostaglandin (PGE ) versus vaginal
misoprostol (1 study) (Meyer 2005).
• Oral misoprostol versus placebo (2 studies) (Gaffaney 2009;
Lyons 2001).
• Mifepristone versus placebo (5 studies) (Elliott 1998;
Frydman 1992; Giacalone 1998; Lelaidier 1994; Stenlund 1999).
• Oestrogen versus placebo (1 study) (Larmon 2002).
• Vaginal isosorbide mononitrate (IMN) versus placebo (7
studies) (Agarwal 2012; Attanayake 2014; Bollapragada 2006a;
Bullarbo 2007; Ghanaie 2013; Habib 2008; Schmitz 2014).
• Acupuncture versus routine care (1 study) (Harper 2006).
• Outpatient amniotomy for induction versus routine care (1
study) (Rijnders 2011).
In all trials it was intended that women would spend part of the
study period at home. In most studies women received the initial
treatment in a hospital setting (and frequently underwent a period
of surveillance) before discharge home. Women were advised to
seek help or return to hospital if any problems arose, if labour
commenced, or after a predefined period. In some studies, women
self-administered the study intervention at home, and again were
advised to return either if they had concerns, if labour started,
or for review after a specified period (e.g. in Bollapragada 2006a
women scheduled for labour induction were given vaginal IMN
with instructions on self-administration 48, 32 and 16 hours be-
fore the scheduled induction time).
The studies almost invariably recruited healthy women at term.
A small number of studies focused on women with particular his-
tories. In the trials by Gittens 1996, Lelaidier 1994 and Rayburn
1999 women who had a previous caesarean birth were recruited;
Incerpi 2001 focused on women with insulin-dependent diabetes
and Newman 1997 included women with diabetes along with
those requiring induction of labour for post maturity. Two studies
(Lelaidier 1994; Rayburn 1999) recruited women who had a pre-
vious caesarean section and who were aiming to achieve a vaginal
birth. In the remaining studies the main indication for induction
of labour was prolonged pregnancy, although recruitment was not
always restricted to this group. Six studies included only primi-
parous women (Bollapragada 2006a; Elliott 1998; Ghanaie 2013;
Hage 1993; Harper 2006; Schmitz 2014) and two multiparous
women only (Lelaidier 1994; Rayburn 1999).
The main recruitment criterion in all of these studies was that
labour had not already started (i.e. women were not having regular
painful contractions).Most studies also specified a Bishop score in-
dicating an unfavourable cervix as an inclusion criterion although
the definition of an unfavourable cervix (low Bishop score) var-
ied. No studies specifically recruited women where the cervix was
favourable. Where it was mentioned, studies invariably recruited
women with intact membranes; no studies specifically focused on
women with ruptured membranes. Most of these studies specifi-
cally mentioned that multiple pregnancies were excluded, and at
recruitment it was usually specified as an inclusion criterion that
the fetus was in good condition with no signs of distress (e.g. nor-
mal fetal heart rate monitoring and normal amniotic fluid vol-
ume).
Further information on interventions, participants and inclusion
and exclusion criteria are set out in the Characteristics of included
studies tables.
Excluded studies
We excluded 25 trials (Characteristics of excluded studies). The
main reason for excluding studies was study design.
Four studies used a cross-over design; we had decided to exclude
cross-over trials as we did not think this design was appropriate
in this topic area; in all of these studies the focus was on breast
stimulation. Women in the control groups initially received no
intervention, while those in intervention groups were asked to
stimulate their nipples for a specified time period; after this time
period, women then crossed over into the control or intervention
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arm (Adewole 1993; Di Lieto 1989; Elliott 1984; Salmon 1986).
In three studies (Damania 1988; Griffin 2003; Manidakis 1999)
there was too little information on study methods to allow us to
ascertain whether group allocation was truly random, or to allow
us to carry out an assessment of risk of bias (the studies by Griffin
2003 and Manidakis 1999 were reported in brief abstracts; we
attempted to contact the authors for more information without
success). Two studies used quasi-randomisation and were at high
risk of bias (Garry 2000; Kadar 1990). Evans 1983 described find-
ings from two separate studies, one of which seemed to be carried
out in a hospital setting and included a control group receiving no
treatment; a second “outpatient” study did not include a control
group; different doses of porcine ovarian relaxin were compared.
In the study by Ohel 1996, whilst there seemed to be random
allocation to treatment groups, results were not reported by ran-
domisation group, and we were not able to include data in the
review. In one study reported in a brief abstract, no original data
were reported in the results section (Krammer 1995).
A number of studies focused on interventions that we had either
specifically excluded (e.g. Doany 1997; Kaul 2004;Magann 1999;
Salamalekis 2000 looked atmembrane sweeping), or interventions
that are not currently used in clinical practice (extra amniotic saline
infusion was examined by Moghtadaei 2007; it was not clear that
women in both arms of this trial were discharged home; Spallicci
2007 examined the use of hyaluronidase injection).
In five studies it was not clear that the study was carried out in an
outpatient setting or that the women were expected to spend some
of the study period at home (Damania 1992; Herabutya 1992;
Rayburn 1988; Voss 1996; Ziaei 2003). One study (Rezk 2014)
was not conducted in an outpatient setting.
Dorfman 1987 looked at homeopathic preparations (caulophyl-
lum-arnica-actea and racemosa-pulsatilla-gelsemium) used with
the intention of generally preparing women for childbirth rather
than for labour induction.
Risk of bias in included studies
Summary of risk bias assessments are presented graphically (Figure
2; Figure 3).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We assessed most of the included studies as using adequate meth-
ods to generate the randomisation sequence and to conceal group
allocation.
Sequence generation was either computer generated or derived
from random number tables in 26 of the 34 included studies. In
eight trials the methods used to generate the randomisation order
were not clear (Elliott 1998; Frydman 1992; Gittens 1996; Hage
1993; Lelaidier 1994; Lyons 2001; Newman 1997; Sawai 1991).
Eighteen studies used either external or pharmacy randomisation
services, or identical coded drug packs from pharmacy to conceal
group allocation (Bollapragada 2006a; Buttino 1990; Frydman
1992; Gaffaney 2009; Giacalone 1998; Habib 2008; Incerpi
2001; Kipikasa 2005; Lelaidier 1994; Lien 1998;McKenna 1999;
McKenna 2004; O’Brien 1995; Stenlund 1999; Rijnders 2011;
Sawai 1994; Schmitz 2014; Stitely 2000). Four trials used sealed,
opaque, sequentially numbered envelopes to conceal allocation
(Bullarbo 2007; Harper 2006; Larmon 2002; Magann 1998).
Opaque envelopes were used in Attanayake 2014 andMeyer 2005
, although it was not stated that they were sealed. Oboro 2005
used sealed envelopes, but did not state they were opaque. In nine
trials, methods to conceal group allocation were not clear (Agarwal
2012; Elliott 1998; Ghanaie 2013; Gittens 1996; Hage 1993;
Lyons 2001; Newman 1997; Rayburn 1999; Sawai 1991).
Blinding
Most (26) of the included studies were placebo controlled, and
women and clinical staff were described as blind to group allo-
cation. However, it was not always clear when the randomisation
code was broken, so it was difficult to assess whether outcome as-
sessment was carried out by blinded investigators. Eighteen studies
were judged to be at low risk of bias by adequately blinding the
women and staff (Bollapragada 2006a; Bullarbo 2007; Buttino
1990; Elliott 1998; Frydman 1992; Gaffaney 2009; Giacalone
1998; Habib 2008; Incerpi 2001; Lelaidier 1994; Lien 1998;
Lyons 2001; O’Brien 1995; Sawai 1991; Sawai 1994; Schmitz
2014; Stenlund 1999; Stitely 2000). In two of the placebo con-
trolled trials, blinding may not have been convincing; in the
Kipikasa 2005 trial women in both groups were given tablet frag-
ments (either an eighth or a quarter of whole tablets) so the tablets
may have not appeared identical (at least to staff ). In the Larmon
2002 study women may have been blind to intravaginal prepara-
tions, but staff are unlikely to have been.
In eight trials women in both arms of the studies were given differ-
ent interventions; therefore blinding of women and staff was not
feasible, or not attempted (Gittens 1996; Harper 2006; Magann
1998; Meyer 2005; Newman 1997; Oboro 2005; Rayburn 1999;
Rijnders 2011). The lack of blinding in these studies may have
affected some of the outcomes examined in the review.
Outcome assessors were not blinded in three studies (Meyer 2005;
Oboro 2005; Rijnders 2011). Six studies reportedly blinded out-
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come assessors until analysis was completed (Giacalone 1998;
Kipikasa 2005; Lien 1998; Schmitz 2014; Stenlund 1999; Stitely
2000). The blinding of outcome assessors was unclear in the re-
maining studies.
Incomplete outcome data
Loss of women to follow up and missing data were not serious
problems in most of the included studies. In 10 studies the levels
of attrition were not clear (Elliott 1998; Frydman 1992; Ghanaie
2013; Gittens 1996; Hage 1993; Harper 2006; Incerpi 2001;
Kipikasa 2005; Lyons 2001; Newman 1997).
Five trials were assessed as high risk of attrition bias. In the study
by Sawai 1994, attrition was approximately 12% and some of the
exclusions were for non-compliance. Attrition was also high in the
study by Bollapragada 2006a; in this trial randomisation occurred
up to nine days before the initiation of treatment, hence 80 of the
350 women did not start treatment as they had already gone into
labour. To reduce risk of bias, the authors reported an intention-
to-treat analysis (including all women randomised) for the trial’s
primary outcomes but not for secondary outcomes. In Gaffaney
2009, nine women were excluded post-randomisation and not in-
cluded for analysis. In Schmitz 2014, 10 women (5 in each group)
were excluded post-randomisation, and the maternal satisfaction
outcome had 23% attrition. Rijnders 2011 and used a satisfaction
survey, however, responses were not balanced (221 at home and
183 in hospital). In Kipikasa 2005, there were inconsistencies in
figures between the text and the tables, hence rated unclear risk of
attrition bias.
Selective reporting
Reporting bias was difficult to assess, as many studies did not
pre-specify all the outcomes that were reported (Frydman 1992;
Ghanaie 2013; Gittens 1996; Hage 1993; Incerpi 2001; Kipikasa
2005; Larmon 2002; Lelaidier 1994; Lien 1998; Lyons 2001;
Magann 1998; McKenna 1999; McKenna 2004; Newman 1997;
O’Brien 1995; Oboro 2005; Rayburn 1999; Stenlund 1999;
Stitely 2000). Schmitz 2014 pre-specified maternal and newborn
intensive care unit admission outcomes, but these were not re-
ported.
Other potential sources of bias
In many included studies women were likely to receive other in-
terventions at some stage in their treatment as well as the study
allocated intervention (e.g. amniotomy, membrane sweeping, ad-
ditional medication) and these in turn may have affected other
outcomes (e.g. length of labour and rate of caesarean section).
Without adequate blinding, it is possible that women in interven-
tion and control groups may have had different co-interventions,
or co-interventions at different stages. For example, in the study
by Harper 2006, women in the intervention group attended for
treatment on three occasions, and at these visits (not available to
women in the control group) may have been exposed to a range
of co-interventions, or additional tests or observations, that may
have had an impact on outcomes.
Other sources of bias included baseline imbalance in parity be-
tween groups (Oboro 2005) and imbalance in numbers of ran-
domisedwomenbetween the treatment and control groups (Elliott
1998).
Effects of interventions
See: Summary of findings for the main comparison Vaginal
PGE compared to placebo or expectant management for the
induction of labour in outpatient settings; Summary of findings
2 Intracervical PGE compared to placebo for the induction of
labour in outpatient settings; Summary of findings 3 Vaginal
misoprostol compared to placebo for the induction of labour in
outpatient settings
1. Vaginal prostaglandin (PGE ) versus placebo or
expectant management: five studies, 335 women
Main outcomes
We included five studies in this comparison (Hage 1993; Newman
1997; O’Brien 1995; Sawai 1991; Sawai 1994). None of the stud-
ies collected information on most of the review’s main outcomes.
We do not have information on the numbers of women achieving
vaginal birth within 24 hours, on length of hospital stay, on the
use of emergency services or on maternal or caregiver satisfaction.
Maternal and perinatal deaths were not reported.
Additional induction agents required
O’Brien 1995 and Sawai 1991 reported the numbers of women
requiring further (non-study) induction agents with fewer women
in the PGE group needing further medication to induce labour.
While 14.8%of the PGE group needed further induction agents
this applied to 28.9% of the control group. However, as only
two relatively small studies contributed data for this outcome,
confidence intervals were wide and very close to the line of no
effect (risk ratio (RR) 0.52, 95% confidence interval (CI) 0.27 to
0.99; 150 women; 2 trials; Analysis 1.1).
Additional outcomes of interest
Measures of effectiveness
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None of the trials reported vaginal birth not achieved within 48
and 72 hours, randomisation to birth interval, or oxytocin aug-
mentation.
Pain relief requirements (epidural, opioids)
O’Brien 1995 examined the use of epidural; again, there was no
strong evidence of any difference between groups (RR 0.83, 95%
CI 0.62 to 1.12; 100 women; 1 study; Analysis 1.2).
Complications
There was no clear evidence of differences between women who
received vaginal PGE and placebo or expectant management for
the following outcomes:
• Uterine hyperstimulation (with or without FHR changes -
unclear) (RR 3.76, 95% CI 0.64 to 22.24; 244 women; 4
studies; Analysis 1.3; low-quality evidence).
• Caesarean section (RR 0.80, 95% CI 0.49 to 1.31; 288
women; 4 studies; Analysis 1.4; low-quality evidence).
• Apgar score less than seven at five minutes (RR 0.45, 95%
CI 0.07 to 2.93; 180 infants; 2 studies; Analysis 1.5).
• Neonatal intensive care unit (NICU) admission (RR 0.32,
95% CI 0.10 to 1.03; 230 infants; 3 studies; Analysis 1.6; low-
quality evidence).
Serious maternal complications (considered as separate
outcomes, e.g. intensive care unit admission, septicaemia,
uterine rupture)
There was only limited information on the impact of interventions
on the health ofmothers andbabies.O’Brien 1995 andSawai 1994
reported rates of chorioamnionitis and results favoured women in
the PGE group (RR 0.37, 95% CI 0.15 to 0.90; 180 women;
2 studies; Analysis 1.7). There was no information on the use of
antibiotics or on rates of endometritis.
Instrumental vaginal birth, perinatal death, postpartum haemor-
rhage (as defined by the trial authors), and serious neonatal com-
plications (considered as separate outcomes) were not reported by
any study.
Non-prespecified outcomes
While none of these five studies reported the numbers of women
achieving vaginal birth within a certain specified period, other
’proxy’measures of progress towards labour or birth were included.
Each study reported different outcomes.
Hage 1993 reported on the rate of change in Bishop scores and,
compared with women receiving PGE , those in the control
group were more likely to have score changes of less than three at
follow-up (RR 0.13, 95% CI 0.03 to 0.47; 36 women; 1 study;
Analysis 1.8) although it was not clear when follow-up occurred.
Newman 1997 reported figures for the number of women go-
ing into “spontaneous labour” within 48 hours of treatment com-
mencing; it was more likely for labour to start in the PGE group
compared with women receiving routine care (RR 6.43, 95% CI
2.12 to 19.48; 58 women; 1 study; Analysis 1.9).
O’Brien 1995 reported that the median interval from study en-
rolment to birth was four days in the PGE group (range 0 to 28
days) versus 10 days (range 0 to 26 days) in the control group (P
= 0.002). The shorter interval between randomisation and birth
was reflected in a lower gestational age (weeks) at birth in the in-
tervention group (mean difference (MD) -0.60 weeks, 95% CI
-0.99 to -0.21; 100 women; 1 study; Analysis 1.11). It was also re-
ported that, during the five-day treatment period, compared with
controls, more women in the intervention group were admitted to
hospital “for labour” (RR 2.70, 95%CI 1.47 to 4.97; 100 women;
1 study; Analysis 1.10), although it was not clear whether this
included women in active labour only, or women admitted after
premature rupture of membranes (PROM) or for other reasons.
The numbers of women diagnosed with post-term pregnancy was
small in both groups (2 women in the intervention group and 3
in the control group).
Sawai 1991 described Bishop scores in control and intervention
groups at hospital admission, but there were differences between
groups at baseline and the authors report no significant differences
between groups at follow-up (data not shown). Sawai 1994 re-
ported the mean gestational age (in days) at hospital admission
(although the indications for admission included pregnancy com-
plications as well as signs of the onset of labour). There was not a
clear difference between groups (MD -2.00 days, 95% CI -4.17
to 0.17; 80 women; 1 study; Analysis 1.12).
2. Intracervical prostaglandin (PGE ) versus expectant
management or placebo: seven studies, 678 women
Main outcomes
We included seven studies in this comparison (Buttino 1990;
Gittens 1996; Larmon 2002; Lien 1998;Magann 1998;McKenna
1999; Rayburn 1999).
Additional induction agents required
Three studies (Lien 1998;McKenna 1999; Rayburn 1999) looked
at whether, compared with no treatment or placebo, women re-
ceiving intracervical PGE were less likely to need further (non-
study) interventions to induce labour. There was no strong evi-
dence of a difference between groups (RR 0.98, 95% CI 0.74 to
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1.32; 445 women; 3 studies; Analysis 2.1). Lien 1998 also exam-
ined whether women given intracervical PGE were less likely
to receive further doses of prostaglandin to induce labour. Again,
there was no evidence to suggest a difference between groups (RR
0.61, 95% CI 0.22 to 1.67; 90 women; 1 study; Analysis 2.2).
Serious maternal morbidity or death (composite outcome will
include, for example, uterine rupture, admission to intensive
care unit, septicaemia)
Rayburn 1999 reported rates of uterine rupture, and there were
no events in either the PGE group or control group participants
(Analysis 2.3).
There was no information on vaginal birth not achieved within 24
hours, length of hospital stay, use of emergency services, maternal
or caregiver satisfaction, or serious neonatal morbidity or perinatal
death.
Additional outcomes of interest
Measures of effectiveness
Vaginal birth not achieved within 48 and 72 hours
Buttino 1990 reported on the number of women not giving birth
within 48 to 72 hours, and although results favoured the PGE
group, did not show a clear difference as the confidence intervals
just crossed the line of no effect (RR 0.83, 95% CI 0.68 to 1.02;
43 women; 1 study; Analysis 2.4; low-quality evidence).
Oxytocin augmentation
There was no strong evidence of differences between groups for
the number of women who received oxytocin augmentation (RR
0.67, 95% CI 0.40 to 1.12; 84 women; 1 study; Analysis 2.5).
Randomisation to birth interval, and pain relief requirements were
not reported under this comparison.
Complications
The impact of interventions on maternal health were explored in
five studies (Buttino 1990; Larmon 2002; Lien 1998; McKenna
1999; Rayburn 1999).
There was no clear evidence of differences between women who
received intracervical PGE and placebo or expectant manage-
ment for the following outcomes:
• Uterine hyperstimulation (with FHR changes) (RR 2.66,
95% CI 0.63 to 11.25; 488 women; 4 studies; Analysis 2.6; low-
quality evidence).
• Assisted (instrumental) vaginal birth (RR 1.29, 95% CI
0.85 to 1.96; 538 women; 4 studies; Analysis 2.7).
• Caesarean section (RR 0.90, 95% CI 0.72 to 1.12; 674
women; 7 studies; Analysis 2.8; moderate-quality evidence).
• Apgar score less than seven at five minutes (RR 0.82, 95%
CI 0.42 to 1.60; 515 infants; 4 studies; Analysis 2.9).
• NICU admission (RR 1.61, 95% CI 0.43 to 6.05; 215
infants; 3 studies; Analysis 2.10; low-quality evidence).
• Postpartum haemorrhage (RR 3.10, 95% CI 0.13 to 73.16;
61 women; 1 study; Analysis 2.11).
• Serious maternal complications (considered as separate
outcomes, e.g. intensive care unit admission, septicaemia, uterine
rupture)
◦ Chorioamnionitis (RR 2.03, 95% CI 0.66 to 6.18;
468 women; 3 studies; Analysis 2.12).
◦ Endometritis (RR 1.60, 95% CI 0.27 to 9.37; 174
women; 2 studies; Analysis 2.13).
◦ Maternal side effects (RR 0.59, 95% CI 0.13 to 2.77;
384 women; 2 studies; Analysis 2.14).
The included studies did not provide information on other re-
view outcomes including uterine hyperstimulation (without FHR
changes), perinatal death, other serious maternal complications
such as admission to intensive care, and other serious neonatal
complications such as the use of antibiotics, and neonatal infec-
tion.
Non-prespecified outcomes
All seven studies collected information on progress towards labour
and birth; again reported outcomes were different in each study
(Buttino 1990; Gittens 1996; Larmon 2002; Lien 1998; Magann
1998; McKenna 1999; Rayburn 1999).
Buttino 1990 and Lien 1998 reported no differences between
women in the PGE and control groups in the time interval
(days) between the first dose of drug or placebo and birth (SMD
-0.20 days, 95% CI -0.55 to 0.14; 133 women; 2 studies; Analysis
2.15).
Larmon 2002 found no differences between groups for themedian
number of days from recruitment to hospital admission (16.8 days
for the PGE group versus 15.4 days for the control group (data
not shown)). For other outcomes reported in this study (Bishop
score on admission, and estimated gestational age on admission)
there were no clear differences between groups. However, some
women were admitted for induction rather than in labour and it
was not clear if these mean figures included all women.
Lien 1998 and Magann 1998 reported the estimated gestational
age at birth (in weeks) and found no difference between groups
for this outcome (MD -0.06 weeks, 95% CI -0.35 to 0.23; 156
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women; 2 studies; I² = 85%; Tau² = 0.04; Chi² = 6.79; Analysis
2.16) (there was high heterogeneity for this outcome and results
should be interpreted with caution). Lien 1998 and Magann
1998 provided information on the number of women requiring
induction for ’postdates’ pregnancy (women reaching 42 weeks’
gestation). In view of high heterogeneity and different clinical
management in the two studies, we did not pool results for this
outcome but have set out the data in Analysis 2.17. While in the
Magann 1998 study more women in the control group required
induction (22 of 35 women) compared to the PGE group (7 of
35 women) the results were difficult to interpret as some women
had been admitted to hospital for induction at an earlier stage
because of changes in Bishop score or for other reasons.
McKenna 1999 reported the median time from recruitment to
admission to hospital; the interval was shorter in the PGE group
compared with control group participants (2.5 days versus 7 days,
P = 0.02). However, reasons for admission included change in
Bishop score, as well as for onset of labour. McKenna 1999 also
reported the number of women delivering within two days of
commencing treatment; more women gave birth within two days
if they had the active treatment (RR 3.10, 95% CI 1.29 to 7.47;
61 women; 1 study; Analysis 2.18).
Rayburn 1999 reported the numbers of women delivering at var-
ious gestational ages (all deliveries). There were no clear differ-
ences between groups at any of the time points measured (data
not shown).
3. Vaginal misoprostol versus placebo: four studies, 274
women
Four studies compared vaginal misoprostol with placebo (Incerpi
2001; McKenna 2004; Oboro 2005; Stitely 2000). In all four
studies the initial dose of misoprostol was 25 µg; in the study by
Incerpi 2001 women received a second dose after three to four
days if labour had not commenced, and in the study by Stitely
2000 a second dose was administered after one day.
Main outcomes
Serious neonatal morbidity or perinatal death (composite
outcome will include, for example, seizures, birth asphyxia
defined by trialists, neonatal encephalopathy, disability in
childhood)
For this comparison, only Oboro 2005 reported on the rate of
perinatal death with no clear differences between groups; there
were no deaths in the active treatment group (N = 38) compared
with one stillbirth (reason not reported) in the control group (N =
39) (RR 0.34, 95% CI 0.01 to 8.14; 77 infants; 1 study; Analysis
3.1; low-quality evidence).
There was no information on other review outcomes such as failure
to achieve vaginal birth within 24 hours, additional induction
agents required, length of hospital stay, use of emergency services,
maternal or caregiver satisfaction, and serious maternal morbidity
or death.
Additional outcomes of interest
Measures of effectiveness
Oxytocin augmentation
Nostudy reported rates of oxytocin augmentationbetween groups;
however,meandose of oxytocin usedwas reported in Incerpi 2001,
and is described in Non-prespecified outcomes.
Pain relief requirements (epidural, opioids)
McKenna 2004 reported similar numbers of women in each group
had epidural anaesthesia (RR 0.98, 95% CI 0.77 to 1.26; 50
women; 1 study; Analysis 3.2). Opioid use was not reported.
Vaginal birth not achieved within 48 and 72 hours, and randomi-
sation to birth interval were not reported in any study.
Complications
There was little information from these studies on the impact of
interventions on mothers’ and babies’ health.
There was no clear evidence of differences between women who
received vaginal misoprostol and placebo for the following out-
comes:
• Uterine hyperstimulation (with fetal heart rate (FHR)
changes) (RR 1.97, 95% CI 0.43 to 9.00; 265 women; 3 studies;
Analysis 3.3; low-quality evidence).
• Uterine hyperstimulation (without FHR changes) (RR
3.64, 95% CI 0.15 to 85.97; 137 women; 2 studies; Analysis
3.4).
• Instrumental vaginal birth (RR 0.91, 95% CI 0.50 to 1.67;
145 women; 2 studies; Analysis 3.5).
• Caesarean section (RR 0.94, 95% CI 0.61 to 1.46; 325
women; 4 studies; Analysis 3.6; low-quality evidence).
• Apgar score less than seven at five minutes (RR 0.21, 95%
CI 0.01 to 4.25; 248 infants; 3 studies; Analysis 3.7).
• NICU admission (RR 0.89, 95% CI 0.54 to 1.47; 325
infants; 4 studies; Analysis 3.8; low-quality evidence).
• Serious neonatal complications (considered as separate
outcomes).
◦ Neonatal infection (RR 0.30, 95% CI 0.07 to 1.36;
68 infants; 1 study; Analysis 3.10).
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No information was provided in these studies on other review out-
comes including postpartum haemorrhage, use of neonatal antibi-
otics or other maternal or neonatal complications.
Non-prespecified outcomes
Incerpi 2001 reported the mean dose of oxytocin used for each
group; there was no evidence of any difference between the groups
(MD 1508.70 mU, 95% CI -2357.55 to 5374.95; 72 women; 1
study; Analysis 3.11).
Stitely 2000 gave information about the number doses of medica-
tion given to the women (MD -0.44, 95% CI -0.49 to -0.39; 60
women; 1 study; Analysis 3.12) and the number of women requir-
ing subsequent doses on study days two and three; fewer women
received further doses in the intravaginal misoprostol group (P <
0.01 for both time points: day two RR 0.61, 95%CI 0.43 to 0.87;
60 women; 1 study; Analysis 3.13, day three RR 0.13, 95% CI
0.04 to 0.38; 60 women; 1 study; Analysis 3.14).
Oboro 2005 reported that the interval from the commencement of
treatment to hospital admission (in days) was shorter for themiso-
prostol group both for nulliparous and parous women (MD -2.90
days, 95% CI -4.99 to -0.81; 77 women; 1 study; Analysis 3.15).
Data are shown separately for nulliparous and parous women in
Analysis 3.16. There was also evidence from this trial that the ges-
tational age at labour (in weeks) was reduced in the misoprostol
group compared with women in the control group, with labour
approximately a week earlier in the misoprostol group (MD -0.80
weeks, 95% CI -1.05 to -0.55; 77 women; 1 study; Analysis 3.17).
There was also evidence that the time to preterm rupture of mem-
branes (in days) was shorter in the misoprostol group (MD -2.50
days, 95% CI -4.14 to -0.86; 77 women; 1 study; Analysis 3.19),
although it was not clear whether this was the interval from com-
mencement of treatment or from hospital admission.
McKenna 2004 provided data on the interval from treatment to
vaginal birth (in days); the difference between groups was not
clear (MD -1.40 days, 95% CI -3.51 to 0.71; 50 women; 1 study;
Analysis 3.20). McKenna 2004 also reported the mean interval
from recruitment to birth (in days), which was less for the miso-
prostol group compared with women receiving placebo (Analysis
3.21); information was provided separately for nulliparous and
multiparous women (Analysis 3.22). It was not clear whether the
figures included those women who had caesarean sections or other
interventions in labour.
4. Vaginal misoprostol 25 µg versus 50 µg: one study with 52
women
Kipikasa 2005 looked at twodifferent doses of vaginalmisoprostol.
Main outcomes
Additional induction agents required
There were no differences between groups in the number of
women requiring further induction agents (oxytocin) (RR 2.26,
95% CI 0.22 to 23.33; 49 women; 1 study; Analysis 4.1).
There was no information on any other of the review’s main out-
comes: vaginal birth not achieved within 24 hours, length of hos-
pital stay, use of emergency services, maternal or caregiver satis-
faction, serious neonatal morbidity or perinatal death (composite
outcome will include, for example, seizures, birth asphyxia defined
by trialists, neonatal encephalopathy, disability in childhood), and
serious maternal morbidity or death (composite outcome will in-
clude, for example, uterine rupture, admission to intensive care
unit, septicaemia).
Additional outcomes
Measures of effectiveness
No outcomes of measures of effectiveness were reported: vaginal
birth not achieved within 48 and 72 hours, randomisation to
birth interval, oxytocin augmentation, pain relief requirements
(epidural, opioids).
Complications
There was little difference between groups for the following out-
comes:
• uterine hyperstimulation - there were no cases of
hyperstimulation in either group (Analysis 4.2);
• rates of caesarean section (RR 0.94, 95% CI 0.33 to 2.68;
49 women; 1 study; Analysis 4.3); and
• NICU admission (RR 0.57, 95% CI 0.05 to 5.83; 49
infants; 1 study; Analysis 4.4).
Apgar score
One baby in the higher dose group had a low Apgar score (< 6) at
five minutes (data not shown).
There was no information on instrumental vaginal birth, perinatal
death, postpartum haemorrhage (as defined by the trial authors),
serious maternal complications (considered as separate outcomes,
e.g. intensive care unit admission, septicaemia, uterine rupture), or
serious neonatal complications (considered as separate outcomes).
Non-prespecified outcomes
The interval to birth (in days) was reported to be shorter in the
group receiving the higher dose of misoprostol; with women re-
ceiving 50 µg delivering, on average, one and a half days earlier
than those receiving 25 µg (MD 1.50 days, 95% CI 1.19 to 1.81;
49 women; 1 study; Analysis 4.5).
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5. Intracervical PGE versus vaginal misoprostol: one study,
84 women
Main outcomes
One study is included in this comparison between intracervical
PGE and vaginal misoprostol (Meyer 2005). None of the re-
view’s primary outcomes were considered in this study.
Additional outcomes
Measures of effectiveness
No outcomes of measures of effectiveness were reported.
Complications
There was no strong evidence of differences between intervention
and control groups for the following outcomes:
• uterine hyperstimulation (with or without FHR changes)
(RR 0.26, 95% CI 0.03 to 2.73; 64 women; 1 study; Analysis
5.1);
• caesarean section (RR 0.89, 95% CI 0.38 to 2.08; 84
women; 1 study; Analysis 5.2)
• Apgar scores less than seven at five minutes (RR 0.33, 95%
CI 0.01 to 7.96; 84 infants; 1 study; Analysis 5.3); and
• NICU admission (RR 1.25, 95% CI 0.36 to 4.33; 84
women; 1 study; Analysis 5.4).
There was no information on instrumental vaginal birth, perinatal
death, postpartum haemorrhage (as defined by the trial authors),
serious maternal complications (considered as separate outcomes,
e.g. intensive care unit admission, septicaemia, uterine rupture), or
serious neonatal complications (considered as separate outcomes).
Non-prespecified outcomes
It was reported that the proportion of women not requiring oxy-
tocin was 22% in the misoprostol group versus 2% in for those in
the PGE group (P = 0.006). The dose of oxytocin used was also
reported to be decreased in those women receiving misoprostol (P
= 0.008 for cumulative dose of oxytocin) (data not shown) (Meyer
2005).
The interval from the administration of the cervical ripening agent
to admission (hours) was shorter for women who received miso-
prostol (MD 2.50 hours, 95% CI 2.22 to 2.78; 75 women; 1
study; Analysis 5.5), and misoprostol was also reported to increase
by 32% the number of women starting labour or with SROM
during the ripening period (RR 0.31, 95% CI 0.14 to 0.69; 83
women; 1 study; Analysis 5.6).
Misoprostol was reported to increase the number of deliveries
within 24 and 48 hours (RR 0.90, 95% CI 0.75 to 1.07; Analysis
5.7; and RR 0.93, 95% CI 0.81 to 1.06; Analysis 5.8 (respec-
tively); 83 women; 1 study), but the differences between groups
were not clear.
6. Oral misoprostol versus placebo: two studies, 127 women
Main outcomes
Two studies were included in this comparison (Gaffaney 2009;
Lyons 2001). Gaffaney 2009 was assessed as being at high risk
of attrition bias so should have been removed according to the
pre-specified sensitivity analysis. However, there were insufficient
studies in this comparison for meaningful sensitivity analysis.
Vaginal birth not achieved within 24 hours
Women in the oral misoprostol group had a higher rate of vaginal
birth achieved within 24 hours (RR 0.65, 95% CI 0.48 to 0.86;
87 women; 1 study; Analysis 6.1).
Additional induction agents required
Women in the oral misoprostol group had lower rates of additional
induction agents compared to the placebo group (RR 0.60, 95%
CI 0.37 to 0.97; 127 women; 2 studies; Analysis 6.2).
There was no information for length of hospital stay, use of emer-
gency services, maternal or caregiver satisfaction, serious neona-
tal morbidity or perinatal death, or serious maternal morbidity or
death.
Additional outcomes
Measures of effectiveness
Oxytocin augmentation
There was no evidence of a difference between groups for women
who received oxytocin augmentation (RR 0.81, 95% CI 0.61 to
1.08; 87 women; 1 study; Analysis 6.3).
Vaginal birth not achieved within 48 and 72 hours, randomisation
to birth interval, and pain relief requirements (epidural, opioids)
were not reported.
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Complications
There was no evidence of differences between the misoprostol and
placebo groups for the following outcomes:
• uterine hyperstimulation with FHR changes (RR 1.53,
95% CI 0.47 to 5.06; 87 women; 1 studies; Analysis 6.4), or
where it was unclear if there were FHR changes (RR 0.61, 95%
CI 0.06 to 6.21; 40 women; 1 study; Analysis 6.5);
• rate of instrumental vaginal birth (RR 0.51, 95% CI 0.17
to 1.57; 87 women; 1 study; Analysis 6.6);
• rate of caesarean section (RR 0.62, 95% CI 0.28 to 1.33;
86 women; 1 study; Analysis 6.7);
• Apgar scores of less than seven at five minutes (there were
none in either group) (Analysis 6.8);
• NICU admission (RR 1.02, 95% CI 0.07 to 15.84; 87
infants; 1 study; Analysis 6.9);
• postpartum haemorrhage (RR 5.11, 95% CI 0.25 to
103.51; 87 women; 1 study; Analysis 6.10);
• serious maternal complications:
◦ chorioamnionitis (RR 1.06, 95% CI 0.52 to 2.17; 124
women; 2 studies; Analysis 6.11); and
◦ endometritis (RR 0.51, 95% CI 0.05 to 5.44; 87
women; 1 study; Analysis 6.12).
Perinatal death, other serious maternal complication, and serious
neonatal complications are not reported.
Non-pre-specified outcomes
Oral misoprostol may be associated with a reduction in the times
(hours) from first dose to active labour and first dose to birth (MD
-37.08, 95% CI -52.44 to -21.72; 127 women; 2 studies; Analysis
6.13, and MD -37.94, 95% CI -57.97 to -17.91; 87 women; 1
study; Analysis 6.14), which is reflected in the larger total doses
of medication in the placebo group (MD -0.51, 95% CI -0.92 to
-0.10; 40 women; 1 study; Analysis 6.15).
7. Mifepristone versus placebo: five studies, 393 women
We included five studies in this comparison (Elliott 1998;
Frydman 1992; Giacalone 1998; Lelaidier 1994; Stenlund 1999).
Main outcomes
Additional induction agents required
Women in themifepristone groupwere less likely to require further
medication to induce labour compared with those in the control
group (average RR 0.59, 95% CI 0.37 to 0.95; 311 women; 4
studies; I² = 74%; Analysis 7.1). However, there was considerable
heterogeneity for this outcome (I² =74%,Tau² =0.16,Chi² test for
heterogeneity P = 0.009). The wide 95% prediction interval (0.08
to 4.39) indicated that this result should be interpreted cautiously
as some further study might yield a negative result.
Serious neonatal morbidity or perinatal death (composite
outcome will include, for example, seizures, birth asphyxia
defined by trialists, neonatal encephalopathy, disability in
childhood)
Stenlund 1999 examined serious neonatal morbidity (the number
of babies requiring antIconvulsive therapy); there was little differ-
ence between groups (RR 1.56, 95% CI 0.07 to 35.67; 36 infants;
1 study; Analysis 7.2). Lelaidier 1994 reported on perinatal mor-
tality and there were no deaths in either group (Analysis 7.9).
There was no information on vaginal birth not achieved within 24
hours, length of hospital stay, use of emergency services, maternal
or caregiver satisfaction, or serious maternal morbidity or death.
Additional outcomes of interest
Measures of effectiveness
Oxytocin augmentation
There was no evidence that mifepristone had an impact on the
number ofwomenwho required oxytocin augmentation (RR0.89,
95% CI 0.63 to 1.26; 116 women; 2 studies; Analysis 7.3).
Pain relief requirements (epidural, opioids)
A similar number of women in each group used epidural anaesthe-
sia (RR 0.87, 95% CI 0.73 to 1.03; 112 women; 1 study; Analysis
7.4).
Vaginal birth not achieved within 48 and 72 hours, and randomi-
sation to birth interval were not reported.
Complications
There was only limited evidence on the impact of mifepristone on
maternal and neonatal health.
There were no clear differences between the groups for the follow-
ing outcomes:
• instrumental vaginal birth (RR 1.35, 95% CI 0.93 to 1.97;
343 women; 5 studies; Analysis 7.5);
• caesarean section (RR 0.88, 95% CI 0.62 to 1.25; 343
women; 5 studies; Analysis 7.6);
• Apgar score < 7 at five minutes (RR 1.56, 95% CI 0.07 to
35.67; 119 infants; 2 studies; Analysis 7.7);
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• NICU admission (RR 0.93, 95% CI 0.31 to 2.79; 163
infants; 2 studies; Analysis 7.8)
• Serious maternal complications:
◦ uterine scar separation (one women in each group)
(RR 1.00, 95% CI 0.07 to 14.64; 32 women; 1 study; Analysis
7.10); and
◦ chorioamnionitis (RR 2.00, 95% CI 0.20 to 19.91; 32
women; 1 study; Analysis 7.11).
Uterine hyperstimulation (with andwithout fetal heart rate (FHR)
changes), postpartum haemorrhage (as defined by the trial au-
thors), other serious maternal complications, and serious neonatal
complications were not reported.
Non-prespecified outcomes
Stenlund 1999 reported that during the first 48 hours after treat-
ment started, 83.3% of women with mifepristone and 41.7% with
placebo went into labour or had a ripe cervix (RR 2.00, 95% CI
1.00 to 4.00; 36 women; 1 study; Analysis 7.12). The median
time to onset of labour from commencing treatment was 24 hours
10 minutes for women who had mifepristone and 52 hours for
women with placebo. Giacalone 1998 and Stenlund 1999 looked
at failure to achieve changes in the cervix after 24 to 48 hours and
here results favoured the mifepristone group (RR 0.36, 95% CI
0.20 to 0.63; 119 women; 2 studies; Analysis 7.13).
None of the studies reported on the number of women achiev-
ing vaginal birth within 24 hours, but Elliott 1998 described the
number of women in spontaneous labour within 72 hours. There
was no evidence of a difference between groups receiving mifepri-
stone versus placebo (RR 1.46, 95% CI 0.68 to 3.10; 80 women;
1 study; Analysis 7.14). The time to onset of labour was similar
in all three study groups, with a median of 81 hours 15 minutes
for placebo, 80 hours 20 minutes for 50 mg mifepristone, and 75
hours 50 minutes for 200 mg mifepristone.
Giacalone 1998 reported on “spontaneous labour”within 48hours
and results favoured the mifepristone group (RR 2.05, 95% CI
1.27 to 3.30; 83 women; 1 study; Analysis 7.15). There was a
shorter interval between the beginning of treatment and onset of
labour, and between treatment and vaginal birth for the mifepri-
stone group (the median interval to labour onset was 31.7 hours
for mifepristone group versus 53.9 hours for placebo, and 31.3
hours versus 58.5 hours between treatment and birth; with a re-
ported P = 0.02 for both outcomes). Lelaidier 1994 reported a
reduction in oxytocin dose (international units, IU) (MD -2.56
IU, 95% CI -4.01 to -1.11; 32 women; 1 study; Analysis 7.16)
and also reported that the interval between the start of treatment
and the onset of labour (hours) was shorter in the mifepristone
group (MD -22.15, 95% CI -35.96 to -8.34; 32 women; 1 study;
Analysis 7.17). In the Frydman 1992 study, mifepristone reduced
the total dose (described in French as “internationalmeasurement”
units, IM) of oxytocin for women having both vaginal (MD -2.07
IM, 95% CI -3.21 to -0.93; 76 women) and caesarean deliveries
(MD -1.97 IM, 95% CI -3.37 to -0.57; 36 women); however, this
should be interpreted with caution (data not shown).
8. Oestrogen versus placebo: one study, analysis for 87
women
Main outcomes
We included one study (Larmon 2002) in this comparison and
there was no information reported on any of the review’s main
outcomes.
Additional outcomes of interest
Measures of effectiveness
Oxytocin augmentation
Similar numbers of women in each group received oxytocin aug-
mentation (RR 0.93, 95% CI 0.61 to 1.43; 87 women; 1 study;
Analysis 8.1)
There was no information on vaginal birth not achieved within
48 and 72 hours, randomisation to birth interval, and pain relief
requirements (epidural, opioids).
Complications
There was no clear differences between the oestrogen and placebo
groups for:
• instrumental vaginal birth (RR 0.84, 95% CI 0.44 to 1.60;
87 women; 1 study; Analysis 8.2);
• caesarean section (RR 1.27, 95% CI 0.63 to 2.58; 87
women; 1 study; Analysis 8.3);
• NICU admission (RR 0.98, 95% CI 0.06 to 15.13; 87
infants; 1 study; Analysis 8.4)
• serious maternal complications:
◦ chorioamnionitis (RR 1.95, 95% CI 0.38 to 10.12; 87
women; 1 study; Analysis 8.5); and
◦ endometritis (RR 2.93, 95% CI 0.32 to 27.10; 87
women; 1 study; Analysis 8.6).
There was no information for uterine hyperstimulation (with or
without FHRchanges), Apgar score less than seven at fiveminutes,
perinatal death, postpartum haemorrhage, other serious maternal
complications, or serious neonatal complications.
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9. Vaginal isosorbide mononitrate (IMN) versus placebo:
seven studies, 2287 women
We included four trials in this comparison group (Bollapragada
2006a; Bullarbo 2007;Habib 2008; Schmitz 2014). Schmitz 2014
was a large multicenter trial of 1362 women in France which
provided additional data for a range of outcomes for this update.
Main outcomes
There was no clear differences between the vaginal isosorbide
mononitrate and placebo groups for:
• vaginal birth not achieved within 24 hours (RR 0.97, 95%
CI 0.83 to 1.15; 238 women; 1 study; Analysis 9.1);
• additional induction agents required (average RR 0.87,
95% CI 0.75 to 1.00; 4 studies; I² = 66%; Tau² = 0.01; Chi² =
8.92; Analysis 9.2);
• serious neonatal morbidity or perinatal death:
◦ perinatal death (average RR 1.61, 95% CI 0.08 to
33.26; 1712 infants; 2 studies; I² = 48%; Tau² = 2.31; Chi² =
1.94; Analysis 9.5);
◦ neonatal trauma (long bone fracture, collarbone
fracture, basal skull fracture, brachial plexus palsy, facial nerve
palsy, phrenic nerve palsy, or subdural haemorrhage) (RR 0.67,
95% CI 0.19 to 2.37; 1362 infants; 1 study; Analysis 9.6);
◦ neonatal convulsions in first 24 hours (there were no
incidences of this outcome in either group; Analysis 9.7);
◦ tracheal ventilation longer than 24 hours (RR 1.01,
95% CI 0.14 to 7.14; 1362 infants; 1 study; Analysis 9.8);
◦ NICU admission for five or more days (RR 0.67, 95%
CI 0.19 to 2.37; 1362 infants; 1 study; Analysis 9.9);
◦ neonatal transfer (RR 1.07, 95% CI 0.67 to 1.70;
1362 infants; 1 study; Analysis 9.10);
• serious maternal morbidity or death:
◦ maternal death (there were no incidences of maternal
death in either group; Analysis 9.11);
◦ severe postpartum haemorrhage (RR 1.55, 95% CI
0.78 to 3.09; 1362 women; 1 study; Analysis 9.12);
◦ deep vein thrombosis (RR 3.03, 95% CI 0.12 to
74.16; 1362 women; 1 study; Analysis 9.13);
◦ perinatal death (average RR 1.61, 95% CI 0.08 to
33.26; 1712 infants; 2 studies; I² = 48%; Tau² = 2.31; Chi² =
1.94; Analysis 9.5);
◦ neonatal trauma (long bone fracture, collarbone
fracture, basal skull fracture, brachial plexus palsy, facial nerve
palsy, phrenic nerve palsy, or subdural haemorrhage) (RR 0.67,
95% CI 0.19 to 2.37; 1362 infants; 1 study; Analysis 9.6);
◦ neonatal convulsions in first 24 hours (there were no
incidences of this outcome in either group; Analysis 9.7);
◦ tracheal ventilation longer than 24 hours (RR 1.01,
95% CI 0.14 to 7.14; 1362 infants; 1 study; Analysis 9.8);
◦ NICU admission for five or more days (RR 0.67, 95%
CI 0.19 to 2.37; 1362 infants; 1 study; Analysis 9.9);
◦ neonatal transfer (RR 1.07, 95% CI 0.67 to 1.70;
1362 infants; 1 study; Analysis 9.10);
Maternal satisfaction
In four trials, women were asked to rate their satisfaction, however
results could not be meta-analysed due to differences in how ques-
tions were structured. Bullarbo 2007 found no difference in levels
of satisfactionbetweenwomen in the two arms of the trial (Analysis
9.4). Schmitz 2014 asked women to rate their satisfaction, and
whether they would recommend the same treatment, finding that
more women in the IMN group felt very or extremely satisfied,
and would recommend the same treatment (Analysis 9.4). In the
study by Bollapragada 2006a, women were asked to rate their sat-
isfaction with the induction process at home. On five of the six
measures of satisfaction, women in the placebo group were slightly
more satisfied with their care compared with those in the IMN
group, although the differences between groups were not large,
and the mean scores in both groups suggested general satisfaction
(Analysis 9.3). Satisfaction data from Attanayake 2014 could not
be meta-analysed, as only narrative results were provided - they re-
ported that greater than 75% of women in both groups considered
the therapy as a good intervention (rather than inpatient therapy),
and greater than 85% were happy to use outpatient therapy in a
subsequent pregnancy, and would recommend to a friend.
Length of hospital stay, use of emergency services, and caregiver
satisfaction were not reported.
Additional outcomes of interest
Measures of effectiveness
There were no clear differences between the groups for the out-
comes:
• oxytocin augmentation (average RR 0.95, 95% CI 0.78 to
1.14; 1816 women; 3 studies; I² = 72%; Tau² = 0.02; Chi² =
7.11; Analysis 9.14); and
• pain relief requirements (epidural) (RR 0.94, 95% CI 0.82
to 1.09; 350 women; 1 study; Analysis 9.15).
No information was available for vaginal birth not achieved within
48 and 72 hours, or randomisation to birth interval.
Complications
There was no evidence of clear difference between groups for:
• uterine hyperstimulation (with FHR changes) (RR 0.20,
95% CI 0.01 to 4.07; 102 women; 1 study; Analysis 9.16);
• uterine hyperstimulation (unclear if with or without FHR
changes) (RR 0.09, 95% CI 0.01 to 1.62; 200 women; 1 study;
Analysis 9.17);
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• Instrumental vaginal birth (RR 0.81, 95% CI 0.61 to 1.07;
1712 women; 2 studies; Analysis 9.18);
• caesarean section (RR 0.99, 95% CI 0.87 to 1.14; 2286
women; 6 studies; Analysis 9.19);
• Apgar score less than seven at five minutes (RR 0.88, 95%
CI 0.44 to 1.76; 2214 infants; 5 studies; Analysis 9.20);
• NICU admission (RR 0.89, 95% CI 0.59 to 1.36; 1068
infants; 6 studies; Analysis 9.21);
• perinatal death (reported in Serious neonatal morbidity or
perinatal death);
• postpartum haemorrhage (> 500 mL) (RR 1.13, 95% CI
0.95 to 1.36; 2214 women; 5 studies; Analysis 9.22); and
• serious neonatal complications:
◦ neonatal infection (RR 1.00, 95% CI 0.26 to 3.89;
200 infants; 1 study; Analysis 9.23).
No other serious maternal complications were reported.
Non-prespecified outcomes
IMN use was associated with increased side effects, including nau-
sea (RR 2.39, 95% CI 1.54 to 3.70; 1926 women; 4 studies; I² =
37%; Tau² = 0.07; Chi² = 4.78; Analysis 9.24), and particularly
headaches (RR 5.45, 95% CI 3.38 to 8.81; 2300 women; 7 stud-
ies; I² = 76%; Tau² = 0.21; Chi² = 21.09; Analysis 9.25). In one
study 22/112 women in the IMN group reported severe headaches
compared with only 1/108 in the placebo group (RR 21.21, 95%
CI 2.91 to 154.65; 220 women; 1 study; Analysis 9.26).
Several measures of progress in labour were reported, with one to
three trials available per outcome. In general, results indicate that
IMN increased the likelihood of being admitted in established
labour within 24 hours (RR 2.75, 95% CI 1.29 to 5.88; 200
women; 1 study; Analysis 9.27) and caused changes in the Bishop
score (Bishop score < 6 or active labour at 36 hours: RR 3.80, 95%
CI 1.54 to 9.40; 102 women; 1 study; Analysis 9.28, Bishop score
on admission after treatment: MD 2.73, 95% CI 2.17 to 3.29;
200 women; 1 study; Analysis 9.30. Change in Bishop score: MD
2.76, 95%CI 2.48 to 3.03; 272 women; 2 studies; Analysis 9.31).
Time in hours from admission to birth (days) was also reduced
(MD -4.7 hours, 95% CI -6.08 to -3.31; I² =42%; Tau² =0.63;
374 women; 3 studies; Analysis 9.29).
However, Agarwal 2012 reported that the interval from onset of
labour to birth (hours)was not different between IMNandplacebo
(MD -1.24 hours, 95% CI -1.82 to -0.66; 200 women; 1 study;
Analysis 9.32), and Bollapragada 2006a reported that the rate of
cervix unchanged after 48 hours was higher in the IMN group
compared to placebo (RR0.83, 95%CI 0.70 to 0.97; 257women;
1 study; Analysis 9.33).
Bollapragada 2006a also reported the mean interval from hospi-
tal admission to birth (hours) for all women (MD -0.70 hours,
95% CI -6.11 to 4.71; 128 women; 1 study; Analysis 9.34), and
for those women having vaginal deliveries, along with the mean
change in Bishop scores at 48 hours after baseline; there were no
differences between groups for any of these outcomes (data not
shown).
Bollapragada 2006a collected information on the cost of provid-
ing care; the mean overall cost of the care (GBP) package was
very similar for women in both groups (MD 11.98 GBP, 95% CI
-105.34 to 129.30; Analysis 9.35).
10. Acupuncture versus routine care: one study 56 women
Harper 2006 presented limited information relevant to this re-
view. The intervention did not appear to have any impact on the
number of women requiring additional agents to induce labour
(RR 0.60, 95% CI 0.31 to 1.17; 56 women; 1 study; Analysis
10.1) or having caesarean section (RR 0.43, 95% CI 0.17 to 1.11;
56 women; 1 study; Analysis 10.2). There were no clear differ-
ences between groups for women starting labour spontaneously,
cervical dilatation at hospital admission, or the mean time from
study enrolment to birth (data not shown). No further main or
additional outcomes were reported in this study.
11. Outpatient amniotomy for induction of labour versus
routine care: one study, 521 women
Rijnders 2011 was an unblinded trial that randomised 521 women
to amniotomy in an outpatient setting (at home) for induction
between 292 and 294 days gestation, or routine care (as per local
guidelines, this was referral to an obstetrician for foetal assessment
on themorning of day 294). Rijnders 2011 was assessed as being at
high risk of attritionbias so should have been removed according to
the pre-specified sensitivity analysis. However as this was the only
study in this comparison, sensitivity analysis was not performed.
Main outcomes
Maternal satisfaction
While measures of maternal satisfaction were higher in the am-
niotomy at home group (look back positively on treatment: RR
1.04, 95% CI 0.97 to 1.10; 404 women; 1 study; Analysis 11.1.
Would have preferred other treatment: RR 0.51, 95% CI 0.36
to 0.72; 472 women; 1 study; Analysis 11.2), the proportion of
women completing the survey was higher in the amniotomy group
(82% versus 73%), and it seems likely that a response bias may
have occurred for surveys conducted in home settings.
There was no information on vaginal birth not achieved within
24 hours, additional induction agents required, length of hospi-
tal stay, use of emergency services, caregiver satisfaction, serious
neonatal morbidity or perinatal death (composite outcome will
include, for example, seizures, birth asphyxia defined by trialists,
neonatal encephalopathy, disability in childhood), or serious ma-
ternal morbidity or death (composite outcome will include, for
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example, uterine rupture, admission to intensive care unit, septi-
caemia).
Additional outcomes of interest
Measures of effectiveness
Oxytocin augmentation
Fewer women had augmentation or induction or both in the out-
patient amniotomy group than in the routine care group (RR0.83,
95% CI 0.71 to 0.97; 521 women; 1 study; Analysis 11.3).
Pain relief requirements (epidural, opioids)
There was little difference between groups for women receiving
epidural or opioids or both (RR 0.99, 95% CI 0.76 to 1.30; 521
women; 1 study; Analysis 11.4).
Vaginal birth not achieved within 48 and 72 hours and randomi-
sation to birth interval were not reported.
Complications
There were no clear differences between the groups for the follow-
ing outcomes:
• instrumental vaginal birth (RR 0.70, 95% CI 0.46 to 1.08;
521 women; 1 study; Analysis 11.5);
• caesarean section (RR 1.20, 95% CI 0.78 to 1.86; 521
women; 1 study; Analysis 11.6);
• Apgar score less than seven at five minutes (RR 1.86, 95%
CI 0.34 to 10.06; 521 women; 1 study; Analysis 11.7); and
• NICU admission (RR 1.09, 95% CI 0.64 to 1.85; 521
women; 1 study; Analysis 11.8).
Therewas no information for uterine hyperstimulation (with FHR
changes), uterine hyperstimulation (without FHR changes), peri-
natal death, postpartum haemorrhage, serious maternal compli-
cations (considered as separate outcomes, e.g. intensive care unit
admission, septicaemia, uterine rupture), or serious neonatal com-
plications (considered as separate outcomes).
Non-prespecified outcomes
Mean duration of birth (hours) was very similar in each group
(MD 0.40 hours, 95% CI -0.72 to 1.52; 521 women; 1 study;
Analysis 11.9).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Intracervical PGE compared to placebo for the induction of labour in outpatient settings
Patient or population: women requiring induct ion of labour
Setting: outpat ient clinics and hospitals in the USA
Intervention: intracervical PGE
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with intracervical
PGE
Vaginal birth not
achieved within 24 h
Study populat ion - (0 study) - No included trial re-
ported this outcome.
see comment see comment
Vaginal birth not
achieved in 48 to 72 h
Study populat ion RR 0.83
(0.68 to 1.02)
43
(1 RCT)
⊕⊕©©
LOW 1
1000 per 1000 830 per 1000
(680 to 1000)
Uterine hyperst imula-
t ion (with fetal heart
rate changes)
Study populat ion RR 2.66
(0.63 to 11.25)
488
(4 RCTs)
⊕⊕©©
LOW 1
4 per 1000 11 per 1000
(3 to 45)
Caesarean sect ion Study populat ion RR 0.90
(0.72 to 1.12)
674
(7 RCTs)
⊕⊕⊕©
MODERATE 2
310 per 1000 279 per 1000
(223 to 347)
Serious neonatal mor-
bidity or death
Study populat ion - (0 study) -
see comment see comment
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Serious maternal mor-
bidity or death
Study populat ion - (0 study) -
see comment see comment
Neonatal intensive care
unit admission
Study populat ion RR 1.61
(0.43 to 6.05)
215
(3 RCTs)
⊕⊕©©
LOW 1
28 per 1000 44 per 1000
(12 to 167)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io; OR: odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Wide conf idence interval crossing the line of no ef fect, few events and small sample size (-2).
2 Wide conf idence interval crossing the line of no ef fect (-1).
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Vaginal misoprostol compared to placebo for the induction of labour in outpatient settings
Patient or population: women requiring induct ion of labour
Setting: outpat ient clinics and hospitals in the USA and Nigeria
Intervention: Vaginal m isoprostol
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with vaginal miso-
prostol
Vaginal birth not
achieved within 24 h
Study populat ion - (0 study) - No included trial re-
ported this outcome.
see comment see comment
Vaginal birth not
achieved within 48 and
72 h
Study populat ion - (0 study) - No included trial re-
ported this outcome.
see comment see comment
Uterine hyperst imula-
t ion (with fetal heart
rate changes)
Study populat ion RR 1.97
(0.43 to 9.00)
265
(3 RCTs)
⊕⊕©©
LOW 1
15 per 1000 29 per 1000
(6 to 131)
Caesarean sect ion Study populat ion RR 0.94
(0.61 to 1.46)
325
(4 RCTs)
⊕⊕©©
LOW 2
206 per 1000 194 per 1000
(126 to 301)
Serious neonatal mor-
bidity or death
Study populat ion RR 0.34
(0.01 to 8.14)
77
(1 RCT)
⊕⊕©©
LOW 1
Study reported perina-
tal deaths.
26 per 1000 9 per 1000
(0 to 209)
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Serious maternal mor-
bidity or death
Study populat ion - (0 study) - No included trial re-
ported this outcome.
see comment see comment
Neonatal intensive care
unit admission
Study populat ion RR 0.89
(0.54 to 1.47)
325
(4 RCTs)
⊕⊕©©
LOW 2
147 per 1000 131 per 1000
(79 to 216)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io; OR: odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Wide conf idence interval crossing the line of no ef fect, few events and small sample size (-2).
2 Wide conf idence interval crossing the line of no ef fect and small sample size (-2).
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D I S C U S S I O N
Summary of main results
The included studies examined 11 different types of interventions
in outpatient settings. Overall, the results demonstrate that out-
patient induction of labour is feasible and that important adverse
events are rare (Table 1; Table 2; Table 3). However, the safety
data should be treated with considerable caution. First, very few of
the studies provided information on maternal and neonatal death
or serious morbidity. It may not be safe to assume that because
adverse outcomes were not reported, they did not occur. Further,
even where outcomes such as perinatal mortality, maternal com-
plications or serious neonatal morbidity were reported, the finding
that there was no apparent difference between groups was not sur-
prising as none of these studies had the statistical power to detect
differences for such rare outcomes in relatively low-risk popula-
tions.
There was some evidence that, compared with placebo or no treat-
ment, induction agents reduced the need for further intervention
to induce labour, and potentially shorten the interval from inter-
vention to birth. However, we were unable to pool results on out-
comes relating to progress in labour, as studies tended to measure
a very broad range of outcomes.
There was no evidence that induction agents increased inter-
ventions in labour such as operative deliveries. Only five studies
(Attanayake 2014; Bollapragada 2006a; Bullarbo 2007; Rijnders
2011; Schmitz 2014) collected information on women’s views
about the induction process, and overall there was very little in-
formation on the costs to health services of different methods of
induction of labour in outpatient settings.
Few studies reported on maternal satisfaction. The Bollapragada
2006a trial suggested that women receiving isosorbide mononi-
trate were less satisfied than controls. This finding may have been
associated with the relatively high number of women in the in-
tervention group experiencing unpleasant side effects (particularly
headaches) during the treatment period.
Overall completeness and applicability of
evidence
It is debatable what would constitute definitive evidence on the
effectiveness and safety of various induction protocols in the out-
patient (home) environment. The issues that are likely to be im-
portant to women and healthcare providers were not adequately
addressed in the included trials in this review or a relatedCochrane
Review comparing home and hospital inductions (Kelly 2013).
Safety
Adverse events in the pregnant populationofwomenwho are likely
to be eligible for outpatient induction are rare (Table 1; Table 2).
There is no consensus on what would be an unacceptable risk of an
outpatient induction; views may vary among different healthcare
systems and among women, doctors and healthcare commission-
ers in the same system. Assuming that one additional serious ad-
verse event (e.g. perinatal death/serious morbidity) for every 500
outpatient inductions is considered unacceptable (irrespective of
the cost savings made), a very large randomised trial or meta-anal-
ysis including thousands of women would be needed to be able to
exclude a possibility of such an excess risk. A trial (or meta-analy-
sis) of this size designed to exclude such an excess risk (equivalence
trial) is unlikely to be funded, irrespective of the method used.
In the absence of adequate safety data from randomised trials,
the only pragmatic solution is to rely on observational data from
large cohorts with relatively robust surrogate outcomes such as
emergency caesarean section for presumed fetal distress or emer-
gency transfer to hospital. A paper from Canada (Salvador 2009)
reported on 567 outpatient inductions with no serious complica-
tions, but it is not entirely clear what was included in this compos-
ite outcome.Other surrogate outcomes, such as uterine hyperstim-
ulation or fetal heart rate abnormalities (which have been reported
in some studies (e.g. Ramsey 2005)), may be difficult to interpret
unless there are clear definitions of what these outcomes mean.
The use of common outcomes with agreed definitions applicable
to all healthcare settings would be welcome; see Implications for
research.
Experience of women and staff
Outpatient induction may be more convenient for women, who
may feel more comfortable at home, and prefer being there rather
than in hospital. On the other hand, women may feel worried
about the induction process (especially if they live at some distance
from emergency facilities) and the induction agent may cause side
effects that are distressing, so some women may prefer the reassur-
ance offered by hospital care. We have very limited information
on what women would prefer, and no evidence on whether any
women were forced to make arrangements for rapid transfer to
hospital.
Outcomes such as average time to ’admission in labour’ may be
difficult to understand if there is no clear definition of what this
means. The time may be partly determined by women’s decisions
about when to attend hospital, which may depend on a broad
range of physiological, psychological, social and practical factors.
For example, a woman experiencing unpleasant side effects, living
at a distance from emergency facilities may seek early admission;
under these circumstances the outcome does not serve as a good
proxy for progress in labour. Criteria for admission to hospital in
the trials were frequently not specified and included active labour
(variously defined), ruptured membranes and a range of other
indications. Further, a short interval to admission is not necessarily
a good thing; a very short interval means that sending women
home may not be worthwhile, a long interval may not be harmful
providedwomen are reasonably comfortable and there is no urgent
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need for birth. A short interval to admission is also meaningless if
it is offset by prolonged and painful labour. Reporting these two
outcomes separately may not, therefore, be helpful.
Measures of cervical change (Bishop score) may also be problem-
atic, for example, mean increases in Bishop scores on hospital ad-
mission, or Bishop scores reaching a certain level at given time
points, are not straightforward to interpret. Such outcomes may
not give any clear idea of when birth will occur, whether more
rapid cervical dilatation is predictive of a more rapid labour, or
whether the birth will be more or less likely to be normal.
Cost
Health service providers may also assume that transferring care to
community or outpatient settings may reduce the total costs of
care; we have no evidence to support this assumption. In the ab-
sence of formal economic evaluation, descriptive information on
the total length of hospital stay for mothers and babies receiving
active or placebo interventions may have been helpful in under-
standing the impact of outpatient procedures on health service
utilisation. Such information was generally not provided. Instead,
studies tended to focus on proxy measures for progress in labour,
but we would advise caution in the way such information is col-
lected and interpreted.
It is possible that different induction agents perform quite differ-
ently at different stages of cervical dilatation or at different gesta-
tional ages. Most included studies recruited women requiring in-
duction for ’postdates pregnancy’. In different studies ’postdates’
was defined differently, and may have been any gestational age be-
tween approximately 39 to 44 weeks; in some studies women were
recruited from 37 weeks. The cervical status at recruitment also
varied considerably with Bishop scores at recruitment being any
value less than nine. One of the included studies recruited women
with diabetes; there is insufficient evidence to know whether out-
patient induction is safe and acceptable for women in high-risk
groups.
With one or two exceptions, information on costs to women was
generally not reported in the included trials. In the absence of
such data the assumption must be that women were not asked
for their views on care, or about costs or inconvenience associated
with hospital or outpatient care. The potential importance of such
outcomes (patient-related outcomemeasures) is increasingly being
recognised by commissioners of healthcare services.
Quality of the evidence
Most included studies were assessed as being at relatively low risk
of bias; most of the trials were placebo controlled with adequate
methods of randomisation and low levels of attrition. There was
no blinding in eight trials where interventions were compared with
no intervention or routine care. Lack of blinding may be a partic-
ular problem in these studies, as many of the outcomes reported
may have depended on clinical judgements by staff (e.g. need
for hospital admission, prescription of additional drugs to induce
or augment labour, and other interventions in labour). In other
words, clinical decisions may have been affected by knowledge of
treatment allocation. Summaries of ’Risk of bias’ assessments are
presented in Figure 3 and Figure 2.
For the comparison of vaginal PGE versus placebo or expectant
management for the induction of labour in outpatient settings,
we graded evidence for uterine hyperstimulation (fetal heart rate
(FHR) changes unclear), caesarean section, and neonatal intensive
care unit (NICU) admission as low quality (Summary of findings
for the main comparison). There was no evidence for vaginal birth
not achieved within 24 hours, vaginal birth not achieved in 48 to
72 hours, serious neonatal morbidity or death, or serious maternal
morbidity or death.
For the comparison of intracervical PGE versus placebo, we
graded the evidence for vaginal birth not achieved in 48 to 72
hours, uterine hyperstimulation (with FHR changes), and NICU
admission as low quality, and evidence for caesarean section as
moderate quality (Summary of findings 2). Vaginal birth not
achieved within 24 hours, serious neonatal morbidity or death,
and serious maternal morbidity or death were not reported.
For the comparison of vaginal misoprostol versus placebo, we
graded the evidence as low for uterine hyperstimulation (with FHR
changes), caesarean section, serious neonatal morbidity or death,
and NICU admission (Summary of findings 3). Vaginal birth not
achieved in 24 hours, vaginal birth not achieved within 48 and 72
hours, and serious maternal morbidity or death were not reported.
Evidence across the three comparisons was downgraded for im-
precision of effect estimates, few events, and small sample sizes.
Potential biases in the review process
We acknowledge that there was a possibility of introducing bias
at every stage of the review process. We attempted to minimise
bias in a number of ways; two review authors assessed eligibility
for inclusion, carried out data extraction and assessed risk of bias.
Each worked independently. Nevertheless, the process of assessing
risk of bias, for example, is not an exact science and includes many
personal judgements. Further, the process of reviewing research
studies is known to be affected by prior beliefs and attitudes. It is
difficult to control for this type of bias.
While we attempted to be as inclusive as possible in the search
strategy, the literature identified was predominantly written in En-
glish and published in North American and European journals.
We did not attempt to formally assess reporting bias, constraints
of time meant that assessment of risk of bias largely relied on in-
formation available in the published trial reports and thus, report-
ing bias was not usually apparent. Too few studies were included
in each comparison in the review to allow us to explore possible
publication bias.
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Agreements and disagreements with other
studies or reviews
A number of related Cochrane Reviews have examined the same
methods of induction of labour considered in this review, namely:
vaginal PGE (Thomas 2014), intracervical PGE (Boulvain
2008), vaginal misoprostol (Hofmeyr 2010), oral misoprostol
(Alfirevic 2014), mifepristone (Hapangama 2009), oestrogens
(Thomas 2001), nitric oxide donors (Ghosh 2016) and acupunc-
ture (Smith 2013). Compared with these other reviews (which
included both hospital (inpatient) and home (outpatient) induc-
tions), the current review contains relatively few studies, and there-
fore, has insufficient statistical power to demonstrate differences
between groups. This is particularly the case for relatively rare out-
comes such as uterine rupture, but is also true for more common
complications such as uterine hyperstimulation.
Evidence from the related Cochrane Reviews is mainly in agree-
ment with the findings of this review. Findings from these reviews
indicate that compared with placebo, PGE (vaginal and intrac-
ervical) and vaginal and oral misoprostol are effective induction
agents in that vaginal birth within 24 hours was more likely for
women receiving these agents. There is less evidence regarding the
effectiveness of mifepristone, oestrogens, nitric oxide donors (in-
cluding IMN) and acupuncture. Findings regarding safety suggest
that some methods of induction (PGE and vaginal misoprostol)
may be associated with an increased risk of uterine hyperstimula-
tion. However, despite the relatively large number of studies in-
cluded in some of these reviews, even pooled results from studies
do not provide strong evidence regarding serious maternal and
neonatal morbidity and death; as we have discussed above, with
such rare outcomes very large trials are needed to exclude excess
risk, or risk must be imputed by examining surrogate outcomes.
None of these reviews specifically considered the issue of outpa-
tient induction and wemust remain cautious about assuming that
methods that appear safe in hospital will achieve the same levels
of safety (and indeed effectiveness) in outpatient settings. As we
have indicated in this review, related reviews also illustrate that
very little attention has been paid to consumer views or the costs
of care.
Most of the related Cochrane Reviews examined the effectiveness
of induction agents compared with placebo. Relatively few studies
have examined differentmethods of induction directly.Where dif-
ferent agents have been compared (e.g. IMN with vaginal PGE
(Osman 2006)) some agents may have advantages over others, and
the safety profile of different agents (and doses) may differ. This
may mean that they are more or less suitable for outpatient use.
Another Cochrane Review compared the same method of induc-
tion in home and hospital settings directly, but this review con-
tained only four trials and was unable to shedmuch light on issues
of either the relative effectiveness, safety or costs associated with
outpatient induction (Kelly 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Induction of labour in outpatient settings appears feasible. We do
not have sufficient evidence to determine which methods are most
safe or effective in outpatient settings.
Implications for research
There have been very few direct comparisons between different
methods of labour induction in outpatient settings. Although it is
likely that impact on cervix and uterine contractility will be sim-
ilar in both inpatient and outpatient settings, it would be unwise
to extrapolate the clinical outcomes from inpatient to outpatient
settings. For this reason, it would be important to carry out fur-
ther studies where various women-friendly outpatient protocols
are compared head-to-head. As part of such work it is important
to ask women what sort of management they would prefer. There
needs to be more careful consideration of outcomes purporting
to measure progress in labour and more consistency in what is
measured in trials. Little is known regarding women’s preferences,
and what combinations of treatment and setting would be most
preferred.
It would be particularly helpful to carry out formal cost-effec-
tiveness analysis which includes the use of emergency services.
Data on the utilisation of out of hours community health services
and emergency ambulance services might enable those providing
health services to decide the best types of induction agents to use,
to set out criteria for selecting women for outpatient induction,
and would enable women to make more informed choices about
their care.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agarwal 2012
Methods Parallel randomised, single-blind, placebo-controlled trial.
Participants Setting: Safdarjung Hospital, New Delhi, India.
200 women randomised.
Inclusion criteria: singleton pregnancy, > 40 completed weeks, unfavourable cervix
(Bishop score < 6), absence of uterine contractions, intact membranes
Exclusion criteria: fetal malpresentation, pre-partum haemorrhage, previous uterine in-
cision, ruptured membranes, high-risk factors such as pre-eclampsia, oligohydramnios,
intrauterine growth restriction, diabetes mellitus, heart disease, and hypertension, or any
contraindication to receive IMN or prostaglandins such as a known allergy to the drugs,
bronchial asthma, hypotension, and palpitations
Interventions Intervention group: 2 x 40 mg tablets of IMN self-administered at home, vaginally, 1 of
the tablets at 9 AM and the other at 9 PM the same day and to report to the hospital
the next day at 9 AM for admission
Control group: 2 x 40 mg tablets of pyridoxine as placebo IMN self-administered at
home, vaginally, 1 of the tablets at 9 AM and the other at 9 PM the same day and to
report to the hospital the next day at 9 AM for admission
Both arms received labour induction protocol on return to hospital
Outcomes Primary outcomes
• Bishop scores at baseline and on admission.
• Time from admission to birth, whether vaginally or caesarean.
• Presence or absence of tachycardia, hypotension, headache, and palpitations.
• The fetal outcome variables were Apgar scores at 1 and 5 minutes
• Whether admission to the neonatal nursery was necessary.
Secondary outcomes
• Unscheduled admissions for reasons other than onset of labour.
• The need for inpatient cervical ripening treatment.
• A subsequent need for oxytocin.
• Operative birth rates, and complications such as uterine hyperstimulation,
tachysystole, meconium-stained liquor, and PPH.
Notes Added for 2017 update.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Paper states the randomisation codes were
generated using a random allocation se-
quence, and that the random number ta-
ble was generated by the statistician using
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Agarwal 2012 (Continued)
a computerised random number table
Allocation concealment (selection bias) Unclear risk The participants were enrolled by the first
author and assignment to the study or con-
trol group was done in accordance with
the list of codes, which was generated by
the second author. However, did not state
whether random sequence was concealed
or not
Blinding (performance bias and detection
bias)
Women
Low risk It was a single-blind trial as the partic-
ipants did not know whether they were
given IMN.However, it seems that person-
nel were unblinded
Blinding (performance bias and detection
bias)
Clinical staff
High risk It was a single-blind trial as the partic-
ipants did not know whether they were
given IMN.However, it seems that person-
nel were unblinded
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not specifically stated, however based on
above it is possible outcome assessors were
unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data complete for all partici-
pants.
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk None identified.
Attanayake 2014
Methods Double blind RCT.
Participants Setting: Academic Obstetric Unit of the Teaching Hospital Mahamodara, Galle, Sri
Lanka
Inclusion criteria: uncomplicated pregnancy at 39 weeks’ gestational age (GA) with a
singleton fetus having a cephalic presentation and a modified Bishop score < 5 out of
10, and consenting to self-administer the vaginal tablets every other day for 5 days
Exclusion criteria: any pregnancy complications, e.g. hypertension or hyperglycaemia in
pregnancy, multiple pregnancies, planned caesarean birth, fetal growth restriction and
history of hypersensitivity or idiosyncratic reaction to nitrates
Interventions Intervention: self-administer vaginally at home every other day, 5 doses of 60 mg of the
sustained release form of isosorbide mononitrate (ISMN) from 273 days to 282 days
Control: pyroxidine 10 mg, using same regimen.
In both arms, participants were instructed to self-administer the tablets vaginally at home
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at GAs of 39 weeks, 39 weeks + 2 days, 39 weeks + 4 days, 39 weeks + 6 days and
40 weeks + 1 day, unless spontaneous onset of labour (SOL) was established and she
needed admission to hospital. If SOL was not established by 40 weeks + 2 days, all
participants were admitted to hospital, the MBS was re-assessed and artificial separation
of membranes was carried out if feasible, and if not feasible, a cervical massage were
carried out. Thereafter the routine management guideline for cervical ripening and IOL
of the unit were followed using artificial separation of membranes, prostaglandin (PGE
3 mg tablets) vaginally or intra cervical Foley catheter, followed by amniotomy and
intravenous oxytocin infusion, if SOL was not established by 41 weeks. On admission
to hospital either with SOL or at 40 weeks + 2 days, compliance to the interventions was
assessed by checking the cards which the participants had been requested to maintain,
indicating when they self administered the study medication
Outcomes Outcomes stratified:
• Spontaneous onset of labour between 39 weeks and 40 weeks + 2 days
• Mode of birth between 39 weeks and 40 weeks + 2 days
• Modified Bishop score at GAs of 40 weeks + 2 days and 40 weeks + 5 days, and
change in modified Bishop score between these dates
• Requirement of additional cervical ripening measures (vaginal PGE
or intracervical Foley catheter) between 40 + 5 weeks and 40 + 6 weeks
• Newborn outcomes: birthweight and vital status outcome; admission to SCBU
• Side effects (headache, dizziness, vomiting, nausea)
Satisfaction and acceptability
For pregnancies reaching 41 weeks:
• Modified Bishop score
• Requirement of IOL or augmentation
• Induction birth interval
• Mode of birth
Notes This study was reported in a brief abstract. We attempted to contact authors for fur-
ther information (1 September 2016), who provided an unpublished version of the
manuscript (accepted for publication)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Article states “Using computer generated random numbers par-
ticipants were allocated into the study and control groups by
stratified (Primips / Multips) block randomization”
Allocation concealment (selection bias) Low risk Article states “Two sets of sequentially numbered opaque en-
velopes (one for Primips and one for Multips) were packed with
five tablets of either ISMN-SR 60mgs (Angifree - SR,Microlabs,
Bangalore, India) or five tablets of Pyridoxine 10mgs (HealthAid
Vitamins, Harrow, Middlesex, United Kingdom ) according to
the random allocation sequence in blocks of four, by the second
author”
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Attanayake 2014 (Continued)
Blinding (performance bias and detection
bias)
Women
Unclear risk Study title describes as double blind, no further detail provided
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Study title describes as double blind, no further detail provided
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Study title describes as double blind, no further detail provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data reported for all participants, except for 1 drop out
from intervention arm (ISMN group) who discontinued due to
anxiety
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No other forms of bias identified.
Bollapragada 2006a
Methods RCT.
Participants Setting: large teaching hospital in Glasgow, Scotland, UK.
350 women randomised.
Inclusion criteria: primiparous women at term (gestational age > 37 weeks) with single-
ton pregnancy and Bishop score < 7. Women were scheduled for induction (97% for
prolonged pregnancy: 40 weeks + 10 days gestation). Women recruited were willing to
self-administer vaginal tablets
Exclusion criteria: women with ruptured membranes, aged < 16 years age, who needed
birth within the next 48 h, or with fetal compromise requiring daily fetal monitoring
Interventions Intervention group: self-administered vaginal IMN 40 mg every 16 h to maximum of 3
doses (48 h, 32 h and 16 h prescheduled admission for induction)
Comparison group: self-administered placebo, same regimen as intervention group
Outcomes Time from hospital admission to birth, women’s views on induction process, pain, mode
of birth, cost to NHS, neonatal outcomes
Notes A review author, JaneNorman (JN), was an investigator on this trial. JNwas not involved
in assessing the eligibility of the study for inclusion, data extraction or assessment of risk
of bias
See Eddama 2009 for associated paper on cost outcomes.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer generated sequence.
Allocation concealment (selection bias) Low risk Central randomisation with automated telephone service.
Women were given information and consented after the deci-
sion to induce labour had been made. Randomisation in the
antenatal clinic up to 9 days before treatment commenced
Blinding (performance bias and detection
bias)
Women
Low risk Treatment packs for intervention and control groups were de-
scribed as identical, prepared by pharmacy
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Treatment packs for intervention and control groups were de-
scribed as identical, prepared by pharmacy
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Blinding of outcomes assessors not explicitly stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk 350 randomised. 80 women did not initiate treatment as they
went in to labour before the scheduled time for taking medi-
cation, a further 11 women withdrew (including 2 with breech
presentation). All women randomised were included in an ITT
analysis for primary outcomes (but not in secondary analysis)
Selective reporting (reporting bias) Low risk We examined the protocol for this study and there is no evidence
of reporting bias
Other bias Low risk No baseline imbalance apparent.
Bullarbo 2007
Methods RCT.
Participants Setting: 2 hospitals in Gothenburg, Sweden.
200 women randomised.
Inclusion criteria: women with uncomplicated pregnancies, singleton, cephalic presen-
tation, intact membranes, > 42 weeks’ gestation (confirmed by ultrasound before 20
weeks) normal AFI, reactive NST
Exclusion criteria: serious medical or obstetric complication (daily use of medication),
history of headache, regular contractions, alcohol abuse, intolerance of IMN
Interventions Intervention group: 40 mg IMN intravaginal.
Comparison: placebo.
Review arranged for the next day, if labour had not started then IOL was carried out
according to local protocol
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Bullarbo 2007 (Continued)
Outcomes Additional induction agents required, maternal satisfaction, CS PPH
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
Allocation concealment (selection bias) Low risk Sealed sequentially numbered envelopes.
Blinding (performance bias and detection
bias)
Women
Low risk Described as double blind. Women unaware of assignment.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Staff unaware of treatment assignment; placebo and treatment
identical
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Blnding of outcome assessors not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Report that all women completed the study.
Selective reporting (reporting bias) Low risk Stated outcomes are reported.
Other bias Low risk Baseline characteristics comparable.
Buttino 1990
Methods RCT, 2 arm trial.
Participants Setting: 43 women attending antenatal clinics in California, USA
Inclusion criteria: women with “post-dates” pregnancies (gestational age > 41 weeks
and 6 days based on reliable menstrual history and early ultrasound confirmation) with
reactive NST
Exclusion criteria: contraindications to prostaglandins.
Interventions Intervention group: intracervical PGE 0.5 mg.
Comparison group: visually identical placebo gel.
Women in both groups were observed for 1 h with external fetal monitoring and then
discharged home
47Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Buttino 1990 (Continued)
Outcomes Bishop score on admission, mode of birth, interval to birth, length of labour, infant
birthweight and Apgar score
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk External sequence generation by hospital pharmacy.
Allocation concealment (selection bias) Low risk Coded syringes of identical appearance were dispensed from
pharmacy
Blinding (performance bias and detection
bias)
Women
Low risk Placebo controlled trial. Women and physicians unaware of
group assignment. Identical treatment and placebo
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Placebo controlled trial. Women and physicians unaware of
group assignment. Identical treatment and placebo
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not clear when code was revealed, but investigators were not
involved in the inpatient care of women
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised appeared to be included in the analyses
Selective reporting (reporting bias) Low risk Stated outcomes are reported.
Other bias Low risk No other bias apparent.
Elliott 1998
Methods RCT. 4 arm trial.
Participants Setting: Edinburgh, UK.
80 women recruited with IOL scheduled 72 h after recruitment
Inclusion criteria: primiparous women aged 18 to 40 years, normal viable fetus, 37 to
41 weeks (confirmed by first trimester ultrasound scan), cephalic presentation, Bishop
score < 5
Exclusion criteria: women who showed signs of labour onset, placental insufficiency or
contraindication to mifepristone,
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Elliott 1998 (Continued)
Interventions Intervention: group 1: (25 women) oral mifepristone 50 mg. Group 2: (25 women) oral
mifepristone 200 mg. (In this review we combined both groups in the analysis although
it was not clear how randomisation was achieved in the higher dose study.)
Comparison groups: placebo (2 groups of women 25 compared with the lower dose and
5 with the higher dose. We have combined placebo groups in the analysis in this review
as data were reported together in the results in the study reports; group size was very
unbalanced for the second part of the study)
Outcomes Additional induction agents required, labour within 72 h, CS, oxytocin augmentation.
NICU admission
Notes It was not clear why the placebo group for the higher dose comparison was so small (5
women) or how randomisation was performed to achieve the unbalanced intervention
and control groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Pre-determined randomisation code.”
Allocation concealment (selection bias) Unclear risk “Treatment in predetermined numeric order.” It was not clear
why the group allocation in the placebo arms of the trial were
very unbalanced
Blinding (performance bias and detection
bias)
Women
Low risk “Neither the patient nor the physicianhad knowledge ofwhether
a simple oral dose of mifepristone or placebo was given.”
Blinding (performance bias and detection
bias)
Clinical staff
Low risk “Neither the patient nor the physicianhad knowledge ofwhether
a simple oral dose of mifepristone or placebo was given.”
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Blinding of outcome assessors not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All women randomised seemed to be accounted for in the anal-
ysis, although there was serious imbalance in group size
Selective reporting (reporting bias) Low risk Stated outcomes are reported.
Other bias Unclear risk In the second part of the study (higher dose) the treatment to
placebo ratio was 1:5. It was not clear how randomisation was
performed, or why the control group was so small
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Frydman 1992
Methods RCT 2 arm parallel group design.
Participants 120 women attending an antenatal clinic in a hospital in France, 1990 to 1991
Inclusion criteria: termpregnancy scheduled for induction (range of indications), Bishop
score < 4
Exclusion criteria: malpresentation, ruptured membranes, multiple pregnancy, > 1 pre-
vious CS or known medical condition
Interventions Intervention group: active tablets mifepristone 200 mg. All women received a box with
2 tablets, the first to be taken on the morning of day 1 and the second on the morning
of day 2
Comparison group: placebo tablets. Same regimen as intervention group
IOL scheduled for 4 days after intervention, women reported to the hospital each day
over the 4 day study period and were asked to report drug reactions, pain, bleeding or
contractions
Outcomes Labour within 4-day study period, other induction agents required, duration of labour,
mode of birth, Apgar score < 7 at 5 min
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Tablets were supplied by pharmacy according to a
“balanced randomisation list”. Block size 4
Allocation concealment (selection bias) Low risk Small block size might mean that allocation order
could potentially be anticipated in advance but the
drug packs were described as being of similar ap-
pearance
Blinding (performance bias and detection
bias)
Women
Low risk Described as a double-blind study.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Placebo described as being of similar appearance.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Blinding of outcome assessors not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 120 women were randomised but 8 were excluded
from the results because of a deterioration in their
condition within 12 h of the first pill (3 in the
mifepristone group and 5 in the placebo group)
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Frydman 1992 (Continued)
Selective reporting (reporting bias) Unclear risk Efficacy and safety outcomes not specified in meth-
ods text but many labour and infant outcomes re-
ported
Other bias Unclear risk Additional induction agents were used for some
women so labour and other outcomes may be af-
fected by co-interventions
Gaffaney 2009
Methods Double-blind, placebo-controlled RCT (pilot study).
Participants Setting: Women’s Pavilion at Miller Children’s Hospital, Long BeachMemorial Medical
Center, Long Beach, California
Inclusion criteria: at hospital for prolonged pregnancy surveillance, women at gestational
age of 40 to 42 weeks, singleton gestation, Bishop score < 6/ unfavourable cervix, vertex
presentation, intact membranes, reactive NST, AFI of more than or equal to 5, willing
to forgo induction for 72 h
Exclusion criteria: none specified.
Interventions Intervention: cervical ripening regimen (N = 43)
Subjects were treated daily for up to 3 days with oral capsule containing 100 mg of
misoprostol
Electronic fetal monitoring for 2 h after administration.
Women were asked to return in 24 h to be evaluated for a repeat dosage
During the 3 days of study observation, labour induction was not allowed
If adequate cervical ripening was achieved on days 1 or 2, the next doses of study drug
were withheld
If the Bishop score was 6 or greater or if the patient went into active labour, she was
removed from the study protocol and managed according to standard hospital protocol
After 3 days, all women removed and management was according to routine care
In hospital, maternal FHR monitoring for 2 h.
Control: placebo (unspecified content) daily for 3 days, according to same regimen for
women in the intervention arm (N = 44)
Outcomes Primary outcome: time from study drug administration to birth
Secondary outcome
• frequency of being undelivered by 72 h
• route of birth
• uterine contractile abnormalities
• neonatal outcomes:
◦ Apgar score < 7 at 5 minutes of life
◦ admission to the NICU.
Adverse events:
• uterine contractile abnormalities of tachysystole (defined as more than 6
contractions in 10 minutes noted for 2 consecutive 10 minute periods)
• hypertonus (defined as a single contraction lasting > 2 minutes)
• hyperstimulation syndrome (defined as the presence of tachysystole or
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Gaffaney 2009 (Continued)
hypertonus, associated with prolonged or late FHR decelerations)
• abnormal FHR patterns
• maternal side effects - nausea, pyrosis, dyspepsia, fever, and shivering.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Article states “Randomization of subjects
was completed using a computerized ran-
dom number generator (True Epistat).
Randomization was coordinated by the La-
bor and Delivery pharmacist, who was ap-
prised of each candidate’s eligibility and as-
signed the treatments in sequence based
on the computer-generated randomization
scheme”
Allocation concealment (selection bias) Low risk Article states “All study drugs were pre-
pared by the research pharmacy staff and
packaged to maintain the blinded assign-
ment”
Blinding (performance bias and detection
bias)
Women
Low risk Article states “All study drugs were pre-
pared by the research pharmacy staff and
packaged to maintain the blinded assign-
ment”
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Article states “All study drugs were pre-
pared by the research pharmacy staff and
packaged to maintain the blinded assign-
ment”
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not specifically stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk 9women were excluded from analysis post-
randomisation:
• 3 for safety concerns
• 2 withdrew or withdrawn by doctor
• 3 did not receive intervention
• 1 ineligible
Data on these 9 women not reported.
Selective reporting (reporting bias) Low risk Pre-specified outcome of being undelivered
by 72 h not reported, but results imply all
women still undelivered at that time. All
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Gaffaney 2009 (Continued)
other outcomes reported
Other bias Low risk None identified.
Ghanaie 2013
Methods A double-blind, placebo-controlled RCT.
Participants Setting: Alzahra educational hospital in Rasht city, Iran.
Inclusion criteria
• Nulliparous women
• No complications in pregnancy
• GA > 40 weeks (based on sonography < 20 weeks)
• Singleton pregnancy
• Cephalic presentation
• Bishop score ≥ 4
• AFI ≥ 5
• Normal FHR
• Intact membranes
Exclusion criteria
• Having regular contractions (at least 3 x 45 minute contractions in 10 minutes)
• History of headache
• IMN intolerance
• History of cardiopulmonary disease
• Placenta previa or vaso previa
• Cord prolapse
• History of CS or myomectomy
• Cephalo-pelvic disproportion (CPD)
• Cervical cancer
• Abnormal FHR (tachycardia, bradycardia, deceleration)
• Twin pregnancy
• Non-cephalic presentation
• Polyhydramnios
• High blood pressure (≥ 160/110 mg and proteinuria ≥+1)
• Fetal weight ≥ 3500 g (based on estimated fetal weight (EFW) or sonography)
• Small mother
Interventions Intervention (N = 36): 20 mg isosorbide-5-mononitrate tablets vaginally twice each 12
h prior to admission for IOL. Women asked to come back urgently to the hospital in
case they had leakage, contractions or bleeding. If they had no symptoms they should
come back after 12 h. In the next visit, women were asked about the side effects of the
tablets including headache and palpitations. If the contraction had not started, another
20 mg of IMN was administered and the patients were asked to come back after 12
h. Immediately after hospitalisation, the Bishop score was assessed and induction with
oxytocin was commenced
Control (N = 36): 2 placebo tablets of similar design inserted vaginally twice each 12 h,
prior to admission for IOL (according to regimen described above)
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Ghanaie 2013 (Continued)
Outcomes Change in Bishop score
Mean time to active phase of labour
Admission to birth interval
Type of birth
CS indications (meconium, failure to progress, fetal distress)
Min Apgar
Headache
Palpitation
Need for NICU
Fetal complications
Need for blood transfusion
Notes Article abstract in English, full article in Iranian. An Iranian-speaking colleague (E Shak-
ibazadeh) kindly completed data extraction for risk of bias assessment and additional
data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly allocated to 2
intervention and control groups using ran-
dom blocks
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
Women
Unclear risk The authors have suggested that their study
is a double blind study. However, there is
no further information provided
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk The authors have suggested that their study
is a double blind study. However, there is
no further information provided
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk The authors have suggested that their study
is a double blind study. However, there is
no further information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Full translation required.
Selective reporting (reporting bias) Unclear risk all specified outcomes were reported.
Other bias Unclear risk Full translation required.
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Giacalone 1998
Methods RCT, 2 arm trial.
Participants Setting: study carried out in 2 hospitals in France, 1991 to 1992
84 women randomised.
Inclusion criteria: womenwith gestational age 41weeks and3 days ormore and scheduled
for induction for “post-dates” pregnancy, Bishop score < 6, induction could be postponed
for 48 h
Exclusion criteria: women with multiple pregnancies, ruptured membranes, contraindi-
cation to vaginal birth, no uterine scarring, parity < 4, no FHR abnormalities, serious
medical disease or obstetric complication
Interventions Intervention group: mifepristone 400 mg, single oral dose.
Comparison group: placebo tablets of identical appearance.
Women in both groups returned after 1 day for review. If Bishop score > 6 then women
had labour induction or returned the next day for labour induction
Outcomes Change in Bishop score after 48 h, treatment to birth interval, mode of birth, oxytocin
augmentation, neonatal condition at birth
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Balanced randomisation list in permuted blocks (block size not
stated)
Allocation concealment (selection bias) Low risk Coded drug bottles. The “code for each subject was to be kept
sealed in an opaque envelope to be opened in case of an emer-
gency”
Blinding (performance bias and detection
bias)
Women
Low risk Described as double blind study. Placebo described as being of
identical appearance
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Obstetricians were blinded to group assignment.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Outcome assessors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 84 women were recruited, 1 woman (from the mifepristone
group) was lost to follow up
Selective reporting (reporting bias) Low risk Specified outcomes are reported.
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Giacalone 1998 (Continued)
Other bias Low risk Baselind characteristics of groups are comparable.
Gittens 1996
Methods RCT (little information on study methods).
Participants 32 women.
Setting: New Jersey, USA
Inclusion criteria: women with previous CS, gestational age 39 weeks with Bishop score
< 6
Interventions Intervention group: intracervical PGE repeated weekly.
Comparison group: expectant management.
Outcomes CS.
Notes Brief abstract, little information provided.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information.
Allocation concealment (selection bias) Unclear risk “prospectively randomised.”
Blinding (performance bias and detection
bias)
Women
High risk Not feasible.
Blinding (performance bias and detection
bias)
Clinical staff
High risk No information.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk No information.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Trial reported as abstract only; numbers un-
clear.
Selective reporting (reporting bias) Unclear risk Not enough information to assess.
Other bias Unclear risk Not enough information to assess.
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Habib 2008
Methods RCT.
Participants Setting: 102 women in a Cairo hospital, Egypt.
Inclusion criteria: women at term (> 37 weeks’ gestation) scheduled for induction, sin-
gleton viable fetus, intact membranes, no uterine contractions
Exclusion criteria: malpresentation, placenta previa, previous uterine surgery, contraindi-
cations to induction
Interventions Intervention group: self-administered IMN, 40 mg, 3 doses 12 h apart (scheduled for
36 h, 24 h and 12 h before induction
Comparison group: placebo same regiment as intervention group
Outcomes CS, further induction agents required, PPH, Apgar score > 7 at 5 minutes, NICU
admission, side effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence.
Allocation concealment (selection bias) Low risk Coded treatment packs prepared by pharmacy.
Blinding (performance bias and detection
bias)
Women
Low risk Placebo controlled trial.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Tablets for intervention and placebo not described as though
physicians would not know the difference between them. Staff
and women would be unaware of assignment
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Blinding of outcome assessors not described specifically, though
obstetric staff were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised appear to be accounted for in the analysis
Selective reporting (reporting bias) Low risk Stated outcomes are reported.
Other bias Low risk Demographic characteristics similar. No other bias noted.
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Hage 1993
Methods RCT, placebo controlled trial.
Participants Setting: not clear but probably USA. 36 women.
Inclusion criteria: healthy, nulliparous women, 41 weeks’ gestation and Bishop score < 9
Interventions Intervention group: 2.5mg intravaginal PGE ,with seconddose if labour not established
24 h later
Comparison group: placebo gel, with second dose after 24 h if labour was not established
Outcomes Change in cervix after 48 h.
Notes Information from brief abstract.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomized”.
Allocation concealment (selection bias) Unclear risk No information.
Blinding (performance bias and detection
bias)
Women
Low risk Described as double-blind trial with placebo gel.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Not described specifically but treatment and placebo
both described as gel
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk No information.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Little information on methods. It appeared that all
women were available at follow up
Selective reporting (reporting bias) Unclear risk Abstract only with limited outcome data available.
Other bias Unclear risk Trial reported as abstract only so not able to assess for
other bias
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Harper 2006
Methods RCT with block randomisation.
Participants Setting: outpatient clinic in North Carolina, USA. 56 women randomised
Inclusion criteria: primiparous women at term (39 weeks and 4 days to 41 weeks) with
singleton, cephalic, pregnancy and Bishop score < 7
Exclusion criteria: cannot tolerate acupuncture, uncertain dates, breech presentation,
placenta praevia, contra-indication to vaginal birth
Interventions Cervical examination and ultrasound at recruitment.
Intervention group: acupuncture + routine care on 3 of 4 consecutive days, visits also
included fetal monitoring, treatment by trained acupuncturist to hands, legs and lower
back and low voltage stimulation
Comparison group: routine care with follow up after 3 or 4 days
Outcomes Vaginal birth not achieved in 24 h, additional induction agents required. CS, mean time
to birth
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence in balanced blocks of
2 or 4.
Allocation concealment (selection bias) Low risk Sealed, opaque, sequentially numbered envelopes.
Blinding (performance bias and detection
bias)
Women
High risk Blinding not feasible.
Blinding (performance bias and detection
bias)
Clinical staff
High risk Women and staff would have been aware of treat-
ment.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not described. Birth outcomes would have been as-
sessed separately from the intervention and control
(outpatient acupuncture or no treatment), but report
states that staff were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data were available for all women randomised but
denominators were not clear for some outcomes
Selective reporting (reporting bias) Low risk Stated primary and secondary outcomes are reported
with neonatal outcomes
Other bias Unclear risk Women receiving acupuncture attended for 3 addi-
tional visits where other interventions occurred as
well as acupuncture that may have affected outcomes
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Incerpi 2001
Methods RCT, 2 arm trial.
Participants Setting: Los Angeles hospital, USA, 1996 to 2000.
120 women with diabetes.
Inclusion criteria: women with insulin dependent or other diabetes, gestational age 38
weeks (confirmed by ultrasound), not in labour, normal AFI (> 5 cm), normal FHR.
Women compliant with hospital appointments and home glucose monitoring
Exclusion criteria: women with multiple pregnancies, ruptured membranes, vaginal
bleeding, prior uterine surgery, active genital herpes, glaucoma, serious medical disease,
parity > 5, fetal weight > 4500 g or < 2000 g
Interventions Study over 7 days.
Intervention group: single dose of vaginal misoprostol 25 µg
Comparison group: placebo of similar appearance.
Both groups were observed for 4 h and if there were no signs of fetal distress of painful
contractions women were sent home. Reviewed after 3 to 4 days. If labour had not started
then intervention/placebo was repeated. At 7 days women not in labour were induced
Outcomes Additional induction agents required (oxytocin), mode of birth, uterine hyperstimula-
tion, neonatal condition at birth
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence.
Allocation concealment (selection bias) Low risk Coded drug boxes. Pharmacy prepared and distributed medica-
tion according to the randomisation schedule
Blinding (performance bias and detection
bias)
Women
Low risk Placebo controlled trial.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Placebo and intervention tablets were similar in appearance.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not clear when code revealed.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 120 women randomised and no loss to follow up was apparent
but denominators in the data tables were not always clear
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Incerpi 2001 (Continued)
Selective reporting (reporting bias) Unclear risk Apart fromoutcomeused for sample size, outcomes not specified
in the methods text
Other bias Low risk Baseline characteristics comparable.
Kipikasa 2005
Methods RCT 2-arm parallel group design (dose comparison study).
Participants 52 women attending a large teaching hospital and scheduled for IOL
Inclusion criteria: singleton, cephalic presentation, not in active labour, gestational age
> 40 weeks (confirmed by menstrual dates and ultrasound before 20 weeks)
Exclusion criteria: previous CS, FHR abnormalities, contraindication to prostaglandin
or vaginal birth
Interventions Intervention group: 50 µg oral misoprostol.
Comparison group: 25 µg misoprostol.
Prior to randomisation women received an ultrasound to assess fetal growth and AFV
and a fetal NST was carried out. In both groups medication was administered by a nurse
and in the absence of labour or contraindications the dose was repeated after 3 days to a
maximum of 3 doses over 9 days. Women returned to hospital every 3 days unless labour
started or there was any reduction in fetal kicks
Outcomes Days to birth, uterine hyperstimulation, further induction agents required, CS, Apgar
score < 6 at 5 min, NICU admission, meconium staining, perinatal death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence.
Allocation concealment (selection bias) Low risk Coded drug boxes.
Blinding (performance bias and detection
bias)
Women
Unclear risk Intervention and placebo tablets were cut
from larger tablets (1/4 or 1/8) and de-
scribed as appearing the same
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Staff were said to be blinded because
placebo and intervention tablets indistin-
guishable. We were unsure if they were in-
distinguishable to knowledgeable staff be-
cause they were cut from larger tablets (1/
4 or 1/8)
61Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kipikasa 2005 (Continued)
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Described as blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were some inconsistencies in the fig-
ures; while 49 women seem to have been
randomised there were 52 in the results ta-
bles
Selective reporting (reporting bias) Unclear risk This was a pilot study and secondary mea-
sures for women and infants not specified
in the methods text
Other bias Unclear risk This was a pilot study with limited sam-
ple size. Authors state secondary outcomes
analysed without stratification, but not
what characteristic on which the sample
would be stratified. The authors state the
possibility of type II error due to inadequate
sample size to evaluate neonatal outcomes
Larmon 2002
Methods RCT, 3 arm trial.
Participants Setting: Mississippi, USA (outpatient setting).
136 women randomised.
Inclusion criteria: women at term (37 weeks’ gestation), Bishop score < 6, candidates for
vaginal birth with uncomplicated pregnancy
Exclusion criteria: women with diabetes or serious pregnancy complications including
hypertension, or chronic medical conditions
Interventions Intervention group (1): PGE 0.5 mg intracervical.
Intervention group (2): vaginal oestrogen cream (estradiol) 4 mg
Comparison group: inert lubricant vaginal jelly.
Womenwere assessed weekly until an indication for birth arose.Medication was repeated
weekly
Outcomes Mode of birth, use of oxytocin, condition of newborn.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
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Larmon 2002 (Continued)
Allocation concealment (selection bias) Low risk Opaque, sequentially numbered envelopes.
Blinding (performance bias and detection
bias)
Women
Low risk Placebo controlled.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Interventions not identical; placebo jelly distinguishable from
estradiol cream for staff
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Assessment of outcomes remote from intervention and placebo
administration, but unclear if staff would have been aware of
group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 136 women were randomised, 8 were excluded after randomi-
sation
Selective reporting (reporting bias) Unclear risk Specific outcomes not stated in methods text, apart from sample
size calculation
Other bias Unclear risk Baseline group characteristics are similar.
Lelaidier 1994
Methods RCT.
Participants Setting: not clear.
32 women.
Inclusion criteria: women who had a previous CS with gestational age > 38 and < 42
weeks confirmed by ultrasound. All women were scheduled for induction (21 for “post-
dates”, 7 for hypertension and 4 for FGR); Bishop score < 4
Interventions The study was carried out over a 4 day observation period, induction was planned for the
fourth day (PGE and amniotomy or oxytocin induction if Bishop score > 3). Women
attended the outpatient’s department for NST daily
Intervention group: 200 mg oral mifepristone on days 1 and 2
Comparison group: placebo, same regime as intervention group
Outcomes CS, assisted birth, uterine scar separation, fetal distress.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomisation list” using block design (block size
4)
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Lelaidier 1994 (Continued)
Allocation concealment (selection bias) Low risk Coded drug boxes.
Blinding (performance bias and detection
bias)
Women
Low risk Described as double-blind placebo controlled study. “External
appearance of the tablets was similar.”
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Intervention and placebo tablet described as similar.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Blinding of outcome assessors not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women appeared to be accounted for in the analysis.
Selective reporting (reporting bias) Unclear risk Outcomes not stated in methods text
Other bias Unclear risk Baseline characteristics similar but no formal test (P value) re-
ported
Lien 1998
Methods RCT 2 arm parallel group design.
Participants 90 women attending 4 USA hospitals.
Inclusion criteria: women with post-dates pregnancy (gestational age > 40 weeks + 3
days) attending for FHR testing. Gestation confirmed by ultrasound before 24 weeks,
AFI > 5 cm, reactive NST
Exclusion criteria: malpresentation, multiple pregnancy, previous CS, evidence of hy-
perstimulation or suspicious FHR patterns, grand multiparity (> 4 previous deliveries),
placenta praevia or other contraindications to vaginal birth
Interventions Intervention group: intracervical PGE gel (Prepidil) 0.5 mg
Comparison group: placebo gel.
Gel was inserted by doctor or midwife in an antenatal testing centre or in the labour
unit within rapid transport distance of birth facilities. After insertion there was 40 min
of continuous monitoring. Women returned to hospital after 3 to 4 days for fetal testing
and further gel up to a maximum of 4 doses
Outcomes Further induction agents required, CS rates, uterine hyperstimulation, FHR changes
and side effects
Notes
Risk of bias
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Lien 1998 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence (permuted block de-
sign, but block size not stated)
Allocation concealment (selection bias) Low risk Central randomisation with coded drug boxes.
Blinding (performance bias and detection
bias)
Women
Low risk Treatment and placebo gels were identical and pro-
duced by manufacturer
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Treatment and placebo gels were identical and pro-
duced by manufacturer
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Unblinding was reported to occur only after com-
pletion of all the data collection
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 women that were randomised were not included
in the analysis as they did not meet the inclusion
criteria (the study was described as ITT)
Selective reporting (reporting bias) Unclear risk Specific outcomes not mentioned in results section
apart from sample size calculation
Other bias Unclear risk This is a pilot study. Women in the prostaglandin
group were further over due than women in the
control group, but other baseline characteristics
similar
Lyons 2001
Methods RCT, 2 arm trial.
Participants Setting: 40 women, setting not clear.
Inclusion criteria: women with gestational age 40 to 42 weeks, singleton, cephalic pre-
sentation, intact membranes, Bishop score < 6, reassuring FHR and < 3 contractions in
10 minutes
Interventions Intervention group: 100 mg oral misoprostol, dose repeated every 24 h with maximum
of 3 doses. 2 h continual fetal monitoring after each dose
Comparison group: placebo, with same regime andmonitoring as the intervention group
Outcomes Chorioamnionitis, meconium aspiration, uterine hyperstimulation, mean time to active
labour
Notes Study reported in brief abstract.
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Lyons 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomized”.
Allocation concealment (selection bias) Unclear risk Placebo controlled, no information on randomisation procedure
Blinding (performance bias and detection
bias)
Women
Low risk Described as double-blind, placebo controlled study.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Described as double-blind, placebo controlled study.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All women appeared to have been followed up, but little infor-
mation
Selective reporting (reporting bias) Unclear risk Study reported in brief abstract; unable to assess this bias domain
Other bias Unclear risk Study reported in brief abstract; unable to assess this bias domain
Magann 1998
Methods RCT. 3 arm trial.
Participants Setting: California, USA, women attending a naval medical centre
70 women included in the analysis (2 of 3 treatment arms included, total recruited 105
women)
Inclusion criteria: women with “post dates” pregnancy - gestational age 41 weeks con-
firmed by menstrual dates and pre-20 weeks ultrasound. Uncomplicated pregnancy.
Bishop score < 5
Exclusion criteria: women with any contraindication to vaginal birth
Interventions (1 intervention group had daily membrane stripping; this group has not been included
in the analysis in this review.)
Intervention group: intracervical PGE 0.5 mg, daily for 3 days
Comparison group: gentle cervical examination, daily for 3 days
Women were instructed to return to hospital is they had bleeding, membrane rupture,
regular contractions of reduction in fetal movements. Once Bishop score = 8 or women
reached 42 weeks they were admitted to hospital for induction
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Magann 1998 (Continued)
Outcomes Induced at 42 weeks, CS, instrumental birth. Apgar score < 7 at 5 min, admission to
NICU
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
Allocation concealment (selection bias) Low risk Sealed, opaque, sequentially numbered envelopes.
Blinding (performance bias and detection
bias)
Women
High risk Not feasible.
Blinding (performance bias and detection
bias)
Clinical staff
High risk Not feasible.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Outcome assessment of cervical changes were reported to be
blind; blinding not described for other outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent loss to follow up.
Selective reporting (reporting bias) Unclear risk Outcomes not stated in methods text.
Other bias Low risk Baseline demographics similar.
McKenna 1999
Methods RCT.
Participants Setting: Ohio hospital USA (65 women).
Inclusion criteria: women at term (gestational age > 37 weeks), age > 17 years, Bishop
score < 7. “Well dated pregnancy” with no indication for immediate induction
Exclusion criteria: multiple pregnancy, insulin dependent diabetes, rupturedmembranes,
non-reassuring NST, contraindications to a trial of labour, chronic hypertension
Interventions Intervention group: intracervical PGE 0.5 mg.
Comparison group: placebo.
Both groups had continuous monitoring for 1 h, if labour started women were admitted
to hospital, otherwise they were discharged home
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McKenna 1999 (Continued)
Outcomes Uterine hyperstimulation, further induction agents required,uterine hyperstimulation,
CS
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
Allocation concealment (selection bias) Low risk Placebo controlled trial.
Blinding (performance bias and detection
bias)
Women
Low risk Placebo was described as identical to active PGE .
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Investigators who administered the gel were blinded; however,
prenatal care sometimes delivered by other staff who were aware
of study participation but not treatment
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Unclear if obstetric care staff were aware of study participation
and/or group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 65 women were randomised, there were 4 post randomisation
exclusions
Selective reporting (reporting bias) Unclear risk Trial outcomes not specified in methods text.
Other bias Low risk No baseline imbalance apparent.
McKenna 2004
Methods RCT, 2 arm trial.
Participants Setting: not clear.
68 women included.
Inclusion criteria: women with “well-dated” pregnancies with gestational age > 40 weeks
and Bishop score < 9
Exclusion criteria: current indication for IOL, malpresentation, multiple pregnancy,
previous CS, oligohydramnios (AFI < 5 cm). any contraindication to a trial of labour,
current regular contractions
Interventions All women were assessed prior to randomisation.
Intervention group: vaginal misoprostol 25 µg.
Comparison group: placebo gel.
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McKenna 2004 (Continued)
Fetal and uterine monitoring for 1 h after treatment then women were discharged home.
Labour was induced if BIshop score > 8 after 41 weeks or all women after 42 weeks
Outcomes Uterine hyperstimulation, mode of birth, epidural, Apgar score, NICU admission.
(Women with PROM were given oxytocin to “stimulate labour” but were not included
as inductions in the analyses.)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence performed in hospital pharmacy.
Allocation concealment (selection bias) Low risk Placebo controlled trial.
Blinding (performance bias and detection
bias)
Women
Low risk Placebo of similar appearance.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Investigators blinded but other prenatal care providers aware of
study participation
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Blinding of outcomes assessors not described. Obstetric staff
aware of study participation. Birth and obstetric data taken from
computerised records
Incomplete outcome data (attrition bias)
All outcomes
Low risk 68 women were randomised, 4 were excluded after randomisa-
tion and did not receive the study medication, but were included
in an ITT analysis
Selective reporting (reporting bias) Unclear risk Outcomes (apart from sample size calculation) not mentioned
in methods text
Other bias Unclear risk No baseline imbalance apparent.
Meyer 2005
Methods RCT 2-arm parallel group design.
Participants 84 women attending a USA hospital between 1999 to 2001.
Inclusion criteria: singleton, cephalic presentation, intact membranes, Bishop score of 6
or less, reactive NST
Exclusion criteria: rupturedmembranes, Bishop score > 6, contraindication to induction,
> 3 contractions in 10 min, uterine scar
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Meyer 2005 (Continued)
Interventions Intervention group: vaginal misoprostol 25 µg.
Comparison group: intracervical PGE gel (dinoprostone) 0.5 mg
Women in both groups were randomised after a reactive NST. After drug administration
women had continuous FHRmonitoring for 3 h with discharge home if clinically stable.
Women were asked to return the next day (after 18 h) for oxytocin induction if labour
was not established
Outcomes Vaginal birth within 24 or 48 h, uterine hyperstimulation, CS, oxytocin required, Apgar
score < 7 at 5 min, NICU admission
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Low risk Opaque sequentially numbered envelopes (not
stated whether sealed)
Blinding (performance bias and detection
bias)
Women
High risk Blinding women would be feasible but the study
was not blinded
Blinding (performance bias and detection
bias)
Clinical staff
High risk Study not blinded.
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Study not blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 84 women were randomised (42 in each group), 2
women were lost to follow up in the misoprostol
group but were included in the denominators
Selective reporting (reporting bias) Low risk Primary and secondary outcomes stated inmethods
text and reported
Other bias Low risk None apparent.
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Newman 1997
Methods RCT, 2 arm trial.
Participants 58 women.
South Carolina, USA.
Inclusion criteria: women with diabetes at term or women with prolonged pregnancy (>
42 weeks) requiring induction, Bishop score < 7
Interventions Intervention group: 2 mg intravaginal PGE after reassuring NST, then continuous
fetal monitoring for 3 h. Women were admitted if labour started or cervix favourable.
Treatment repeated after 24 h and 48 h and admitted after third dose
Comparison group: expectant management with weekly assessment of AFI and NST.
Admission in labour or if signs of fetal distress. IOL at 44 weeks
Outcomes Spontaneous labour within 48 h, uterine hyperstimulation, CS
Notes Results reported in brief abstract.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “prospectively randomised”.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
Women
High risk Not feasible.
Blinding (performance bias and detection
bias)
Clinical staff
High risk Not feasible.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Outcomes assessors not mentioned in brief abstract.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Little information. No loss to follow up apparent.
Selective reporting (reporting bias) Unclear risk Trial reported only in brief abstract so unable to assess this bias
domain
Other bias Unclear risk Trial reported only in brief abstract so unable to assess this bias
domain
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O’Brien 1995
Methods Placebo controlled RCT.
Participants Setting: outpatient clinic in Memphis, USA.
100 women recruited.
Inclusion criteria: gestation 38 to 40 weeks with Bishop score < 7
Exclusion criteria: non-reactive NST, oligohydramnios (AFI < 5.0 cm) macrosomia (>
4000 g or 10th centile), medical indication for birth, > 1 previous CS
Interventions All women underwent NST, AFV and ultrasound assessment.
Intervention group: 2 mg intravaginal PGE for 5 consecutive days
Comparison group: identical placebo for 5 consecutive days.
After each dose women were monitored for 30 min to rule out labour or fetal distress.
Women were reviewed twice weekly (NST and AFV)
Outcomes Other induction agents required, uterine hyperstimulation, CS, epidural, chorioam-
nionitis, Apgar score, NICU admission, gestational age at birth
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table. Permuted blocks with variable block
size. The randomisation schedule was kept in pharmacy
Allocation concealment (selection bias) Low risk Coded drug boxes prepared by pharmacy.
Blinding (performance bias and detection
bias)
Women
Low risk Placebo controlled trial.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Investigators blind.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Unclear if obstetric staff other than investigators blind to
study participation. Outcome assessment not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk State that “no post randomisation exclusions were allowed”.
All women included in the analysis
Selective reporting (reporting bias) Unclear risk Specific outcomes not specified in methods text, though cat-
egories were such as ’neonatal outcomes’
Other bias Low risk No baseline imbalance apparent.
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Oboro 2005
Methods RCT, 2 arm trial.
Participants Setting: district hospital in southern Nigeria, 2000 to 2001
77 women randomised.
Inclusion criteria: women with gestational age > 40 weeks, Bishop score < 9, uncompli-
cated pregnancy, candidates for vaginal birth (lack of current indication for induction),
singleton gestation in cephalic presentation
Exclusion criteria: women with previous CS, vaginal bleeding, ruptured membranes of
indication for immediate IOL, uncertain dates, non reactive stress test or estimated fetal
weight > 4500 g
Interventions Intervention group: vaginal misoprostol 25 µg (quarter of 100 µg tablet)
Comparison group: expectant management with gentle vaginal examinations only
Women were monitored for 1 h after treatment. If regular contractions started women
were admitted otherwise they were discharged home
Outcomes Time to birth, GA at birth, proportion of women requiring induction for post-term
birth, length of labour, incidence and severity of side effects, perinatal mortality, Apgar
score, NICU admission
Notes Unbalanced randomisation 24 in intervention group versus 12 in control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated.
Allocation concealment (selection bias) Low risk Sealed, sequentially numbered envelopes (not stated that en-
velopes opaque)
Blinding (performance bias and detection
bias)
Women
High risk Described as an “open” RCT.
Blinding (performance bias and detection
bias)
Clinical staff
High risk Blinding not mentioned; trial described as open.
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Blinding not mentioned; trial described as open.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were available for all women randomised.
Selective reporting (reporting bias) Unclear risk Outcomes mentioned in the methods text are reported, but so
are many other outcomes. Side effects are mentioned in the
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Oboro 2005 (Continued)
methods text and abstract but not defined specifically, so unable
to say if these are reported
Other bias High risk Nulliparous women was different in either arm (58% in miso-
prostol arm versus 49% in control arm). Groups otherwise sim-
ilar at baseline
Rayburn 1999
Methods RCT, 2 arm trial.
Participants Setting: USA. FHR tracings and uterine activity monitored for 20 minutes before ran-
domisation
Inclusion criteria: 294 women who had 1 previous CS and were candidates for vaginal
birth with accurate gestational age dating (39 to 41 weeks) by ultrasound before 20
weeks, with no signs of labour, no fetal growth abnormalities and reassuring FHR tracing.
Bishop score < 6
Exclusion criteria: malpresentation, multiple pregnancies, diabetes, hypertension, vagi-
nal bleeding, ruptured membranes, cephalopelvic disproportion, contraindication to
oxytocic drugs or hypersensitivity to PGE , > 1 previous CS
Interventions Intervention group: intracervical PGE 0.5 mg. Women were monitored for 2 h after
insertion
Comparison group: expectant management.
Women in both groups were reviewed at 40 and 41 weeks for routine assessments
Outcomes Further induction agents required, uterine hyperstimulation, CS, instrumental vaginal
birth, maternal infection, Apgar score at 5 min, side effects, birthweight
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence provided by pharmaceutical com-
pany
Allocation concealment (selection bias) Unclear risk “Blocks of the list were sent with the drugs to the study centres
where new subjects were assigned to the next number on the list
to determine treatment group.”
Blinding (performance bias and detection
bias)
Women
High risk Study described as “open-label”; women in the intervention
group would have been aware of having to go for additional ap-
pointments to receive a gel
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Rayburn 1999 (Continued)
Blinding (performance bias and detection
bias)
Clinical staff
High risk Not feasible. Study says investigators masked to assignment but
unclear if study investigators were in charge of prenatal and
obstetric care of all participant women
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Outcome assessors not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 300 were enrolled but 6 were not included in analysis “because
of improper entry or non compliance with clinic visits”
Selective reporting (reporting bias) Unclear risk Several categories of possible outcomes mentioned in methods
text
Other bias Unclear risk Groups appeared similar at baseline. Research was supported by
the manufacturers of the study intervention (Prepidil)
Rijnders 2011
Methods Unblinded, pragmatic, parallel multicenter RCT.
Participants Setting:multicentre,midwifery practices inNetherlands. The study began in4midwifery
practices, but by the end of the study period recruitment had been rolled out to 46
midwifery practices in the Netherlands
Inclusion criteria
• Low risk pregnant women after 290 days
• Singleton fetus in cephalic presentation
• Received prenatal care in an independent midwifery practice
• Women who fulfilled the criteria and those who gave written informed consent
were enrolled between 292 and 294 days gestation
Exclusion criteria
• Aged < 18 years
• Having had a previous birth resulting in a neonatal infection
• Maternal culture positive for group B streptococcus
• Fetal heartbeat abnormalities
• Being in labour
• Prelabour rupture of membranes
• Non-descended head
• Temperature > 37.5° C
• Language barriers
Interventions Intervention group (N = 270): amniotomy in an outpatient setting (at home) for induc-
tion between 292 and 294 days gestation
Control group (N = 251): routine care following the Dutch guideline for management
of post term pregnancy. The Guideline prescribed referral to an obstetrician for fetal
assessment on the morning of day 294
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Rijnders 2011 (Continued)
Outcomes Primary outcomes
• Spontaneous birth without intervention - intervention defined as induction other
than amniotomy, augmentation of labour, pharmacological pain relief or intra partum
antibiotic treatment
• (A non-medical birth could include continuous or intermittent electronic fetal
monitoring with cardiotocography or an episiotomy.)
Secondary outcomes
• A composite of adverse neonatal outcomes (mortality, admission to NICU,
neonatal infection, Apgar score < 7 after 5 minutes)
• Maternal outcomes: mode of birth, place of birth, duration of birth, medical
interventions, use of antibiotics intrapartum, costs, satisfaction of the woman with the
birth
Intervention group only
• Percentage of women who started labour after amniotomy
Notes PhD thesis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computerised randomisation service was
carried out by an independentMedical Call
Centre available for telephone contact 24
h per day, 7 days a week
While random sequence generationwas ad-
equate, there were 2 problems:
• randomisation was stratified by
parity, and sampling nulliparous to
multiparous in 1:1. However, after 140
cases it was identified that randomisation
procedure was over-sampling primiparous
women. Randomisation procedure was
corrected, and imbalance was ultimately
minor
• In 8 women, midwives called the
randomisation service twice (reason
unspecified). Women who had already
been randomised and allocated were given
a second allocation. This was identified
and corrected. The initial allocation was
used in all 8 cases, and the second
allocation discarded
Above issues do not appear to have affected
the random sequence itself. Hence, low risk
of bias
Allocation concealment (selection bias) Low risk Telephone assignment.
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Rijnders 2011 (Continued)
Blinding (performance bias and detection
bias)
Women
High risk It was not possible to blind participants.
Blinding (performance bias and detection
bias)
Clinical staff
High risk It was not possible to blind participants,
midwives, or other caregivers
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Outcome assessors stated as not blind.
Incomplete outcome data (attrition bias)
All outcomes
High risk Intervention
• Excluded from analysis (N = 1)
• 1 in labour at time of randomisation
Control
• Excluded from analysis (N = 2)
• 1 in labour at time of randomisation
• 1 birth before 292 days gestation
• 3 randomised participants were
found to be ineligible. Analysis data not
available for these participants, so we are
not able to re-include for this review.
These are relatively small and balanced (1
versus 2) so overall impact likely low.
Responses to the satisfaction survey were
not balanced (221 and 183), the response
rate was likely affected by the intervention
(women in intervention arm were in the
home, so response rate was higher)
Selective reporting (reporting bias) Low risk Stated outcomes are reported.
Other bias Low risk Baseline demographics similar.
Sawai 1991
Methods RCT.
Participants Setting: post-dates clinic in Florida hospital USA.
50 women with prolonged pregnancy (> 41 weeks, 287 days).
Inclusion criteria: reactive NST and normal ultrasound, EDD confirmed by menstrual
dates, clinical exam and early ultrasound. Bishop score < 9
Exclusion criteria: malpresentations, multiple pregnancy, diabetes, hypertension, vaginal
bleeding, abnormal FHR, established contractions, macrosomia (> 4500 g), FGR, fetal
abnormalities or oligohydramnios
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Sawai 1991 (Continued)
Interventions Intervention group: Intravaginal PGE gel 2 mg. Repeated twice weekly
Comparison group: placebo gel. Repeated twice weekly.
Uterine activity and FHRwas monitored for 1 to 2 h after gel insertion, if no regular con-
tractions or side effects, women were discharged home returning for weekly sonograms
and AFV assessment, and returning twice weekly for NST and repeat interventions
Outcomes Further induction agents required, uterine hyperstimulation, CS, NICU admission
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly generated assignments.”
Allocation concealment (selection bias) Unclear risk “drawing of envelopes.”
Blinding (performance bias and detection
bias)
Women
Low risk Placebo controlled study.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Placebo controlled study.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised accounted for in the analysis.
Selective reporting (reporting bias) Low risk Stated outcomes are reported.
Other bias Low risk Baseline demographics similar between groups.
Sawai 1994
Methods RCT.
Participants Setting: 91 women with prolonged pregnancy (gestational age > 41 weeks) attending a
Florida, USA hospital
Inclusion criteria: uncomplicated pregnancy, reliable dating, Bishop score < 9, reactive
NST and ultrasound
Exclusion criteria: vaginal bleeding, ruptured membranes, macrosomia (estimated fetal
weight > 4500 g) previous uterine surgery or stillbirth, abnormal FHR or ultrasound,
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Sawai 1994 (Continued)
regular contractions
Interventions Intervention group: daily self-administered vaginal PGE 2mg before bed (women were
given instructions re placement and storage of suppositories)
Comparison group: self-administered placebo.
Telephone contact available 24 h for both groups. Twice weekly clinic attendance for
post-dates surveillance (NST and AFV); induction if indicated or at 44 weeks
Outcomes CS rates, chorioamnionitis, Apgar score at 5 min, NICU admission
Notes Costs data reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated.
Allocation concealment (selection bias) Low risk Coded drug boxes.
Blinding (performance bias and detection
bias)
Women
Low risk Described as “double blind” placebo controlled.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Described as “double blind” placebo controlled.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Outcomes assessors not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk 91 were enrolled but 11 were lost to follow up (3 were excluded
as they were non compliant)
Selective reporting (reporting bias) Low risk Outcomes stated in methods text are reported.
Other bias Low risk baseline demographics similar between groups.
Schmitz 2014
Methods Randomised, multicentre, double-blind, placebo-controlled RCT
Participants Setting: 11 French university hospital referral maternity units that collaborate in the
“Groupe de Recherche en Obstétrique et Gynécologie” (Obstetrics and Gynecology
Research Group)
Inclusion criteria
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Schmitz 2014 (Continued)
• All nulliparous women at 41 0/7 weeks of gestation
• Intact membranes
• Bishop score less than 6
• Singleton fetus in cephalic presentation
Exclusion criteria
• Age < 18 years
• No social security coverage
• Indication for immediate labour induction
• Antihypertensive treatment
• Fetal death
Contra-indications to IMN treatment (known hypersensitivity to it, cardiovascular col-
lapse, aortic stenosis, mitral stenosis, obstructive myocardial hypertrophy, systolic blood
pressure < 95 mm Hg)
Interventions Experimental intervention (N = 684)
Cervical ripening:
2 tablets of 20 mg isosorbide-5-mononitrate were taken from identical blister packs and
inserted by midwives into the posterior vaginal fornix
Intervention protocol: administered at 41 + 0, 41 + 2 and 41 + 4 weeks, or until cervix
favourable, or fetal status abnormal, where labour was induced
If 41 + 5 weeks was reached, labour was induced (in hospital)
Control (N = 689)
2 placebo tablets of similar design were taken from identical blister packs and inserted
by midwives into the posterior vaginal fornix
Outcomes Primary outcome
• CS birth rate
Secondary outcomes
• Bishop score
• Gestational age at birth
• Time from treatment to birth
• Duration of labour
• Spontaneous deliveries
• Instrumental deliveries
• Indications for caesarean birth:
• Failure to progress
• Non-reassuring fetal status
• Failed induction (caesarean birth performed at less than 5-cm dilated)
• Spontaneous labour
• Labour induction with oxytocin
• Labour induction with prostaglandin
• Oxytocin augmentation
• PPH
• Severe PPH (PPH requiring blood transfusion, embolization or surgery,
hysterectomy, transfer to ICU, or death)
• Transfer to intensive care unit
• Venous thromboembolism
• Death
• Maternal side effects
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Schmitz 2014 (Continued)
• Maternal satisfaction
• Perinatal morbidity, defined as: as a composite of any of the following: fetal or
neonatal death, 5 min Apgar score less than 4, neonatal trauma, convulsions in the first
24 h of life, tracheal ventilation > 24 h, or hospitalisation in the intensive care unit for
5 days or more
• Birthweight
• 5 min Apgar score
• Arterial cord blood pH
• Admission to intensive and intermediate care nurseries and reasons
• Fetal death and neonatal death
• Neonatal trauma (defined as long bone fracture, collarbone fracture, basal skull
fracture, brachial plexus palsy, facial nerve palsy, phrenic nerve palsy, or subdural
haemorrhage)
• Convulsions in the first 24 h of life
• Tracheal ventilation for > 24 h
• NICU hospitalisation for 5 d or more
Notes Schmitz 2014 is a brief abstract published on the same trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible women were randomly assigned
by obstetricians or midwives using a web-
based application in a 1-to-1 ratio to the
IMN or placebo groups; the application
was based on a computer-generated list
with permuted blocks of 4 stratified by ma-
ternity units
Allocation concealment (selection bias) Low risk The allocation sequence was not available
to any member of the research team un-
til the database was completed and locked.
Patients, study staff, and data analysts were
masked to assignment
Blinding (performance bias and detection
bias)
Women
Low risk Article states “Patients, study staff, and data
analysts were masked to assignment”
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Article states “Patients, study staff, and data
analysts were masked to assignment“
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Trained research nurses recorded outcomes
from hospital notes and entered data into
a web-based data-capture system. Article
states “Patients, study staff, and data ana-
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Schmitz 2014 (Continued)
lysts were masked to assignment”
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 1 woman lost to follow up.
Missing values accounted for < 1% of all
results, except for arterial cord blood pH
(18%) and maternal satisfaction criteria
(23%)
Article states a post-randomisation exclu-
sion, that were not included in analysis:
“Ten women (0.7%), five in each group,
were secondarily excluded from the analysis
because they did notmeet the inclusion cri-
teria”. While balanced, this exclusion may
cause bias
Selective reporting (reporting bias) High risk Maternal and neonatal ICU admission
rates not reported, although were pre-spec-
ified outcomes
Other bias Low risk Baseline characteristics similar apart from
maternal age; women were slightly older in
the treatment group
Stenlund 1999
Methods RCT, 2 arm trial.
Participants Setting: 36 women attending hospital in Stockholm, Sweden.
Inclusion criteria: maternal or fetal indications for labour induction, women in whom
labour induction could be deferred for 48 h, Bishop score < 6, single pregnancy, head
presentation and intact membranes. All women were 14 days post-term and scheduled
for induction, but where IOL could be postponed for 48 h
Exclusion criteria: parity > 4, contra-indications to vaginal birth, oligohydramnios, prior
uterine surgery, obstetric or medical complications
Interventions Intervention group: 400 mg mifepristone.
Comparison group: placebo.
Women returned for review after 24 h and 48 h if labour did not start. If Bishop score
> 6 then ARM and oxytocin induction, if < 6 then PGE 0.5 mg intracervical up to 2
treatments
Outcomes Labour within 48 h, Mode of onset of labour, ripe cervix within 48 h, birth within 48
h, need for PGE for cervical ripening, change in Bishop score,
duration of labour, interval from treatment to admission in labour, Apgar score, umbilical
pH, maternal and neonatal serum concentrations of mifepristone at birth
Notes
Risk of bias
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Stenlund 1999 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
Allocation concealment (selection bias) Low risk Coded drug boxes, “sealed pre-numbered boxes containing ei-
ther mifepristone or placebo tablets”
Blinding (performance bias and detection
bias)
Women
Low risk “...the type of treatment the women were given was not known
until the entire study was finished”
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Study described as blinded.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Study described as blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow up apparent.
Selective reporting (reporting bias) Unclear risk Manymore outcomes reported thanmentioned inmethods text.
FHR and uterine contractility not mentioned specifically in re-
sults text
Other bias Unclear risk Some baseline imbalance, intervention group 79% primiparous
versus 58% in the control group
Stitely 2000
Methods RCT.
Participants Setting: USA, naval medical centre. 50 women.
Inclusion criteria: women with prolonged pregnancy (41 to 42 weeks’ gestation) con-
firmed by ultrasound, clinical examination and menstrual dates. Singleton, cephalic pre-
sentation, intact membranes, Bishop score < 5, < 8 contractions per h, AFI > 5 cm,
reactive NST, maternal age > 18, < 50 years
Exclusion criteria: malpresentations, multiple pregnancy, previous CS, vaginal bleeding,
ruptured membranes, non reactive NST, estimated fetal weight > 4500 g or < 2000
g, placenta previa, active herpes, hypersensitivity to prostaglandin, signs of infection,
asthma or serious disease
Interventions Intervention group: vaginal misoprostol 25 µg (with second dose after 24 h)
Comparison group: placebo, packaged and labelled to appear indistinguishable
Both groups were observed for 4 h with FHR and uterine activity monitoring. If women
showed no sign of labour of fetal distress they were discharged and asked to return after
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Stitely 2000 (Continued)
24 h for a second dose, then review after a further 24 h for inpatient management
Outcomes Uterine hyperstimulation, CS, Apgar score < 7 at 5 min, meconium staining
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence by pharmacy (permuted block
design)
Allocation concealment (selection bias) Low risk The list was maintained by inpatient pharmacy and drugs were
dispensed to appear identical
Blinding (performance bias and detection
bias)
Women
Low risk Women would not have been aware of assignment; treatment
and placebo identical
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Investigators and other obstetric staff blind to group assignment
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Outcome assessors not described, but all staff described as blind
until analysis completed
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent loss to follow up.
Selective reporting (reporting bias) Unclear risk Only primary outcome stated in methods text; fetal outcomes
not specified
Other bias Low risk Baseline demographics comparable.
AFI: amniotic fluid index
AFV: amniotic fluid volume
ARM: artificial rupture of membranes
CPD: cephalo-pelvic disproportion
CS: caesarean section
EDD: expected date of delivery
EFW: estimated fetal weight
FGR: fetal growth retardation
FHR: fetal heart rate
GA: gestational age
h: hour/s
IMN: isosorbide mononitrate
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ISMN:isosorbide mononitrate
IOL: induction of labour
ITT: intention-to-treat
NHS: National Health Service (UK)
NICU: neonatal intensive care unit
NST: non-stress test
PGE: progesterone
PPH: postpartum haemorrhage
PROM: premature rupture of the membranes
RCT: randomised controlled trial
SOL: spontaneous onset of labour
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adewole 1993 This study examined breast stimulation and used a cross-over design. Women were allocated to either breast
stimulation versus no stimulation; after 3 days, if labour had not started women crossed over into the other study
group
Damania 1988 Very little information was provided on study methods. It was not clear this was a RCT
Damania 1992 In this study breast stimulation was compared with an oxytocin infusion. It was not clear that women in the
oxytocin group were discharged home
Di Lieto 1989 This study used a cross-over design.
Doany 1997 In this study intravaginal PGE with or withoutmembrane sweepingwas comparedwith placebowith or without
membrane sweeping. Complex interventions or interventions involving membrane sweeping are not included
in this review
Dorfman 1987 In this study women received a range of homeopathic herbal preparations versus placebo. The intervention was
to prepare women for childbirth generally rather than to induce labour
Elliott 1984 This study focused on breast stimulation and used a cross-over design
Evans 1983 It was not clear that this was a RCT: “the assignment [of medication] to patients was by consecutive entry into
either of the studies”. The paper described findings for 2 separate studies both examining the use of intracervical
porcine ovarian relaxin. The first study appeared to be conducted in hospital and women receiving medication
were compared with a control group. In the “outpatient study” there was no control group; women received
either 2 mg or 4 mg of relaxin 5 to 7 days before scheduled induction; no outcomes were reported relevant for
inclusion in the review
Garry 2000 This study compared castor oil with no treatment, women were alternately allocated to groups; otherwise there
was little information on methods
Griffin 2003 This study was reported in a brief abstract and insufficient information was available on methods and results to
include the study. We contacted the study author and further data are not available
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Herabutya 1992 This study examined intracervical prostaglandin. Little information was provided on study methods. Women
“randomized” to the intervention group received intracervical PGE and then monitored for 4 h to 6 h, some
had a repeat dose after 6 h, some had a repeat dose the next day and if labour did not start on the third day
these women were admitted to hospital for amniotomy and oxytocin infusion. It was not clear what happened to
women in the control group other than that they had weekly fetal monitoring; these women were not admitted
unless there were signs of abnormality or until they reached 44 weeks’ gestation. The management of women in
the 2 groups was so different that results are difficult to interpret
Kadar 1990 This study focused on nipple stimulation. Group allocation was by a quasi-randomised method; there were
serious protocol violations and analysis was not by randomisation group making results very difficult to interpret
Kaul 2004 This study focused on membrane sweeping. This intervention is not included in this review
Krammer 1995 This study was reported in a very brief abstract. No original data were presented in the results
Magann 1999 This study compared PGE and membrane sweeping. Membrane sweeping is not included in this review
Manidakis 1999 This study was reported in a brief abstract. It was not clear that it was a RCT. We were unable to find contact
details for the author to obtain further information
Moghtadaei 2007 This study focused on extra-amniotic saline infusion, an intervention rarely used nowadays. It was not clear that
this intervention was carried out in an outpatient setting
Ohel 1996 This quasi randomised trial compared women receiving vaginal PGE with expectant management. Analysis
was not by randomisation group. Of 96 cases randomised to PGE 26 preferred expectant management and
were therefore omitted from the analysis. As there was no intention-to-treat analysis results of this study were
very difficult to interpret
Rayburn 1988 In this study some of the women included in the study were admitted to hospital rather that being treated as
outpatients. No separate results were available for women in the outpatient group
Rezk 2014 This RCT was not conducted in outpatient setting.
Salamalekis 2000 In this study membrane sweeping was compared with oxytocin for labour induction. It was not clear that women
were discharged home after interventions and membrane sweeping is not included in this review
Salmon 1986 This study focused on breast stimulation and used a cross-over design. Women were allocated to either breast
stimulation versus no stimulation; after 3 days, if labour had not started women crossed over into the other study
group
Spallicci 2007 The intervention in this trial was an intracervical injection of hyaluronidase. This intervention is no longer used
in clinical practice
Voss 1996 It was not clear that this intervention was carried out in an outpatient setting or that women were discharged
home after treatment
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Ziaei 2003 This study compared dexamethasone with oxytocin. it was not clear that the intervention was carried out in an
outpatient setting
h: hour/s
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Ascher-Walsh 2000
Methods Double blind RCT.
Participants 30 women at term (40 to 41 weeks) with a Bishop score < 7.
Interventions Intervention: (2 groups) 200 µg or 100 µg of oral misoprostol
Comparison group: placebo.
FHR and uterine monitoring for 2 h after medication. Procedure was repeated after 3 days if labour did not start
until 42 weeks
Outcomes Interval to birth, CS, Induction at 42 weeks, hyperstimulation, Apgar scores
Notes This study was reported in a brief abstract and the data were described as “preliminary”. We attempted to contact
authors for further information (8 September 2009)
A repeat attempt was made to contact authors as part of the update of this review (1 September 2016)
Mostaghel 2009
Methods Open RCT.
Participants Setting: Mahdieh hospital, Tehran, Iran.
Eligibility criteria not specified.
Interventions Randomised at 40 weeks’ gestation to receive 25 µg vaginal misoprostol (N = 22) or placebo (N = 22) on an outpatient
basis
Women allowed to go into spontaneous labour, unless an indication for induction developed
Outcomes Incidence of post term birth, misoprostol side-effects and neonatal outcomes
Notes This study was reported in a brief abstract, and available data did not align with primary outcomes of the review. We
attempted to contact authors for further information (1 September 2016)
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Thakur 2005
Methods Double blind RCT.
Participants 50 primiparous women with unfavourable cervix with gestational age > 41 weeks
Interventions Intervention group: 2 tablets (400 mg) mifepristone 48 h before scheduled induction of labour
Comparison group: 2 tablets placebo.
Outcomes Interval to birth, CS, onset of spontaneous labour.
Notes This study was reported in a brief abstract. The setting was not clear. We attempted to contact the authors for further
information (11 September 2009)
A repeat attempt was made to contact authors as part of the update of this review (1 September 2016)
CS: caesarean section
FHR: fetal heart rate
h: hour/s
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Intravaginal PGE gel versus placebo or expectant management
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional induction agents
required
2 150 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.27, 0.99]
2 Epidural 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.62, 1.12]
3 Uterine hyperstimulation (FHR
changes unclear)
4 244 Risk Ratio (M-H, Fixed, 95% CI) 3.76 [0.64, 22.24]
4 Caesarean section 4 288 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.49, 1.31]
5 Apgar score < 7 at 5 minutes 2 180 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.07, 2.93]
6 NICU admission 3 230 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.10, 1.03]
7 Chorioamnionitis 2 180 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.15, 0.90]
8 Indicator of ’progress’ in labour -
Cervix unchanged at follow up
(not pre-specified)
1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.03, 0.47]
9 ’Spontaneous labour’ within 48
hours
1 58 Risk Ratio (M-H, Fixed, 95% CI) 6.43 [2.12, 19.48]
10 Indicator of ’progress’ in labour
- Admitted to hospital for
labour
1 100 Risk Ratio (M-H, Fixed, 95% CI) 2.7 [1.47, 4.97]
11 Time to birth - Gestational age
at birth (weeks)
1 100 Mean Difference (IV, Fixed, 95% CI) -0.60 [-0.99, -0.21]
12 Time to birth - Gestational age
on admission (days)
1 80 Mean Difference (IV, Fixed, 95% CI) -2.0 [-4.17, 0.17]
Comparison 2. Intracervical PGE versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional induction agent
required (induction with
oxytocin or other means)
3 445 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.32]
2 Additional induction agents
required (further prostaglandin
required)
1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.22, 1.67]
3 Uterine rupture 1 294 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Birth not achieved in 48 to 72
hours
1 43 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
5 Oxytocin augmentation 1 84 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.40, 1.12]
6 Uterine hyperstimulation (with
FHR changes)
4 488 Risk Ratio (M-H, Fixed, 95% CI) 2.66 [0.63, 11.25]
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7 Assisted (instrumental) vaginal
birth
4 538 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.85, 1.96]
8 Caesarean section 7 674 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.72, 1.12]
9 Apgar score < 7 at 5 minutes 4 515 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.42, 1.60]
10 NICU admission 3 215 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [0.43, 6.05]
11 Postpartum haemorrhage (>
500 mL)
1 61 Risk Ratio (M-H, Fixed, 95% CI) 3.10 [0.13, 73.16]
12 Chorioamnionitis 3 468 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.66, 6.18]
13 Endometritis 2 174 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.27, 9.37]
14 Side effects - Maternal side
effects
2 384 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.13, 2.77]
15 Time to birth - Interval from
intervention to birth (days)
2 133 Std. Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.55, 0.14]
16 Time to birth - Gestational age
at birth (weeks)
2 156 Mean Difference (IV, Random, 95% CI) -0.06 [-0.35, 0.23]
17 Indicator of ’progress’ in labour
- Induction for gestational age
> 42 weeks
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
18 Time to birth - Birth within 48
hours of treatment (all births)
1 61 Risk Ratio (M-H, Fixed, 95% CI) 3.1 [1.29, 7.47]
Comparison 3. Vaginal misoprostol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious neonatal morbidity or
death
1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.14]
2 Epidural 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.77, 1.26]
3 Uterine hyperstimulation (with
FHR changes)
3 265 Risk Ratio (M-H, Fixed, 95% CI) 1.97 [0.43, 9.00]
4 Uterine hyperstimulation
(without FHR changes)
2 137 Risk Ratio (M-H, Fixed, 95% CI) 3.64 [0.15, 85.97]
5 Assisted (instrumental) vaginal
birth
2 145 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.50, 1.67]
6 Caesarean section 4 325 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.61, 1.46]
7 Apgar score < 7 at 5 minutes 3 248 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.25]
8 NICU admission 4 325 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.54, 1.47]
9 Perinatal death 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.14]
10 Neonatal infection 1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.07, 1.36]
11 Indicator of ’progress’ in labour
- Oxytocin dose used (mU)
1 72 Mean Difference (IV, Fixed, 95% CI) 1508.70 [-2357.55,
5374.95]
12 Indicator of ’progress’ in labour
- Number of medication dose
1 60 Mean Difference (IV, Fixed, 95% CI) -0.44 [-0.49, -0.39]
13 Indicator of ’progress’ in labour
- Number of women requiring
dosing on day 2
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.43, 0.87]
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14 Indicator of ’progress’ in labour
- Number of women requiring
induction on day 3
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.04, 0.38]
15 Indicator of ’progress’ in labour
- Days to admission (all) (days)
1 77 Mean Difference (IV, Fixed, 95% CI) -2.90 [-4.99, -0.81]
16 Indicator of ’progress’ in labour
- Days to admission (subgroups
by parity) (days)
1 77 Mean Difference (IV, Fixed, 95% CI) -3.15 [-5.40, -0.89]
16.1 Nulliparous women 1 41 Mean Difference (IV, Fixed, 95% CI) -3.20 [-6.44, 0.04]
16.2 Parous women 1 36 Mean Difference (IV, Fixed, 95% CI) -3.10 [-6.24, 0.04]
17 Indicator of ’progress’ in labour
- Gestational age at labour
(weeks)
1 77 Mean Difference (IV, Fixed, 95% CI) -0.80 [-1.05, -0.55]
18 Indicator of ’progress’ in labour
- Days to admission (parous)
(weeks)
1 36 Mean Difference (IV, Fixed, 95% CI) -3.10 [-6.24, 0.04]
19 Indicator of ’progress’ in labour
- Days to PROM (days)
1 77 Mean Difference (IV, Fixed, 95% CI) -2.5 [-4.14, -0.86]
20 Time to birth - Interval from
intervention to vaginal birth
(days)
1 50 Mean Difference (IV, Fixed, 95% CI) -1.4 [-3.51, 0.71]
21 Time to birth - Days to birth
(all) (days)
1 68 Mean Difference (IV, Fixed, 95% CI) -1.90 [-3.74, -0.06]
22 Time to birth - Days to birth
(subgroups by parity) (days)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
22.1 Nulliparous women 1 39 Mean Difference (IV, Fixed, 95% CI) -3.0 [-5.42, -0.58]
22.2 Parous women 1 29 Mean Difference (IV, Fixed, 95% CI) -0.60 [-3.51, 2.31]
Comparison 4. Vaginal misoprostol 25 µg versus 50 µg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional induction agents
required (oxytocin)
1 49 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [0.22, 23.33]
2 Uterine hyperstimulation 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Caesarean section 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.33, 2.68]
4 NICU admission 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.05, 5.83]
5 Interval from treatment to birth
(in days, all births)
1 49 Mean Difference (IV, Fixed, 95% CI) 1.5 [1.19, 1.81]
91Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 5. Intracervical PGE versus vaginal misoprostol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Uterine hyperstimulation (with
or without FHR changes)
1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.03, 2.73]
2 Caesarean section 1 84 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.38, 2.08]
3 Apgar score < 7 after 5 minutes 1 84 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.96]
4 Admission to NICU 1 84 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.36, 4.33]
5 Indicator of ’progress’ in labour -
Interval from administration to
admission (hours)
1 75 Mean Difference (IV, Fixed, 95% CI) 2.5 [2.22, 2.78]
6 Indicator of ’progress’ in labour
- Labour or SROM during
ripening
1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.14, 0.69]
7 Time to birth - Birth within 24
hours
1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.75, 1.07]
8 Time to birth - Birth within 48
hours (cumulative)
1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.81, 1.06]
Comparison 6. Oral misoprostol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vaginal delivery not achieved
within 24 hours
1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.48, 0.86]
2 Additional induction agents
required
2 127 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.37, 0.97]
3 Oxytocin augmentation 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.61, 1.08]
4 Uterine hyperstimulation (with
FHR changes)
1 87 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.47, 5.06]
5 Uterine hyperstimulation (FHR
changes unclear)
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.06, 6.21]
6 Instrumental vaginal birth 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.17, 1.57]
7 Caesarean section 1 86 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.28, 1.33]
8 Apgar score < 7 at 5 minutes 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Neonatal intensive care unit
admission
1 87 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.07, 15.84]
10 Postpartum haemorrhage 1 87 Risk Ratio (M-H, Fixed, 95% CI) 5.11 [0.25, 103.51]
11 Chorioamnionitis 2 124 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.52, 2.17]
12 Endometritis 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.44]
13 Indicator of ’progress’ in labour
- Time from first dose to active
labor (hours)
2 127 Mean Difference (IV, Fixed, 95% CI) -37.08 [-52.44, -21.
72]
14 Time to birth - First dose to
birth (hours)
1 87 Mean Difference (IV, Fixed, 95% CI) -37.94 [-57.97, -17.
91]
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15 Indicator of ’progress’ in labour
- Total doses of medication
1 40 Mean Difference (IV, Fixed, 95% CI) -0.51 [-0.92, -0.10]
Comparison 7. Mifepristone versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional induction agents
required
4 311 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.37, 0.95]
2 Serious neonatal morbidity or
death
1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.07, 35.67]
3 Oxytocin augmentation 2 116 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.63, 1.26]
4 Epidural 1 112 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.73, 1.03]
5 Assisted (instrumental) vaginal
birth
5 343 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.93, 1.97]
6 Caesarean section 5 343 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.62, 1.25]
7 Apgar score < 7 at 5 minutes 2 119 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.07, 35.67]
8 NICU admission 2 163 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.31, 2.79]
9 Perinatal death 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Uterine scar separation 1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.64]
11 Chorioamnionitis 1 32 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.20, 19.91]
12 Indicator of ’progress’ in labour
- Labour or ripe cervix in 48
hours
1 36 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [1.00, 4.00]
13 Indicator of ’progress’ in labour
- Cervix unchanged after 24/48
hours
2 119 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.20, 0.63]
14 Indicator of ’progress’ in labour
- Spontaneous labour within
72 hours
1 80 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.68, 3.10]
15 Indicator of ’progress’ in labour
- Spontaneous labour within
48 hours
1 83 Risk Ratio (M-H, Fixed, 95% CI) 2.05 [1.27, 3.30]
16 Indicator of ’progress’ in labour
- Oxytocin requirements (IU)
1 32 Mean Difference (IV, Fixed, 95% CI) -2.56 [-4.01, -1.11]
17 Indicator of ’progress’ in labour
- Interval between day 1 and
start of labour (hours)
1 32 Mean Difference (IV, Fixed, 95% CI) -22.15 [-35.96, -8.
34]
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Comparison 8. Oestrogens versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oxytocin augmentation 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.61, 1.43]
2 Assisted (instrumental) vaginal
birth
1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.44, 1.60]
3 Caesarean section 1 87 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.63, 2.58]
4 NICU admission 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.13]
5 Chorioamnionitis 1 87 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [0.38, 10.12]
6 Endometritis 1 87 Risk Ratio (M-H, Fixed, 95% CI) 2.93 [0.32, 27.10]
Comparison 9. Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vaginal birth not achieved in
24/48 hours
1 238 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.83, 1.15]
2 Additional induction agents
required
4 1921 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.75, 1.00]
3 Maternal satisfaction 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 How do you think
your labour went? (easy/very
difficult)
1 227 Mean Difference (IV, Fixed, 95% CI) -0.34 [-0.94, 0.26]
3.2 What do you think about
home treatment? (extremely
good/not at all good)
1 227 Mean Difference (IV, Fixed, 95% CI) 0.61 [0.03, 1.19]
3.3 How painful was the
treatment at home? (not at all/
very)
1 227 Mean Difference (IV, Fixed, 95% CI) 0.58 [-0.00, 1.16]
3.4 How anxious were you
being at home taking the
treatment? (not at all/very)
1 227 Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.39, 0.61]
3.5 Would you have the same
treatment at home again?
(definitely/definitely not)
1 227 Mean Difference (IV, Fixed, 95% CI) 0.62 [-0.02, 1.26]
3.6 Would you advise a friend
to have the same treatment at
home? (definitely/definitely
not)
1 227 Mean Difference (IV, Fixed, 95% CI) 0.41 [-0.17, 0.99]
4 Maternal satisfaction 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Felt satisfied (very or
extremely)
1 1049 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.67, 0.94]
4.2 Would recommend the
same treatment
1 1049 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.77, 0.90]
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4.3 Would recommend
procedure
1 193 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.94, 1.08]
5 Perinatal death 2 1712 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.08, 33.26]
6 Neonatal trauma (long bone
fracture, collarbone fracture,
basal skull fracture, brachial
plexus palsy, facial nerve palsy,
phrenic nerve palsy, or subdural
haemorrhage)
1 1362 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.19, 2.37]
7 Neonatal convulsions in the first
24 hours
1 1362 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Tracheal ventilation > 24 hours 1 1362 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.14, 7.14]
9 Neonatal ICU admission for 5
or more days
1 1362 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.19, 2.37]
10 Neonatal transfer 1 1362 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.67, 1.70]
11 Maternal death 1 1362 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Severe postpartum
haemorrhage
1 1362 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.78, 3.09]
13 Deep vein thrombosis 1 1362 Risk Ratio (M-H, Fixed, 95% CI) 3.03 [0.12, 74.16]
14 Oxytocin augmentation 3 1816 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.78, 1.14]
15 Epidural 1 350 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.82, 1.09]
16 Uterine hyperstimulation (with
FHR changes)
1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 4.07]
17 Uterine hyperstimulation
(FHR changes unclear)
1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.62]
18 Assisted (instrumental) vaginal
birth
2 1712 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.61, 1.07]
19 Caesarean section 6 2286 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.87, 1.14]
20 Apgar score < 7 at 5 minutes 5 2214 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.44, 1.76]
21 NICU (or SCBU) admission 6 1068 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.59, 1.36]
22 Postpartum haemorrhage (>
500 mL)
5 2214 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.95, 1.36]
23 Neonatal infection 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.26, 3.89]
24 Side effects - Maternal side
effect - nausea
4 1926 Risk Ratio (M-H, Random, 95% CI) 2.39 [1.54, 3.70]
25 Side effects - Maternal side
effect - headache
7 2300 Risk Ratio (M-H, Random, 95% CI) 5.45 [3.38, 8.81]
26 Side effects - Maternal side
effects - severe headache
1 220 Risk Ratio (M-H, Fixed, 95% CI) 21.21 [2.91, 154.65]
27 Indicator of ’progress’ in labour
- Admitted in established
labour within 24 hours
1 200 Risk Ratio (M-H, Fixed, 95% CI) 2.75 [1.29, 5.88]
28 Indicator of ’progress’ in labour
- Bishop score > 6 or active
labour at 36 hours
1 102 Risk Ratio (M-H, Fixed, 95% CI) 3.8 [1.54, 9.40]
29 Time to birth - Time in hours
from admission to birth (all
women)
3 374 Mean Difference (IV, Random, 95% CI) -4.70 [-6.08, -3.31]
30 Indicator of ’progress’ in labour
- Bishop score on admission
after treatment
1 200 Mean Difference (IV, Fixed, 95% CI) 2.73 [2.17, 3.29]
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31 Indicator of ’progress’ in labour
- Change in Bishop score
2 272 Mean Difference (IV, Fixed, 95% CI) 2.76 [2.48, 3.03]
32 Time to birth - Interval from
onset of labour to birth (hours)
1 200 Mean Difference (IV, Fixed, 95% CI) -1.24 [-1.82, -0.66]
33 Indicator of ’progress’ in labour
- Cervix unchanged after 48
hours
1 257 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.70, 0.97]
34 Time to birth - Interval from
admission to vaginal birth
(hours)
1 128 Mean Difference (IV, Fixed, 95% CI) -0.70 [-6.11, 4.71]
35 Total cost of care package
(GBP)
1 350 Mean Difference (IV, Fixed, 95% CI) 11.98 [-105.34, 129.
30]
Comparison 10. Acupuncture versus routine care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional induction agents
required
1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.31, 1.17]
2 Caesarean section 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.17, 1.11]
Comparison 11. Outpatient amniotomy for induction versus routine care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction - I
look back positively on the
treatment I received
1 404 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.97, 1.10]
2 Maternal satisfaction - In
retrospect, I would have
preferred another treatment
than received
1 472 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.36, 0.72]
3 Augmentation, induction or
both
1 521 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.71, 0.97]
4 Epidural, opioids or both for
pain relief
1 521 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.76, 1.30]
5 Instrumental vaginal birth 1 521 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.46, 1.08]
6 Caesarean section 1 521 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.78, 1.86]
7 Apgar < 7 at 5 minutes 1 521 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [0.34, 10.06]
8 Neonatal intensive care unit
admission
1 521 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.64, 1.85]
9 Duration of birth (hours) 1 521 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.72, 1.52]
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Analysis 1.1. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 1
Additional induction agents required.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 1 Additional induction agents required
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Brien 1995 6/50 14/50 64.6 % 0.43 [ 0.18, 1.03 ]
Sawai 1991 5/24 8/26 35.4 % 0.68 [ 0.26, 1.79 ]
Total (95% CI) 74 76 100.0 % 0.52 [ 0.27, 0.99 ]
Total events: 11 (PGE2), 22 (Placebo/ expt)
Heterogeneity: Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.045)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours control
Analysis 1.2. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 2
Epidural.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 2 Epidural
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Brien 1995 29/50 35/50 100.0 % 0.83 [ 0.62, 1.12 ]
Total (95% CI) 50 50 100.0 % 0.83 [ 0.62, 1.12 ]
Total events: 29 (PGE2), 35 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours control
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Analysis 1.3. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 3
Uterine hyperstimulation (FHR changes unclear).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 3 Uterine hyperstimulation (FHR changes unclear)
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hage 1993 1/18 0/18 33.7 % 3.00 [ 0.13, 69.09 ]
Newman 1997 2/28 0/30 32.6 % 5.34 [ 0.27, 106.70 ]
O’Brien 1995 1/50 0/50 33.7 % 3.00 [ 0.13, 71.92 ]
Sawai 1991 0/24 0/26 Not estimable
Total (95% CI) 120 124 100.0 % 3.76 [ 0.64, 22.24 ]
Total events: 4 (PGE2), 0 (Placebo/ expt)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours control
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Analysis 1.4. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 4
Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 4 Caesarean section
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Newman 1997 8/28 9/30 30.8 % 0.95 [ 0.43, 2.12 ]
O’Brien 1995 7/50 10/50 35.4 % 0.70 [ 0.29, 1.69 ]
Sawai 1991 6/24 4/26 13.6 % 1.63 [ 0.52, 5.07 ]
Sawai 1994 1/38 6/42 20.2 % 0.18 [ 0.02, 1.46 ]
Total (95% CI) 140 148 100.0 % 0.80 [ 0.49, 1.31 ]
Total events: 22 (PGE2), 29 (Placebo/ expt)
Heterogeneity: Chi2 = 3.70, df = 3 (P = 0.30); I2 =19%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours PGE2 Favours control
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Analysis 1.5. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 5
Apgar score < 7 at 5 minutes.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 5 Apgar score < 7 at 5 minutes
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Brien 1995 0/50 2/50 72.5 % 0.20 [ 0.01, 4.06 ]
Sawai 1994 1/38 1/42 27.5 % 1.11 [ 0.07, 17.06 ]
Total (95% CI) 88 92 100.0 % 0.45 [ 0.07, 2.93 ]
Total events: 1 (PGE2), 3 (Placebo/ expt)
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours control
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Analysis 1.6. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 6
NICU admission.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 6 NICU admission
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Brien 1995 1/50 5/50 44.6 % 0.20 [ 0.02, 1.65 ]
Sawai 1991 0/24 2/26 21.5 % 0.22 [ 0.01, 4.28 ]
Sawai 1994 2/38 4/42 33.9 % 0.55 [ 0.11, 2.85 ]
Total (95% CI) 112 118 100.0 % 0.32 [ 0.10, 1.03 ]
Total events: 3 (PGE2), 11 (Placebo/ expt)
Heterogeneity: Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours control
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Analysis 1.7. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 7
Chorioamnionitis.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 7 Chorioamnionitis
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Brien 1995 4/50 7/50 42.4 % 0.57 [ 0.18, 1.83 ]
Sawai 1994 2/38 10/42 57.6 % 0.22 [ 0.05, 0.95 ]
Total (95% CI) 88 92 100.0 % 0.37 [ 0.15, 0.90 ]
Total events: 6 (PGE2), 17 (Placebo/ expt)
Heterogeneity: Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 2.19 (P = 0.029)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours control
Analysis 1.8. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 8
Indicator of ’progress’ in labour - Cervix unchanged at follow up (not pre-specified).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 8 Indicator of ’progress’ in labour - Cervix unchanged at follow up (not pre-specified)
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hage 1993 2/18 16/18 100.0 % 0.13 [ 0.03, 0.47 ]
Total (95% CI) 18 18 100.0 % 0.13 [ 0.03, 0.47 ]
Total events: 2 (PGE2), 16 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 3.10 (P = 0.0020)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
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Analysis 1.9. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 9
’Spontaneous labour’ within 48 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 9 ’Spontaneous labour’ within 48 hours
Study or subgroup PGE2 Routine care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Newman 1997 18/28 3/30 100.0 % 6.43 [ 2.12, 19.48 ]
Total (95% CI) 28 30 100.0 % 6.43 [ 2.12, 19.48 ]
Total events: 18 (PGE2), 3 (Routine care)
Heterogeneity: not applicable
Test for overall effect: Z = 3.29 (P = 0.0010)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours routine care Favours PGE2
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Analysis 1.10. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 10
Indicator of ’progress’ in labour - Admitted to hospital for labour.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 10 Indicator of ’progress’ in labour - Admitted to hospital for labour
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Brien 1995 27/50 10/50 100.0 % 2.70 [ 1.47, 4.97 ]
Total (95% CI) 50 50 100.0 % 2.70 [ 1.47, 4.97 ]
Total events: 27 (PGE2), 10 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours PGE2
Analysis 1.11. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 11
Time to birth - Gestational age at birth (weeks).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 11 Time to birth - Gestational age at birth (weeks)
Study or subgroup PGE2 Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
O’Brien 1995 50 39.9 (1) 50 40.5 (0.99) 100.0 % -0.60 [ -0.99, -0.21 ]
Total (95% CI) 50 50 100.0 % -0.60 [ -0.99, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0026)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours PGE2 Favours control
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Analysis 1.12. Comparison 1 Intravaginal PGE gel versus placebo or expectant management, Outcome 12
Time to birth - Gestational age on admission (days).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 1 Intravaginal PGE gel versus placebo or expectant management
Outcome: 12 Time to birth - Gestational age on admission (days)
Study or subgroup PGE2 Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sawai 1994 38 295 (4.5) 42 297 (5.4) 100.0 % -2.00 [ -4.17, 0.17 ]
Total (95% CI) 38 42 100.0 % -2.00 [ -4.17, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.071)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours PGE2 Favours control
Analysis 2.1. Comparison 2 Intracervical PGE versus placebo, Outcome 1 Additional induction agent
required (induction with oxytocin or other means).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 1 Additional induction agent required (induction with oxytocin or other means)
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lien 1998 18/43 25/47 38.0 % 0.79 [ 0.51, 1.23 ]
McKenna 1999 4/30 6/31 9.4 % 0.69 [ 0.22, 2.20 ]
Rayburn 1999 38/143 34/151 52.6 % 1.18 [ 0.79, 1.76 ]
Total (95% CI) 216 229 100.0 % 0.98 [ 0.74, 1.32 ]
Total events: 60 (PGE2), 65 (Placebo/ expt)
Heterogeneity: Chi2 = 2.13, df = 2 (P = 0.35); I2 =6%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
105Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Intracervical PGE versus placebo, Outcome 2 Additional induction agents
required (further prostaglandin required).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 2 Additional induction agents required (further prostaglandin required)
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lien 1998 5/43 9/47 100.0 % 0.61 [ 0.22, 1.67 ]
Total (95% CI) 43 47 100.0 % 0.61 [ 0.22, 1.67 ]
Total events: 5 (PGE2), 9 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
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Analysis 2.3. Comparison 2 Intracervical PGE versus placebo, Outcome 3 Uterine rupture.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 3 Uterine rupture
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1999 0/143 0/151 Not estimable
Total (95% CI) 143 151 Not estimable
Total events: 0 (PGE2), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours control
Analysis 2.4. Comparison 2 Intracervical PGE versus placebo, Outcome 4 Birth not achieved in 48 to 72
hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 4 Birth not achieved in 48 to 72 hours
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Buttino 1990 19/23 20/20 100.0 % 0.83 [ 0.68, 1.02 ]
Total (95% CI) 23 20 100.0 % 0.83 [ 0.68, 1.02 ]
Total events: 19 (PGE2), 20 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
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Analysis 2.5. Comparison 2 Intracervical PGE versus placebo, Outcome 5 Oxytocin augmentation.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 5 Oxytocin augmentation
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 14/41 22/43 100.0 % 0.67 [ 0.40, 1.12 ]
Total (95% CI) 41 43 100.0 % 0.67 [ 0.40, 1.12 ]
Total events: 14 (PGE2), 22 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
Analysis 2.6. Comparison 2 Intracervical PGE versus placebo, Outcome 6 Uterine hyperstimulation (with
FHR changes).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 6 Uterine hyperstimulation (with FHR changes)
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Buttino 1990 1/23 0/20 21.6 % 2.63 [ 0.11, 61.05 ]
Lien 1998 2/43 1/47 38.7 % 2.19 [ 0.21, 23.26 ]
McKenna 1999 1/30 0/31 19.9 % 3.10 [ 0.13, 73.16 ]
Rayburn 1999 (1) 1/143 0/151 19.7 % 3.17 [ 0.13, 77.10 ]
Total (95% CI) 239 249 100.0 % 2.66 [ 0.63, 11.25 ]
Total events: 5 (PGE2), 1 (Placebo/ expt)
Heterogeneity: Chi2 = 0.05, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
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(1) Not clear if FHR changes
Analysis 2.7. Comparison 2 Intracervical PGE versus placebo, Outcome 7 Assisted (instrumental) vaginal
birth.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 7 Assisted (instrumental) vaginal birth
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 17/41 14/43 45.1 % 1.27 [ 0.73, 2.24 ]
Lien 1998 6/43 3/47 9.5 % 2.19 [ 0.58, 8.21 ]
Magann 1998 3/35 5/35 16.5 % 0.60 [ 0.16, 2.32 ]
Rayburn 1999 12/143 9/151 28.9 % 1.41 [ 0.61, 3.24 ]
Total (95% CI) 262 276 100.0 % 1.29 [ 0.85, 1.96 ]
Total events: 38 (PGE2), 31 (Placebo/ expt)
Heterogeneity: Chi2 = 1.89, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Intracervical PGE versus placebo, Outcome 8 Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 8 Caesarean section
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Buttino 1990 5/23 7/20 7.2 % 0.62 [ 0.23, 1.65 ]
Gittens 1996 (1) 3/17 5/15 5.1 % 0.53 [ 0.15, 1.85 ]
Larmon 2002 5/41 10/43 9.4 % 0.52 [ 0.20, 1.40 ]
Lien 1998 6/43 8/47 7.3 % 0.82 [ 0.31, 2.17 ]
Magann 1998 8/35 5/35 4.8 % 1.60 [ 0.58, 4.41 ]
McKenna 1999 4/30 3/31 2.8 % 1.38 [ 0.34, 5.64 ]
Rayburn 1999 (2) 61/143 68/151 63.4 % 0.95 [ 0.73, 1.23 ]
Total (95% CI) 332 342 100.0 % 0.90 [ 0.72, 1.12 ]
Total events: 92 (PGE2), 106 (Placebo/ expt)
Heterogeneity: Chi2 = 4.17, df = 6 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
(1) All women had had a previous CS
(2) All women had had one previous CS
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Analysis 2.9. Comparison 2 Intracervical PGE versus placebo, Outcome 9 Apgar score < 7 at 5 minutes.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 9 Apgar score < 7 at 5 minutes
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lien 1998 0/43 1/47 8.2 % 0.36 [ 0.02, 8.70 ]
Magann 1998 1/35 1/35 5.7 % 1.00 [ 0.07, 15.36 ]
McKenna 1999 0/30 2/31 14.0 % 0.21 [ 0.01, 4.13 ]
Rayburn 1999 (1) 12/143 13/151 72.1 % 0.97 [ 0.46, 2.06 ]
Total (95% CI) 251 264 100.0 % 0.82 [ 0.42, 1.60 ]
Total events: 13 (PGE2), 17 (Placebo/ expt)
Heterogeneity: Chi2 = 1.29, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
(1) < 8 at 5 mins.
111Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.10. Comparison 2 Intracervical PGE versus placebo, Outcome 10 NICU admission.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 10 NICU admission
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 1/41 1/43 28.3 % 1.05 [ 0.07, 16.22 ]
Magann 1998 3/35 0/35 14.5 % 7.00 [ 0.37, 130.69 ]
McKenna 1999 1/30 2/31 57.1 % 0.52 [ 0.05, 5.40 ]
Total (95% CI) 106 109 100.0 % 1.61 [ 0.43, 6.05 ]
Total events: 5 (PGE2), 3 (Placebo/ expt)
Heterogeneity: Chi2 = 1.96, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Intracervical PGE versus placebo, Outcome 11 Postpartum haemorrhage (>
500 mL).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 11 Postpartum haemorrhage (> 500 mL)
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McKenna 1999 1/30 0/31 100.0 % 3.10 [ 0.13, 73.16 ]
Total (95% CI) 30 31 100.0 % 3.10 [ 0.13, 73.16 ]
Total events: 1 (PGE2), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours control
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Analysis 2.12. Comparison 2 Intracervical PGE versus placebo, Outcome 12 Chorioamnionitis.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 12 Chorioamnionitis
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 1/41 2/43 44.9 % 0.52 [ 0.05, 5.57 ]
Lien 1998 5/43 2/47 43.9 % 2.73 [ 0.56, 13.36 ]
Rayburn 1999 (1) 2/143 0/151 11.2 % 5.28 [ 0.26, 108.99 ]
Total (95% CI) 227 241 100.0 % 2.03 [ 0.66, 6.18 ]
Total events: 8 (PGE2), 4 (Placebo/ expt)
Heterogeneity: Chi2 = 1.78, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
(1) Not clear. Described as ”maternal fever”.
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Analysis 2.13. Comparison 2 Intracervical PGE versus placebo, Outcome 13 Endometritis.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 13 Endometritis
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 2/41 1/43 50.5 % 2.10 [ 0.20, 22.26 ]
Lien 1998 1/43 1/47 49.5 % 1.09 [ 0.07, 16.94 ]
Total (95% CI) 84 90 100.0 % 1.60 [ 0.27, 9.37 ]
Total events: 3 (PGE2), 2 (Placebo/ expt)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PGE2 Favours placebo
Analysis 2.14. Comparison 2 Intracervical PGE versus placebo, Outcome 14 Side effects - Maternal side
effects.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 14 Side effects - Maternal side effects
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lien 1998 0/43 2/47 55.1 % 0.22 [ 0.01, 4.42 ]
Rayburn 1999 (1) 2/143 2/151 44.9 % 1.06 [ 0.15, 7.40 ]
Total (95% CI) 186 198 100.0 % 0.59 [ 0.13, 2.77 ]
Total events: 2 (PGE2), 4 (Placebo/ expt)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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(1) Nausea and vomiting
Analysis 2.15. Comparison 2 Intracervical PGE versus placebo, Outcome 15 Time to birth - Interval from
intervention to birth (days).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 15 Time to birth - Interval from intervention to birth (days)
Study or subgroup PGE2 Placebo/ expt
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Buttino 1990 (1) 23 12.97 (10.2) 20 15.8 (7.78) 32.1 % -0.30 [ -0.91, 0.30 ]
Lien 1998 43 5.5 (3.5) 47 6 (2.8) 67.9 % -0.16 [ -0.57, 0.26 ]
Total (95% CI) 66 67 100.0 % -0.20 [ -0.55, 0.14 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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(1) Reported in hours in paper.
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Analysis 2.16. Comparison 2 Intracervical PGE versus placebo, Outcome 16 Time to birth - Gestational
age at birth (weeks).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 16 Time to birth - Gestational age at birth (weeks)
Study or subgroup PGE2 Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lien 1998 43 41.7 (0.5) 43 41.6 (0.4) 46.8 % 0.10 [ -0.09, 0.29 ]
Magann 1998 35 41.7 (0.2) 35 41.9 (0.3) 53.2 % -0.20 [ -0.32, -0.08 ]
Total (95% CI) 78 78 100.0 % -0.06 [ -0.35, 0.23 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.79, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 2.17. Comparison 2 Intracervical PGE versus placebo, Outcome 17 Indicator of ’progress’ in
labour - Induction for gestational age > 42 weeks.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 17 Indicator of ’progress’ in labour - Induction for gestational age > 42 weeks
Study or subgroup PGE2 Placebo/ expt Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lien 1998 14/43 12/47 1.28 [ 0.67, 2.44 ]
Magann 1998 7/35 22/35 0.32 [ 0.16, 0.65 ]
0.1 0.2 0.5 1 2 5 10
Favours PGE2 Favours control
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Analysis 2.18. Comparison 2 Intracervical PGE versus placebo, Outcome 18 Time to birth - Birth within
48 hours of treatment (all births).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 2 Intracervical PGE versus placebo
Outcome: 18 Time to birth - Birth within 48 hours of treatment (all births)
Study or subgroup PGE2 Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McKenna 1999 15/30 5/31 100.0 % 3.10 [ 1.29, 7.47 ]
Total (95% CI) 30 31 100.0 % 3.10 [ 1.29, 7.47 ]
Total events: 15 (PGE2), 5 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours PGE2
Analysis 3.1. Comparison 3 Vaginal misoprostol versus placebo, Outcome 1 Serious neonatal morbidity or
death.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 1 Serious neonatal morbidity or death
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Oboro 2005 0/38 1/39 100.0 % 0.34 [ 0.01, 8.14 ]
Total (95% CI) 38 39 100.0 % 0.34 [ 0.01, 8.14 ]
Total events: 0 (Misoprostol), 1 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours misoprostol Favours control
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Analysis 3.2. Comparison 3 Vaginal misoprostol versus placebo, Outcome 2 Epidural.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 2 Epidural
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McKenna 2004 20/24 22/26 100.0 % 0.98 [ 0.77, 1.26 ]
Total (95% CI) 24 26 100.0 % 0.98 [ 0.77, 1.26 ]
Total events: 20 (Misoprostol), 22 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Vaginal misoprostol versus placebo, Outcome 3 Uterine hyperstimulation (with
FHR changes).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 3 Uterine hyperstimulation (with FHR changes)
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Incerpi 2001 (1) 3/57 2/63 79.6 % 1.66 [ 0.29, 9.57 ]
McKenna 2004 1/33 0/35 20.4 % 3.18 [ 0.13, 75.33 ]
Oboro 2005 0/38 0/39 Not estimable
Total (95% CI) 128 137 100.0 % 1.97 [ 0.43, 9.00 ]
Total events: 4 (Misoprostol), 2 (Placebo/ expt)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours misoprostol Favours placebo
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(1) Not clear if FHR changes
Analysis 3.4. Comparison 3 Vaginal misoprostol versus placebo, Outcome 4 Uterine hyperstimulation
(without FHR changes).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 4 Uterine hyperstimulation (without FHR changes)
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Oboro 2005 0/38 0/39 Not estimable
Stitely 2000 1/27 0/33 100.0 % 3.64 [ 0.15, 85.97 ]
Total (95% CI) 65 72 100.0 % 3.64 [ 0.15, 85.97 ]
Total events: 1 (Misoprostol), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Vaginal misoprostol versus placebo, Outcome 5 Assisted (instrumental) vaginal
birth.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 5 Assisted (instrumental) vaginal birth
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McKenna 2004 3/33 6/35 34.9 % 0.53 [ 0.14, 1.95 ]
Oboro 2005 12/38 11/39 65.1 % 1.12 [ 0.56, 2.22 ]
Total (95% CI) 71 74 100.0 % 0.91 [ 0.50, 1.67 ]
Total events: 15 (Misoprostol), 17 (Placebo/ expt)
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Vaginal misoprostol versus placebo, Outcome 6 Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 6 Caesarean section
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Incerpi 2001 14/57 11/63 31.4 % 1.41 [ 0.70, 2.84 ]
McKenna 2004 9/33 9/35 26.2 % 1.06 [ 0.48, 2.34 ]
Oboro 2005 3/38 7/39 20.8 % 0.44 [ 0.12, 1.58 ]
Stitely 2000 4/27 8/33 21.6 % 0.61 [ 0.21, 1.81 ]
Total (95% CI) 155 170 100.0 % 0.94 [ 0.61, 1.46 ]
Total events: 30 (Misoprostol), 35 (Placebo/ expt)
Heterogeneity: Chi2 = 3.31, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Vaginal misoprostol versus placebo, Outcome 7 Apgar score < 7 at 5 minutes.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 7 Apgar score < 7 at 5 minutes
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Incerpi 2001 0/57 0/63 Not estimable
McKenna 2004 0/33 2/35 100.0 % 0.21 [ 0.01, 4.25 ]
Stitely 2000 0/27 0/33 Not estimable
Total (95% CI) 117 131 100.0 % 0.21 [ 0.01, 4.25 ]
Total events: 0 (Misoprostol), 2 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Vaginal misoprostol versus placebo, Outcome 8 NICU admission.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 8 NICU admission
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Incerpi 2001 18/57 20/63 78.7 % 0.99 [ 0.59, 1.68 ]
McKenna 2004 0/33 1/35 6.0 % 0.35 [ 0.01, 8.37 ]
Oboro 2005 1/38 1/39 4.1 % 1.03 [ 0.07, 15.82 ]
Stitely 2000 1/27 3/33 11.2 % 0.41 [ 0.04, 3.70 ]
Total (95% CI) 155 170 100.0 % 0.89 [ 0.54, 1.47 ]
Total events: 20 (Misoprostol), 25 (Placebo/ expt)
Heterogeneity: Chi2 = 0.99, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Vaginal misoprostol versus placebo, Outcome 9 Perinatal death.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 9 Perinatal death
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Oboro 2005 0/38 1/39 100.0 % 0.34 [ 0.01, 8.14 ]
Total (95% CI) 38 39 100.0 % 0.34 [ 0.01, 8.14 ]
Total events: 0 (Misoprostol), 1 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Vaginal misoprostol versus placebo, Outcome 10 Neonatal infection.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 10 Neonatal infection
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McKenna 2004 (1) 2/33 7/35 100.0 % 0.30 [ 0.07, 1.36 ]
Total (95% CI) 33 35 100.0 % 0.30 [ 0.07, 1.36 ]
Total events: 2 (Misoprostol), 7 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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(1) Described as febrile morbidity
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Analysis 3.11. Comparison 3 Vaginal misoprostol versus placebo, Outcome 11 Indicator of ’progress’ in
labour - Oxytocin dose used (mU).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 11 Indicator of ’progress’ in labour - Oxytocin dose used (mU)
Study or subgroup Misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Incerpi 2001 38 7221.6 (8625.2) 34 5712.9 (8107.9) 100.0 % 1508.70 [ -2357.55, 5374.95 ]
Total (95% CI) 38 34 100.0 % 1508.70 [ -2357.55, 5374.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 Vaginal misoprostol versus placebo, Outcome 12 Indicator of ’progress’ in
labour - Number of medication dose.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 12 Indicator of ’progress’ in labour - Number of medication dose
Study or subgroup Misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stitely 2000 27 1.41 (0.1) 33 1.85 (0.1) 100.0 % -0.44 [ -0.49, -0.39 ]
Total (95% CI) 27 33 100.0 % -0.44 [ -0.49, -0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 16.96 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 Vaginal misoprostol versus placebo, Outcome 13 Indicator of ’progress’ in
labour - Number of women requiring dosing on day 2.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 13 Indicator of ’progress’ in labour - Number of women requiring dosing on day 2
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stitely 2000 15/27 30/33 100.0 % 0.61 [ 0.43, 0.87 ]
Total (95% CI) 27 33 100.0 % 0.61 [ 0.43, 0.87 ]
Total events: 15 (Misoprostol), 30 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
Test for subgroup differences: Not applicable
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Analysis 3.14. Comparison 3 Vaginal misoprostol versus placebo, Outcome 14 Indicator of ’progress’ in
labour - Number of women requiring induction on day 3.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 14 Indicator of ’progress’ in labour - Number of women requiring induction on day 3
Study or subgroup Misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stitely 2000 3/27 28/33 100.0 % 0.13 [ 0.04, 0.38 ]
Total (95% CI) 27 33 100.0 % 0.13 [ 0.04, 0.38 ]
Total events: 3 (Misoprostol), 28 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 3.70 (P = 0.00021)
Test for subgroup differences: Not applicable
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Analysis 3.15. Comparison 3 Vaginal misoprostol versus placebo, Outcome 15 Indicator of ’progress’ in
labour - Days to admission (all) (days).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 15 Indicator of ’progress’ in labour - Days to admission (all) (days)
Study or subgroup Misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Oboro 2005 38 4.5 (4.1) 39 7.4 (5.2) 100.0 % -2.90 [ -4.99, -0.81 ]
Total (95% CI) 38 39 100.0 % -2.90 [ -4.99, -0.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0065)
Test for subgroup differences: Not applicable
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Analysis 3.16. Comparison 3 Vaginal misoprostol versus placebo, Outcome 16 Indicator of ’progress’ in
labour - Days to admission (subgroups by parity) (days).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 16 Indicator of ’progress’ in labour - Days to admission (subgroups by parity) (days)
Study or subgroup Misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Nulliparous women
Oboro 2005 22 4.9 (4.3) 19 8.1 (6) 48.4 % -3.20 [ -6.44, 0.04 ]
Subtotal (95% CI) 22 19 48.4 % -3.20 [ -6.44, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
2 Parous women
Oboro 2005 16 3.8 (4) 20 6.9 (5.6) 51.6 % -3.10 [ -6.24, 0.04 ]
Subtotal (95% CI) 16 20 51.6 % -3.10 [ -6.24, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
Total (95% CI) 38 39 100.0 % -3.15 [ -5.40, -0.89 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0062)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 3.17. Comparison 3 Vaginal misoprostol versus placebo, Outcome 17 Indicator of ’progress’ in
labour - Gestational age at labour (weeks).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 17 Indicator of ’progress’ in labour - Gestational age at labour (weeks)
Study or subgroup Misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Oboro 2005 38 40.6 (0.6) 39 41.4 (0.5) 100.0 % -0.80 [ -1.05, -0.55 ]
Total (95% CI) 38 39 100.0 % -0.80 [ -1.05, -0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.35 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.18. Comparison 3 Vaginal misoprostol versus placebo, Outcome 18 Indicator of ’progress’ in
labour - Days to admission (parous) (weeks).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 18 Indicator of ’progress’ in labour - Days to admission (parous) (weeks)
Study or subgroup Misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Oboro 2005 16 3.8 (4) 20 6.9 (5.6) 100.0 % -3.10 [ -6.24, 0.04 ]
Total (95% CI) 16 20 100.0 % -3.10 [ -6.24, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 3.19. Comparison 3 Vaginal misoprostol versus placebo, Outcome 19 Indicator of ’progress’ in
labour - Days to PROM (days).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 19 Indicator of ’progress’ in labour - Days to PROM (days)
Study or subgroup misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Oboro 2005 38 4.5 (3.2) 39 7 (4.1) 100.0 % -2.50 [ -4.14, -0.86 ]
Total (95% CI) 38 39 100.0 % -2.50 [ -4.14, -0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Not applicable
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Analysis 3.20. Comparison 3 Vaginal misoprostol versus placebo, Outcome 20 Time to birth - Interval from
intervention to vaginal birth (days).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 20 Time to birth - Interval from intervention to vaginal birth (days)
Study or subgroup Misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
McKenna 2004 24 3.9 (4.2) 26 5.3 (3.3) 100.0 % -1.40 [ -3.51, 0.71 ]
Total (95% CI) 24 26 100.0 % -1.40 [ -3.51, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 3.21. Comparison 3 Vaginal misoprostol versus placebo, Outcome 21 Time to birth - Days to birth
(all) (days).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 21 Time to birth - Days to birth (all) (days)
Study or subgroup Misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
McKenna 2004 33 4.2 (4.1) 35 6.1 (3.6) 100.0 % -1.90 [ -3.74, -0.06 ]
Total (95% CI) 33 35 100.0 % -1.90 [ -3.74, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 3.22. Comparison 3 Vaginal misoprostol versus placebo, Outcome 22 Time to birth - Days to birth
(subgroups by parity) (days).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 3 Vaginal misoprostol versus placebo
Outcome: 22 Time to birth - Days to birth (subgroups by parity) (days)
Study or subgroup Experimental Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Nulliparous women
McKenna 2004 20 4.2 (4) 19 7.2 (3.7) 100.0 % -3.00 [ -5.42, -0.58 ]
Subtotal (95% CI) 20 19 100.0 % -3.00 [ -5.42, -0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
2 Parous women
McKenna 2004 13 4 (4.5) 16 4.6 (3.2) 100.0 % -0.60 [ -3.51, 2.31 ]
Subtotal (95% CI) 13 16 100.0 % -0.60 [ -3.51, 2.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 1.55, df = 1 (P = 0.21), I2 =35%
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Analysis 4.1. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 1 Additional induction agents
required (oxytocin).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 4 Vaginal misoprostol 25 g versus 50 g
Outcome: 1 Additional induction agents required (oxytocin)
Study or subgroup Lower dose Higher dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kipikasa 2005 2/23 1/26 100.0 % 2.26 [ 0.22, 23.33 ]
Total (95% CI) 23 26 100.0 % 2.26 [ 0.22, 23.33 ]
Total events: 2 (Lower dose), 1 (Higher dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 2 Uterine hyperstimulation.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 4 Vaginal misoprostol 25 g versus 50 g
Outcome: 2 Uterine hyperstimulation
Study or subgroup Lower dose Higher dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kipikasa 2005 0/23 0/26 Not estimable
Total (95% CI) 23 26 Not estimable
Total events: 0 (Lower dose), 0 (Higher dose)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 3 Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 4 Vaginal misoprostol 25 g versus 50 g
Outcome: 3 Caesarean section
Study or subgroup Lower dose Higher dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kipikasa 2005 5/23 6/26 100.0 % 0.94 [ 0.33, 2.68 ]
Total (95% CI) 23 26 100.0 % 0.94 [ 0.33, 2.68 ]
Total events: 5 (Lower dose), 6 (Higher dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 4 NICU admission.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 4 Vaginal misoprostol 25 g versus 50 g
Outcome: 4 NICU admission
Study or subgroup Lower dose Higher dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kipikasa 2005 1/23 2/26 100.0 % 0.57 [ 0.05, 5.83 ]
Total (95% CI) 23 26 100.0 % 0.57 [ 0.05, 5.83 ]
Total events: 1 (Lower dose), 2 (Higher dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Vaginal misoprostol 25 µg versus 50 µg, Outcome 5 Interval from treatment to
birth (in days, all births).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 4 Vaginal misoprostol 25 g versus 50 g
Outcome: 5 Interval from treatment to birth (in days, all births)
Study or subgroup Lower dose Higher dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kipikasa 2005 23 3.9 (0.7) 26 2.4 (0.3) 100.0 % 1.50 [ 1.19, 1.81 ]
Total (95% CI) 23 26 100.0 % 1.50 [ 1.19, 1.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.53 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 1 Uterine
hyperstimulation (with or without FHR changes).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 5 Intracervical PGE versus vaginal misoprostol
Outcome: 1 Uterine hyperstimulation (with or without FHR changes)
Study or subgroup PGE2 Misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meyer 2005 1/42 2/22 100.0 % 0.26 [ 0.03, 2.73 ]
Total (95% CI) 42 22 100.0 % 0.26 [ 0.03, 2.73 ]
Total events: 1 (PGE2), 2 (Misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 2 Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 5 Intracervical PGE versus vaginal misoprostol
Outcome: 2 Caesarean section
Study or subgroup PGE2 Misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meyer 2005 8/42 9/42 100.0 % 0.89 [ 0.38, 2.08 ]
Total (95% CI) 42 42 100.0 % 0.89 [ 0.38, 2.08 ]
Total events: 8 (PGE2), 9 (Misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 3 Apgar score < 7
after 5 minutes.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 5 Intracervical PGE versus vaginal misoprostol
Outcome: 3 Apgar score < 7 after 5 minutes
Study or subgroup PGE2 Misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meyer 2005 0/42 1/42 100.0 % 0.33 [ 0.01, 7.96 ]
Total (95% CI) 42 42 100.0 % 0.33 [ 0.01, 7.96 ]
Total events: 0 (PGE2), 1 (Misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 4 Admission to NICU.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 5 Intracervical PGE versus vaginal misoprostol
Outcome: 4 Admission to NICU
Study or subgroup PGE2 Misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meyer 2005 5/42 4/42 100.0 % 1.25 [ 0.36, 4.33 ]
Total (95% CI) 42 42 100.0 % 1.25 [ 0.36, 4.33 ]
Total events: 5 (PGE2), 4 (Misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 5 Indicator of
’progress’ in labour - Interval from administration to admission (hours).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 5 Intracervical PGE versus vaginal misoprostol
Outcome: 5 Indicator of ’progress’ in labour - Interval from administration to admission (hours)
Study or subgroup PGE2 Misoprostol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Meyer 2005 38 15.1 (0.5) 37 12.6 (0.7) 100.0 % 2.50 [ 2.22, 2.78 ]
Total (95% CI) 38 37 100.0 % 2.50 [ 2.22, 2.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 17.76 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 6 Indicator of
’progress’ in labour - Labour or SROM during ripening.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 5 Intracervical PGE versus vaginal misoprostol
Outcome: 6 Indicator of ’progress’ in labour - Labour or SROM during ripening
Study or subgroup PGE2 Misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meyer 2005 6/42 19/41 100.0 % 0.31 [ 0.14, 0.69 ]
Total (95% CI) 42 41 100.0 % 0.31 [ 0.14, 0.69 ]
Total events: 6 (PGE2), 19 (Misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0044)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 7 Time to birth -
Birth within 24 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 5 Intracervical PGE versus vaginal misoprostol
Outcome: 7 Time to birth - Birth within 24 hours
Study or subgroup PGE2 Misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meyer 2005 34/42 37/41 100.0 % 0.90 [ 0.75, 1.07 ]
Total (95% CI) 42 41 100.0 % 0.90 [ 0.75, 1.07 ]
Total events: 34 (PGE2), 37 (Misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours misoprostol Favours PGE2
138Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.8. Comparison 5 Intracervical PGE versus vaginal misoprostol, Outcome 8 Time to birth -
Birth within 48 hours (cumulative).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 5 Intracervical PGE versus vaginal misoprostol
Outcome: 8 Time to birth - Birth within 48 hours (cumulative)
Study or subgroup PGE2 Misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meyer 2005 37/42 39/41 100.0 % 0.93 [ 0.81, 1.06 ]
Total (95% CI) 42 41 100.0 % 0.93 [ 0.81, 1.06 ]
Total events: 37 (PGE2), 39 (Misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Oral misoprostol versus placebo, Outcome 1 Vaginal delivery not achieved
within 24 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 1 Vaginal delivery not achieved within 24 hours
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 24/43 38/44 100.0 % 0.65 [ 0.48, 0.86 ]
Total (95% CI) 43 44 100.0 % 0.65 [ 0.48, 0.86 ]
Total events: 24 (Oral misoprostol), 38 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0032)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Oral misoprostol versus placebo, Outcome 2 Additional induction agents
required.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 2 Additional induction agents required
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 12/43 18/44 60.3 % 0.68 [ 0.38, 1.24 ]
Lyons 2001 5/18 13/22 39.7 % 0.47 [ 0.21, 1.07 ]
Total (95% CI) 61 66 100.0 % 0.60 [ 0.37, 0.97 ]
Total events: 17 (Oral misoprostol), 31 (Placebo/ expt)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.036)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Oral misoprostol versus placebo, Outcome 3 Oxytocin augmentation.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 3 Oxytocin augmentation
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 27/43 34/44 100.0 % 0.81 [ 0.61, 1.08 ]
Total (95% CI) 43 44 100.0 % 0.81 [ 0.61, 1.08 ]
Total events: 27 (Oral misoprostol), 34 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Oral misoprostol versus placebo, Outcome 4 Uterine hyperstimulation (with
FHR changes).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 4 Uterine hyperstimulation (with FHR changes)
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 6/43 4/44 100.0 % 1.53 [ 0.47, 5.06 ]
Total (95% CI) 43 44 100.0 % 1.53 [ 0.47, 5.06 ]
Total events: 6 (Oral misoprostol), 4 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 Oral misoprostol versus placebo, Outcome 5 Uterine hyperstimulation (FHR
changes unclear).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 5 Uterine hyperstimulation (FHR changes unclear)
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lyons 2001 1/18 2/22 100.0 % 0.61 [ 0.06, 6.21 ]
Total (95% CI) 18 22 100.0 % 0.61 [ 0.06, 6.21 ]
Total events: 1 (Oral misoprostol), 2 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 Oral misoprostol versus placebo, Outcome 6 Instrumental vaginal birth.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 6 Instrumental vaginal birth
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 4/43 8/44 100.0 % 0.51 [ 0.17, 1.57 ]
Total (95% CI) 43 44 100.0 % 0.51 [ 0.17, 1.57 ]
Total events: 4 (Oral misoprostol), 8 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 Oral misoprostol versus placebo, Outcome 7 Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 7 Caesarean section
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 8/43 13/43 100.0 % 0.62 [ 0.28, 1.33 ]
Total (95% CI) 43 43 100.0 % 0.62 [ 0.28, 1.33 ]
Total events: 8 (Oral misoprostol), 13 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 6.8. Comparison 6 Oral misoprostol versus placebo, Outcome 8 Apgar score < 7 at 5 minutes.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 8 Apgar score < 7 at 5 minutes
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 0/43 0/44 Not estimable
Total (95% CI) 43 44 Not estimable
Total events: 0 (Oral misoprostol), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.9. Comparison 6 Oral misoprostol versus placebo, Outcome 9 Neonatal intensive care unit
admission.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 9 Neonatal intensive care unit admission
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 1/43 1/44 100.0 % 1.02 [ 0.07, 15.84 ]
Total (95% CI) 43 44 100.0 % 1.02 [ 0.07, 15.84 ]
Total events: 1 (Oral misoprostol), 1 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 6.10. Comparison 6 Oral misoprostol versus placebo, Outcome 10 Postpartum haemorrhage.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 10 Postpartum haemorrhage
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 2/43 0/44 100.0 % 5.11 [ 0.25, 103.51 ]
Total (95% CI) 43 44 100.0 % 5.11 [ 0.25, 103.51 ]
Total events: 2 (Oral misoprostol), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 6.11. Comparison 6 Oral misoprostol versus placebo, Outcome 11 Chorioamnionitis.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 11 Chorioamnionitis
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 8/43 9/43 77.0 % 0.89 [ 0.38, 2.09 ]
Lyons 2001 4/17 3/21 23.0 % 1.65 [ 0.43, 6.38 ]
Total (95% CI) 60 64 100.0 % 1.06 [ 0.52, 2.17 ]
Total events: 12 (Oral misoprostol), 12 (Placebo/ expt)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 6.12. Comparison 6 Oral misoprostol versus placebo, Outcome 12 Endometritis.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 12 Endometritis
Study or subgroup Oral misoprostol Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaffaney 2009 1/43 2/44 100.0 % 0.51 [ 0.05, 5.44 ]
Total (95% CI) 43 44 100.0 % 0.51 [ 0.05, 5.44 ]
Total events: 1 (Oral misoprostol), 2 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 6.13. Comparison 6 Oral misoprostol versus placebo, Outcome 13 Indicator of ’progress’ in labour
- Time from first dose to active labor (hours).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 13 Indicator of ’progress’ in labour - Time from first dose to active labor (hours)
Study or subgroup Oral misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gaffaney 2009 43 37.91 (38.02) 44 76.08 (51.27) 65.8 % -38.17 [ -57.11, -19.23 ]
Lyons 2001 18 38.3 (35.52) 22 73.28 (49.03) 34.2 % -34.98 [ -61.23, -8.73 ]
Total (95% CI) 61 66 100.0 % -37.08 [ -52.44, -21.72 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.73 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.14. Comparison 6 Oral misoprostol versus placebo, Outcome 14 Time to birth - First dose to
birth (hours).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 14 Time to birth - First dose to birth (hours)
Study or subgroup Oral misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gaffaney 2009 43 46.23 (42.58) 44 84.17 (52.35) 100.0 % -37.94 [ -57.97, -17.91 ]
Total (95% CI) 43 44 100.0 % -37.94 [ -57.97, -17.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Not applicable
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Analysis 6.15. Comparison 6 Oral misoprostol versus placebo, Outcome 15 Indicator of ’progress’ in labour
- Total doses of medication.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 6 Oral misoprostol versus placebo
Outcome: 15 Indicator of ’progress’ in labour - Total doses of medication
Study or subgroup Oral misoprostol Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lyons 2001 18 1.22 (0.55) 22 1.73 (0.77) 100.0 % -0.51 [ -0.92, -0.10 ]
Total (95% CI) 18 22 100.0 % -0.51 [ -0.92, -0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Mifepristone versus placebo, Outcome 1 Additional induction agents required.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 1 Additional induction agents required
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elliott 1998 33/50 23/30 32.6 % 0.86 [ 0.65, 1.14 ]
Frydman 1992 13/57 32/55 25.2 % 0.39 [ 0.23, 0.66 ]
Giacalone 1998 19/41 25/42 28.7 % 0.78 [ 0.52, 1.18 ]
Stenlund 1999 4/24 7/12 13.6 % 0.29 [ 0.10, 0.79 ]
Total (95% CI) 172 139 100.0 % 0.59 [ 0.37, 0.95 ]
Total events: 69 (Mifepristone), 87 (Placebo/ expt)
Heterogeneity: Tau2 = 0.16; Chi2 = 11.46, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Mifepristone versus placebo, Outcome 2 Serious neonatal morbidity or death.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 2 Serious neonatal morbidity or death
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stenlund 1999 (1) 1/24 0/12 100.0 % 1.56 [ 0.07, 35.67 ]
Total (95% CI) 24 12 100.0 % 1.56 [ 0.07, 35.67 ]
Total events: 1 (Mifepristone), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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(1) Convulsions (receiving anti-convulsive therapy)
Analysis 7.3. Comparison 7 Mifepristone versus placebo, Outcome 3 Oxytocin augmentation.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 3 Oxytocin augmentation
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliott 1998 20/50 14/30 59.3 % 0.86 [ 0.51, 1.43 ]
Stenlund 1999 17/24 9/12 40.7 % 0.94 [ 0.62, 1.43 ]
Total (95% CI) 74 42 100.0 % 0.89 [ 0.63, 1.26 ]
Total events: 37 (Mifepristone), 23 (Placebo/ expt)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Mifepristone versus placebo, Outcome 4 Epidural.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 4 Epidural
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frydman 1992 44/57 49/55 100.0 % 0.87 [ 0.73, 1.03 ]
Total (95% CI) 57 55 100.0 % 0.87 [ 0.73, 1.03 ]
Total events: 44 (Mifepristone), 49 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Mifepristone versus placebo, Outcome 5 Assisted (instrumental) vaginal birth.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 5 Assisted (instrumental) vaginal birth
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliott 1998 (1) 13/50 6/30 20.8 % 1.30 [ 0.55, 3.06 ]
Frydman 1992 20/57 17/55 48.0 % 1.14 [ 0.67, 1.93 ]
Giacalone 1998 9/41 6/42 16.4 % 1.54 [ 0.60, 3.93 ]
Lelaidier 1994 5/16 4/16 11.1 % 1.25 [ 0.41, 3.82 ]
Stenlund 1999 8/24 1/12 3.7 % 4.00 [ 0.56, 28.40 ]
Total (95% CI) 188 155 100.0 % 1.35 [ 0.93, 1.97 ]
Total events: 55 (Mifepristone), 34 (Placebo/ expt)
Heterogeneity: Chi2 = 1.70, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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(1) Figures estimated from graph
Analysis 7.6. Comparison 7 Mifepristone versus placebo, Outcome 6 Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 6 Caesarean section
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliott 1998 (1) 11/50 8/30 21.6 % 0.83 [ 0.37, 1.82 ]
Frydman 1992 18/57 18/55 39.6 % 0.96 [ 0.56, 1.65 ]
Giacalone 1998 7/41 6/42 12.8 % 1.20 [ 0.44, 3.25 ]
Lelaidier 1994 5/16 8/16 17.3 % 0.63 [ 0.26, 1.50 ]
Stenlund 1999 4/24 3/12 8.6 % 0.67 [ 0.18, 2.51 ]
Total (95% CI) 188 155 100.0 % 0.88 [ 0.62, 1.25 ]
Total events: 45 (Mifepristone), 43 (Placebo/ expt)
Heterogeneity: Chi2 = 1.25, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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(1) Figures estimated from graph
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Analysis 7.7. Comparison 7 Mifepristone versus placebo, Outcome 7 Apgar score < 7 at 5 minutes.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 7 Apgar score < 7 at 5 minutes
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giacalone 1998 0/41 0/42 Not estimable
Stenlund 1999 1/24 0/12 100.0 % 1.56 [ 0.07, 35.67 ]
Total (95% CI) 65 54 100.0 % 1.56 [ 0.07, 35.67 ]
Total events: 1 (Mifepristone), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 7.8. Comparison 7 Mifepristone versus placebo, Outcome 8 NICU admission.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 8 NICU admission
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliott 1998 0/50 1/30 32.1 % 0.20 [ 0.01, 4.82 ]
Giacalone 1998 5/41 4/42 67.9 % 1.28 [ 0.37, 4.44 ]
Total (95% CI) 91 72 100.0 % 0.93 [ 0.31, 2.79 ]
Total events: 5 (Mifepristone), 5 (Placebo/ expt)
Heterogeneity: Chi2 = 1.14, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 7.9. Comparison 7 Mifepristone versus placebo, Outcome 9 Perinatal death.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 9 Perinatal death
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lelaidier 1994 0/16 0/16 Not estimable
Total (95% CI) 16 16 Not estimable
Total events: 0 (Mifepristone), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.10. Comparison 7 Mifepristone versus placebo, Outcome 10 Uterine scar separation.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 10 Uterine scar separation
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lelaidier 1994 (1) 1/16 1/16 100.0 % 1.00 [ 0.07, 14.64 ]
Total (95% CI) 16 16 100.0 % 1.00 [ 0.07, 14.64 ]
Total events: 1 (Mifepristone), 1 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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(1) ”uterine scar separation”
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Analysis 7.11. Comparison 7 Mifepristone versus placebo, Outcome 11 Chorioamnionitis.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 11 Chorioamnionitis
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lelaidier 1994 (1) 2/16 1/16 100.0 % 2.00 [ 0.20, 19.91 ]
Total (95% CI) 16 16 100.0 % 2.00 [ 0.20, 19.91 ]
Total events: 2 (Mifepristone), 1 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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(1) ”Fever during labour”
Analysis 7.12. Comparison 7 Mifepristone versus placebo, Outcome 12 Indicator of ’progress’ in labour -
Labour or ripe cervix in 48 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 12 Indicator of ’progress’ in labour - Labour or ripe cervix in 48 hours
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stenlund 1999 20/24 5/12 100.0 % 2.00 [ 1.00, 4.00 ]
Total (95% CI) 24 12 100.0 % 2.00 [ 1.00, 4.00 ]
Total events: 20 (Mifepristone), 5 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Not applicable
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Analysis 7.13. Comparison 7 Mifepristone versus placebo, Outcome 13 Indicator of ’progress’ in labour -
Cervix unchanged after 24/48 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 13 Indicator of ’progress’ in labour - Cervix unchanged after 24/48 hours
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giacalone 1998 8/41 21/42 69.0 % 0.39 [ 0.20, 0.78 ]
Stenlund 1999 4/24 7/12 31.0 % 0.29 [ 0.10, 0.79 ]
Total (95% CI) 65 54 100.0 % 0.36 [ 0.20, 0.63 ]
Total events: 12 (Mifepristone), 28 (Placebo/ expt)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.52 (P = 0.00043)
Test for subgroup differences: Not applicable
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Analysis 7.14. Comparison 7 Mifepristone versus placebo, Outcome 14 Indicator of ’progress’ in labour -
Spontaneous labour within 72 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 14 Indicator of ’progress’ in labour - Spontaneous labour within 72 hours
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliott 1998 17/50 7/30 100.0 % 1.46 [ 0.68, 3.10 ]
Total (95% CI) 50 30 100.0 % 1.46 [ 0.68, 3.10 ]
Total events: 17 (Mifepristone), 7 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 7.15. Comparison 7 Mifepristone versus placebo, Outcome 15 Indicator of ’progress’ in labour -
Spontaneous labour within 48 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 15 Indicator of ’progress’ in labour - Spontaneous labour within 48 hours
Study or subgroup Mifepristone Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giacalone 1998 28/41 14/42 100.0 % 2.05 [ 1.27, 3.30 ]
Total (95% CI) 41 42 100.0 % 2.05 [ 1.27, 3.30 ]
Total events: 28 (Mifepristone), 14 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0031)
Test for subgroup differences: Not applicable
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Analysis 7.16. Comparison 7 Mifepristone versus placebo, Outcome 16 Indicator of ’progress’ in labour -
Oxytocin requirements (IU).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 16 Indicator of ’progress’ in labour - Oxytocin requirements (IU)
Study or subgroup Mifepristone Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lelaidier 1994 16 2.11 (1.92) 16 4.67 (2.26) 100.0 % -2.56 [ -4.01, -1.11 ]
Total (95% CI) 16 16 100.0 % -2.56 [ -4.01, -1.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00055)
Test for subgroup differences: Not applicable
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Analysis 7.17. Comparison 7 Mifepristone versus placebo, Outcome 17 Indicator of ’progress’ in labour -
Interval between day 1 and start of labour (hours).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 7 Mifepristone versus placebo
Outcome: 17 Indicator of ’progress’ in labour - Interval between day 1 and start of labour (hours)
Study or subgroup Mifepristone Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lelaidier 1994 16 60.35 (18.4) 16 82.5 (21.35) 100.0 % -22.15 [ -35.96, -8.34 ]
Total (95% CI) 16 16 100.0 % -22.15 [ -35.96, -8.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Oestrogens versus placebo, Outcome 1 Oxytocin augmentation.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 8 Oestrogens versus placebo
Outcome: 1 Oxytocin augmentation
Study or subgroup Vaginal oestrogen Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 21/44 22/43 100.0 % 0.93 [ 0.61, 1.43 ]
Total (95% CI) 44 43 100.0 % 0.93 [ 0.61, 1.43 ]
Total events: 21 (Vaginal oestrogen), 22 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Oestrogens versus placebo, Outcome 2 Assisted (instrumental) vaginal birth.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 8 Oestrogens versus placebo
Outcome: 2 Assisted (instrumental) vaginal birth
Study or subgroup Vaginal oestrogen Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 12/44 14/43 100.0 % 0.84 [ 0.44, 1.60 ]
Total (95% CI) 44 43 100.0 % 0.84 [ 0.44, 1.60 ]
Total events: 12 (Vaginal oestrogen), 14 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Oestrogens versus placebo, Outcome 3 Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 8 Oestrogens versus placebo
Outcome: 3 Caesarean section
Study or subgroup Vaginal oestrogen Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 13/44 10/43 100.0 % 1.27 [ 0.63, 2.58 ]
Total (95% CI) 44 43 100.0 % 1.27 [ 0.63, 2.58 ]
Total events: 13 (Vaginal oestrogen), 10 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Oestrogens versus placebo, Outcome 4 NICU admission.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 8 Oestrogens versus placebo
Outcome: 4 NICU admission
Study or subgroup Vaginal oestrogen Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 1/44 1/43 100.0 % 0.98 [ 0.06, 15.13 ]
Total (95% CI) 44 43 100.0 % 0.98 [ 0.06, 15.13 ]
Total events: 1 (Vaginal oestrogen), 1 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Oestrogens versus placebo, Outcome 5 Chorioamnionitis.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 8 Oestrogens versus placebo
Outcome: 5 Chorioamnionitis
Study or subgroup Vaginal oestrogen Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 4/44 2/43 100.0 % 1.95 [ 0.38, 10.12 ]
Total (95% CI) 44 43 100.0 % 1.95 [ 0.38, 10.12 ]
Total events: 4 (Vaginal oestrogen), 2 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 Oestrogens versus placebo, Outcome 6 Endometritis.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 8 Oestrogens versus placebo
Outcome: 6 Endometritis
Study or subgroup Vaginal oestrogen Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Larmon 2002 3/44 1/43 100.0 % 2.93 [ 0.32, 27.10 ]
Total (95% CI) 44 43 100.0 % 2.93 [ 0.32, 27.10 ]
Total events: 3 (Vaginal oestrogen), 1 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 1 Vaginal birth
not achieved in 24/48 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 1 Vaginal birth not achieved in 24/48 hours
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bollapragada 2006a 81/117 86/121 100.0 % 0.97 [ 0.83, 1.15 ]
Total (95% CI) 117 121 100.0 % 0.97 [ 0.83, 1.15 ]
Total events: 81 (IMN), 86 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 2 Additional
induction agents required.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 2 Additional induction agents required
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bollapragada 2006a 83/130 94/127 25.8 % 0.86 [ 0.73, 1.02 ]
Bullarbo 2007 64/100 74/100 23.6 % 0.86 [ 0.72, 1.04 ]
Habib 2008 32/51 46/51 19.7 % 0.70 [ 0.55, 0.88 ]
Schmitz 2014 309/678 312/684 31.0 % 1.00 [ 0.89, 1.12 ]
Total (95% CI) 959 962 100.0 % 0.87 [ 0.75, 1.00 ]
Total events: 488 (IMN), 526 (Placebo/ expt)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.92, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 3 Maternal
satisfaction.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 3 Maternal satisfaction
Study or subgroup IMN Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 How do you think your labour went? (easy/very difficult)
Bollapragada 2006a (1) 116 6.18 (2.46) 111 6.52 (2.16) 100.0 % -0.34 [ -0.94, 0.26 ]
Subtotal (95% CI) 116 111 100.0 % -0.34 [ -0.94, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
2 What do you think about home treatment? (extremely good/not at all good)
Bollapragada 2006a (2) 116 3.84 (2.3) 111 3.23 (2.15) 100.0 % 0.61 [ 0.03, 1.19 ]
Subtotal (95% CI) 116 111 100.0 % 0.61 [ 0.03, 1.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
3 How painful was the treatment at home? (not at all/very)
Bollapragada 2006a (3) 116 2.76 (2.3) 111 2.18 (2.18) 100.0 % 0.58 [ 0.00, 1.16 ]
Subtotal (95% CI) 116 111 100.0 % 0.58 [ 0.00, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
4 How anxious were you being at home taking the treatment? (not at all/very)
Bollapragada 2006a (4) 116 2.5 (1.96) 111 2.39 (1.88) 100.0 % 0.11 [ -0.39, 0.61 ]
Subtotal (95% CI) 116 111 100.0 % 0.11 [ -0.39, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
5 Would you have the same treatment at home again? (definitely/definitely not)
Bollapragada 2006a (5) 116 3.39 (2.74) 111 2.77 (2.19) 100.0 % 0.62 [ -0.02, 1.26 ]
Subtotal (95% CI) 116 111 100.0 % 0.62 [ -0.02, 1.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
6 Would you advise a friend to have the same treatment at home? (definitely/definitely not)
-1 -0.5 0 0.5 1
Favours IMN Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup IMN Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bollapragada 2006a (6) 116 3.1 (2.38) 111 2.69 (2.07) 100.0 % 0.41 [ -0.17, 0.99 ]
Subtotal (95% CI) 116 111 100.0 % 0.41 [ -0.17, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
-1 -0.5 0 0.5 1
Favours IMN Favours control
(1) (low score= satisfied, high score = dissatisfied, score out of 10)
(2) (low score= satisfied, high score = dissatisfied, score out of 10)
(3) (low score= satisfied, high score = dissatisfied, score out of 10)
(4) (low score= satisfied, high score = dissatisfied, score out of 10)
(5) (low score= satisfied, high score = dissatisfied, score out of 10)
(6) (low score= satisfied, high score = dissatisfied, score out of 10)
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Analysis 9.4. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 4 Maternal
satisfaction.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 4 Maternal satisfaction
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Felt satisfied (very or extremely)
Schmitz 2014 162/525 203/524 100.0 % 0.80 [ 0.67, 0.94 ]
Subtotal (95% CI) 525 524 100.0 % 0.80 [ 0.67, 0.94 ]
Total events: 162 (IMN), 203 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0077)
2 Would recommend the same treatment
Schmitz 2014 339/525 405/524 100.0 % 0.84 [ 0.77, 0.90 ]
Subtotal (95% CI) 525 524 100.0 % 0.84 [ 0.77, 0.90 ]
Total events: 339 (IMN), 405 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 4.49 (P < 0.00001)
3 Would recommend procedure
Bullarbo 2007 89/94 93/99 100.0 % 1.01 [ 0.94, 1.08 ]
Subtotal (95% CI) 94 99 100.0 % 1.01 [ 0.94, 1.08 ]
Total events: 89 (IMN), 93 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
0.5 0.7 1 1.5 2
Favours IMN Favours control
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Analysis 9.5. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 5 Perinatal
death.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 5 Perinatal death
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bollapragada 2006a 0/177 1/173 48.1 % 0.33 [ 0.01, 7.94 ]
Schmitz 2014 (1) 3/678 0/684 51.9 % 7.06 [ 0.37, 136.45 ]
Total (95% CI) 855 857 100.0 % 1.61 [ 0.08, 33.26 ]
Total events: 3 (IMN), 1 (Placebo/ expt)
Heterogeneity: Tau2 = 2.31; Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMN Favours control
(1) Perinatal death calculated by adding fetal death plus neonatal death
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Analysis 9.6. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 6 Neonatal
trauma (long bone fracture, collarbone fracture, basal skull fracture, brachial plexus palsy, facial nerve palsy,
phrenic nerve palsy, or subdural haemorrhage).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 6 Neonatal trauma (long bone fracture, collarbone fracture, basal skull fracture, brachial plexus palsy, facial nerve palsy, phrenic nerve palsy, or subdural
haemorrhage)
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmitz 2014 4/678 6/684 100.0 % 0.67 [ 0.19, 2.37 ]
Total (95% CI) 678 684 100.0 % 0.67 [ 0.19, 2.37 ]
Total events: 4 (IMN), 6 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMN Favours control
Analysis 9.7. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 7 Neonatal
convulsions in the first 24 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 7 Neonatal convulsions in the first 24 hours
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmitz 2014 0/678 0/684 Not estimable
Total (95% CI) 678 684 Not estimable
Total events: 0 (IMN), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMN Favours control
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Analysis 9.8. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 8 Tracheal
ventilation > 24 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 8 Tracheal ventilation > 24 hours
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmitz 2014 2/678 2/684 100.0 % 1.01 [ 0.14, 7.14 ]
Total (95% CI) 678 684 100.0 % 1.01 [ 0.14, 7.14 ]
Total events: 2 (IMN), 2 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 9.9. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 9 Neonatal
ICU admission for 5 or more days.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 9 Neonatal ICU admission for 5 or more days
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmitz 2014 4/678 6/684 100.0 % 0.67 [ 0.19, 2.37 ]
Total (95% CI) 678 684 100.0 % 0.67 [ 0.19, 2.37 ]
Total events: 4 (IMN), 6 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMN Favours control
Analysis 9.10. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 10 Neonatal
transfer.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 10 Neonatal transfer
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmitz 2014 35/678 33/684 100.0 % 1.07 [ 0.67, 1.70 ]
Total (95% CI) 678 684 100.0 % 1.07 [ 0.67, 1.70 ]
Total events: 35 (IMN), 33 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 9.11. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 11 Maternal
death.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 11 Maternal death
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmitz 2014 0/678 0/684 Not estimable
Total (95% CI) 678 684 Not estimable
Total events: 0 (IMN), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMN Favours control
Analysis 9.12. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 12 Severe
postpartum haemorrhage.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 12 Severe postpartum haemorrhage
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmitz 2014 20/678 13/684 100.0 % 1.55 [ 0.78, 3.09 ]
Total (95% CI) 678 684 100.0 % 1.55 [ 0.78, 3.09 ]
Total events: 20 (IMN), 13 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 9.13. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 13 Deep vein
thrombosis.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 13 Deep vein thrombosis
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmitz 2014 1/678 0/684 100.0 % 3.03 [ 0.12, 74.16 ]
Total (95% CI) 678 684 100.0 % 3.03 [ 0.12, 74.16 ]
Total events: 1 (IMN), 0 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 9.14. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 14 Oxytocin
augmentation.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 14 Oxytocin augmentation
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Agarwal 2012 56/100 74/100 29.8 % 0.76 [ 0.61, 0.93 ]
Bollapragada 2006a 80/127 75/127 31.1 % 1.07 [ 0.88, 1.30 ]
Schmitz 2014 295/678 291/684 39.1 % 1.02 [ 0.91, 1.16 ]
Total (95% CI) 905 911 100.0 % 0.95 [ 0.78, 1.14 ]
Total events: 431 (IMN), 440 (Placebo/ expt)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.11, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 9.15. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 15 Epidural.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 15 Epidural
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bollapragada 2006a 116/177 120/173 100.0 % 0.94 [ 0.82, 1.09 ]
Total (95% CI) 177 173 100.0 % 0.94 [ 0.82, 1.09 ]
Total events: 116 (IMN), 120 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 9.16. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 16 Uterine
hyperstimulation (with FHR changes).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 16 Uterine hyperstimulation (with FHR changes)
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Habib 2008 0/51 2/51 100.0 % 0.20 [ 0.01, 4.07 ]
Total (95% CI) 51 51 100.0 % 0.20 [ 0.01, 4.07 ]
Total events: 0 (IMN), 2 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 9.17. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 17 Uterine
hyperstimulation (FHR changes unclear).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 17 Uterine hyperstimulation (FHR changes unclear)
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Agarwal 2012 0/100 5/100 100.0 % 0.09 [ 0.01, 1.62 ]
Total (95% CI) 100 100 100.0 % 0.09 [ 0.01, 1.62 ]
Total events: 0 (IMN), 5 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMN Favours control
171Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.18. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 18 Assisted
(instrumental) vaginal birth.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 18 Assisted (instrumental) vaginal birth
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bollapragada 2006a 47/177 54/173 61.1 % 0.85 [ 0.61, 1.18 ]
Schmitz 2014 (1) 26/678 35/684 38.9 % 0.75 [ 0.46, 1.23 ]
Total (95% CI) 855 857 100.0 % 0.81 [ 0.61, 1.07 ]
Total events: 73 (IMN), 89 (Placebo/ expt)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMN Favours control
(1) The Schmitz paper reports instrumental delivery, but it seems to include CS + instrumental VD in this figure (211 and 221). Hence we have calculated the instrumental
VD as 211-185 (CS) = 26 and 221-186 (CS) =35
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Analysis 9.19. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 19 Caesarean
section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 19 Caesarean section
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Agarwal 2012 22/100 31/100 10.0 % 0.71 [ 0.44, 1.14 ]
Bollapragada 2006a 65/177 56/173 18.2 % 1.13 [ 0.85, 1.52 ]
Bullarbo 2007 14/100 17/100 5.5 % 0.82 [ 0.43, 1.58 ]
Ghanaie 2013 8/36 4/36 1.3 % 2.00 [ 0.66, 6.06 ]
Habib 2008 15/51 17/51 5.5 % 0.88 [ 0.50, 1.57 ]
Schmitz 2014 185/678 186/684 59.6 % 1.00 [ 0.84, 1.19 ]
Total (95% CI) 1142 1144 100.0 % 0.99 [ 0.87, 1.14 ]
Total events: 309 (IMN), 311 (Placebo/ expt)
Heterogeneity: Chi2 = 4.80, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 9.20. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 20 Apgar
score < 7 at 5 minutes.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 20 Apgar score < 7 at 5 minutes
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Agarwal 2012 0/100 3/100 20.6 % 0.14 [ 0.01, 2.73 ]
Bollapragada 2006a 3/177 2/173 11.9 % 1.47 [ 0.25, 8.67 ]
Bullarbo 2007 2/100 1/100 5.9 % 2.00 [ 0.18, 21.71 ]
Habib 2008 0/51 1/51 8.8 % 0.33 [ 0.01, 8.00 ]
Schmitz 2014 9/678 9/684 52.8 % 1.01 [ 0.40, 2.53 ]
Total (95% CI) 1106 1108 100.0 % 0.88 [ 0.44, 1.76 ]
Total events: 14 (IMN), 16 (Placebo/ expt)
Heterogeneity: Chi2 = 2.67, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 9.21. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 21 NICU (or
SCBU) admission.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 21 NICU (or SCBU) admission
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Agarwal 2012 5/100 14/100 33.6 % 0.36 [ 0.13, 0.95 ]
Attanayake 2014 1/72 1/72 2.4 % 1.00 [ 0.06, 15.68 ]
Bollapragada 2006a 18/177 16/173 38.8 % 1.10 [ 0.58, 2.09 ]
Bullarbo 2007 13/100 9/100 21.6 % 1.44 [ 0.65, 3.23 ]
Ghanaie 2013 0/36 0/36 Not estimable
Habib 2008 0/51 1/51 3.6 % 0.33 [ 0.01, 8.00 ]
Total (95% CI) 536 532 100.0 % 0.89 [ 0.59, 1.36 ]
Total events: 37 (IMN), 41 (Placebo/ expt)
Heterogeneity: Chi2 = 5.50, df = 4 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 9.22. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 22
Postpartum haemorrhage (> 500 mL).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 22 Postpartum haemorrhage (> 500 mL)
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Agarwal 2012 2/100 3/100 1.7 % 0.67 [ 0.11, 3.90 ]
Bollapragada 2006a 59/177 47/173 26.9 % 1.23 [ 0.89, 1.69 ]
Bullarbo 2007 (1) 14/100 12/100 6.8 % 1.17 [ 0.57, 2.40 ]
Habib 2008 2/51 3/51 1.7 % 0.67 [ 0.12, 3.82 ]
Schmitz 2014 124/678 112/684 63.0 % 1.12 [ 0.89, 1.41 ]
Total (95% CI) 1106 1108 100.0 % 1.13 [ 0.95, 1.36 ]
Total events: 201 (IMN), 177 (Placebo/ expt)
Heterogeneity: Chi2 = 0.96, df = 4 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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(1) PPH >1000ml
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Analysis 9.23. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 23 Neonatal
infection.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 23 Neonatal infection
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bullarbo 2007 (1) 4/100 4/100 100.0 % 1.00 [ 0.26, 3.89 ]
Total (95% CI) 100 100 100.0 % 1.00 [ 0.26, 3.89 ]
Total events: 4 (IMN), 4 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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(1) Infection leading to ICU admission
Analysis 9.24. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 24 Side
effects - Maternal side effect - nausea.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 24 Side effects - Maternal side effect - nausea
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bollapragada 2006a 19/112 13/108 26.7 % 1.41 [ 0.73, 2.71 ]
Attanayake 2014 3/72 2/72 5.7 % 1.50 [ 0.26, 8.71 ]
Schmitz 2014 153/678 54/684 51.4 % 2.86 [ 2.14, 3.83 ]
Bullarbo 2007 19/100 5/100 16.2 % 3.80 [ 1.48, 9.78 ]
Total (95% CI) 962 964 100.0 % 2.39 [ 1.54, 3.70 ]
Total events: 194 (IMN), 74 (Placebo/ expt)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.78, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 3.90 (P = 0.000095)
Test for subgroup differences: Not applicable
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Analysis 9.25. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 25 Side
effects - Maternal side effect - headache.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 25 Side effects - Maternal side effect - headache
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Agarwal 2012 63/100 2/100 8.5 % 31.50 [ 7.92, 125.23 ]
Attanayake 2014 32/72 11/72 19.6 % 2.91 [ 1.59, 5.31 ]
Bollapragada 2006a 74/112 22/108 23.7 % 3.24 [ 2.18, 4.82 ]
Bullarbo 2007 88/100 8/100 18.3 % 11.00 [ 5.64, 21.47 ]
Ghanaie 2013 0/36 0/36 Not estimable
Habib 2008 6/51 0/51 2.6 % 13.00 [ 0.75, 224.89 ]
Schmitz 2014 522/678 117/684 27.4 % 4.50 [ 3.80, 5.34 ]
Total (95% CI) 1149 1151 100.0 % 5.45 [ 3.38, 8.81 ]
Total events: 785 (IMN), 160 (Placebo/ expt)
Heterogeneity: Tau2 = 0.21; Chi2 = 21.09, df = 5 (P = 0.00078); I2 =76%
Test for overall effect: Z = 6.93 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.26. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 26 Side
effects - Maternal side effects - severe headache.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 26 Side effects - Maternal side effects - severe headache
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bollapragada 2006a 22/112 1/108 100.0 % 21.21 [ 2.91, 154.65 ]
Total (95% CI) 112 108 100.0 % 21.21 [ 2.91, 154.65 ]
Total events: 22 (IMN), 1 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.0026)
Test for subgroup differences: Not applicable
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Analysis 9.27. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 27 Indicator
of ’progress’ in labour - Admitted in established labour within 24 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 27 Indicator of ’progress’ in labour - Admitted in established labour within 24 hours
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bullarbo 2007 22/100 8/100 100.0 % 2.75 [ 1.29, 5.88 ]
Total (95% CI) 100 100 100.0 % 2.75 [ 1.29, 5.88 ]
Total events: 22 (IMN), 8 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0091)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours IMN
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Analysis 9.28. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 28 Indicator
of ’progress’ in labour - Bishop score > 6 or active labour at 36 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 28 Indicator of ’progress’ in labour - Bishop score > 6 or active labour at 36 hours
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Habib 2008 19/51 5/51 100.0 % 3.80 [ 1.54, 9.40 ]
Total (95% CI) 51 51 100.0 % 3.80 [ 1.54, 9.40 ]
Total events: 19 (IMN), 5 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0039)
Test for subgroup differences: Not applicable
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Analysis 9.29. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 29 Time to
birth - Time in hours from admission to birth (all women).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 29 Time to birth - Time in hours from admission to birth (all women)
Study or subgroup IMN Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Agarwal 2012 100 9.7 (5.28) 100 13.49 (4.35) 45.6 % -3.79 [ -5.13, -2.45 ]
Ghanaie 2013 36 6.61 (3.74) 36 11.48 (3.55) 36.6 % -4.87 [ -6.55, -3.19 ]
Habib 2008 51 13.45 (6.63) 51 20.12 (8.19) 17.8 % -6.67 [ -9.56, -3.78 ]
Total (95% CI) 187 187 100.0 % -4.70 [ -6.08, -3.31 ]
Heterogeneity: Tau2 = 0.63; Chi2 = 3.43, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 6.65 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.30. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 30 Indicator
of ’progress’ in labour - Bishop score on admission after treatment.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 30 Indicator of ’progress’ in labour - Bishop score on admission after treatment
Study or subgroup IMN Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Agarwal 2012 100 4.84 (2.4) 100 2.11 (1.58) 100.0 % 2.73 [ 2.17, 3.29 ]
Total (95% CI) 100 100 100.0 % 2.73 [ 2.17, 3.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.50 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 9.31. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 31 Indicator
of ’progress’ in labour - Change in Bishop score.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 31 Indicator of ’progress’ in labour - Change in Bishop score
Study or subgroup IMN Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Agarwal 2012 100 3.17 (2.02) 100 0.25 (0.93) 41.1 % 2.92 [ 2.48, 3.36 ]
Ghanaie 2013 36 3.69 (0.89) 36 1.05 (0.67) 58.9 % 2.64 [ 2.28, 3.00 ]
Total (95% CI) 136 136 100.0 % 2.76 [ 2.48, 3.03 ]
Heterogeneity: Chi2 = 0.93, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 19.33 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.32. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 32 Time to
birth - Interval from onset of labour to birth (hours).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 32 Time to birth - Interval from onset of labour to birth (hours)
Study or subgroup IMN Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Agarwal 2012 100 5.67 (1.88) 100 6.91 (2.27) 100.0 % -1.24 [ -1.82, -0.66 ]
Total (95% CI) 100 100 100.0 % -1.24 [ -1.82, -0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.21 (P = 0.000026)
Test for subgroup differences: Not applicable
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Analysis 9.33. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 33 Indicator
of ’progress’ in labour - Cervix unchanged after 48 hours.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 33 Indicator of ’progress’ in labour - Cervix unchanged after 48 hours
Study or subgroup IMN Placebo/ expt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bollapragada 2006a 83/130 98/127 100.0 % 0.83 [ 0.70, 0.97 ]
Total (95% CI) 130 127 100.0 % 0.83 [ 0.70, 0.97 ]
Total events: 83 (IMN), 98 (Placebo/ expt)
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 9.34. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 34 Time to
birth - Interval from admission to vaginal birth (hours).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 34 Time to birth - Interval from admission to vaginal birth (hours)
Study or subgroup IMN Placebo/ expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bollapragada 2006a 65 17.4 (15.9) 63 18.1 (15.3) 100.0 % -0.70 [ -6.11, 4.71 ]
Total (95% CI) 65 63 100.0 % -0.70 [ -6.11, 4.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 9.35. Comparison 9 Vaginal isosorbide mononitrate (IMN) versus placebo, Outcome 35 Total cost
of care package (GBP).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 9 Vaginal isosorbide mononitrate (IMN) versus placebo
Outcome: 35 Total cost of care package (GBP)
Study or subgroup IMN Placebo/expt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bollapragada 2006a 177 1254.86 (625.26) 173 1242.88 (487.56) 100.0 % 11.98 [ -105.34, 129.30 ]
Total (95% CI) 177 173 100.0 % 11.98 [ -105.34, 129.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Acupuncture versus routine care, Outcome 1 Additional induction agents
required.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 10 Acupuncture versus routine care
Outcome: 1 Additional induction agents required
Study or subgroup Acupuncture Routine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Harper 2006 9/30 13/26 100.0 % 0.60 [ 0.31, 1.17 ]
Total (95% CI) 30 26 100.0 % 0.60 [ 0.31, 1.17 ]
Total events: 9 (Acupuncture), 13 (Routine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Acupuncture versus routine care, Outcome 2 Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 10 Acupuncture versus routine care
Outcome: 2 Caesarean section
Study or subgroup Acupuncture Routine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Harper 2006 5/30 10/26 100.0 % 0.43 [ 0.17, 1.11 ]
Total (95% CI) 30 26 100.0 % 0.43 [ 0.17, 1.11 ]
Total events: 5 (Acupuncture), 10 (Routine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 1
Maternal satisfaction - I look back positively on the treatment I received.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 11 Outpatient amniotomy for induction versus routine care
Outcome: 1 Maternal satisfaction - I look back positively on the treatment I received
Study or subgroup Amniotomy Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rijnders 2011 205/221 164/183 100.0 % 1.04 [ 0.97, 1.10 ]
Total (95% CI) 221 183 100.0 % 1.04 [ 0.97, 1.10 ]
Total events: 205 (Amniotomy), 164 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 2
Maternal satisfaction - In retrospect, I would have preferred another treatment than received.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 11 Outpatient amniotomy for induction versus routine care
Outcome: 2 Maternal satisfaction - In retrospect, I would have preferred another treatment than received
Study or subgroup Amniotomy Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rijnders 2011 36/221 80/251 100.0 % 0.51 [ 0.36, 0.72 ]
Total (95% CI) 221 251 100.0 % 0.51 [ 0.36, 0.72 ]
Total events: 36 (Amniotomy), 80 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.77 (P = 0.00017)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 3
Augmentation, induction or both.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 11 Outpatient amniotomy for induction versus routine care
Outcome: 3 Augmentation, induction or both
Study or subgroup Amniotomy Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rijnders 2011 136/270 152/251 100.0 % 0.83 [ 0.71, 0.97 ]
Total (95% CI) 270 251 100.0 % 0.83 [ 0.71, 0.97 ]
Total events: 136 (Amniotomy), 152 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 4
Epidural, opioids or both for pain relief.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 11 Outpatient amniotomy for induction versus routine care
Outcome: 4 Epidural, opioids or both for pain relief
Study or subgroup Amniotomy Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rijnders 2011 79/270 74/251 100.0 % 0.99 [ 0.76, 1.30 ]
Total (95% CI) 270 251 100.0 % 0.99 [ 0.76, 1.30 ]
Total events: 79 (Amniotomy), 74 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 11.5. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 5
Instrumental vaginal birth.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 11 Outpatient amniotomy for induction versus routine care
Outcome: 5 Instrumental vaginal birth
Study or subgroup Amniotomy Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rijnders 2011 31/270 41/251 100.0 % 0.70 [ 0.46, 1.08 ]
Total (95% CI) 270 251 100.0 % 0.70 [ 0.46, 1.08 ]
Total events: 31 (Amniotomy), 41 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 11.6. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 6
Caesarean section.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 11 Outpatient amniotomy for induction versus routine care
Outcome: 6 Caesarean section
Study or subgroup Amniotomy Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rijnders 2011 40/270 31/251 100.0 % 1.20 [ 0.78, 1.86 ]
Total (95% CI) 270 251 100.0 % 1.20 [ 0.78, 1.86 ]
Total events: 40 (Amniotomy), 31 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 11.7. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 7 Apgar
< 7 at 5 minutes.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 11 Outpatient amniotomy for induction versus routine care
Outcome: 7 Apgar < 7 at 5 minutes
Study or subgroup Amniotomy Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rijnders 2011 4/270 2/251 100.0 % 1.86 [ 0.34, 10.06 ]
Total (95% CI) 270 251 100.0 % 1.86 [ 0.34, 10.06 ]
Total events: 4 (Amniotomy), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 11.8. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 8
Neonatal intensive care unit admission.
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 11 Outpatient amniotomy for induction versus routine care
Outcome: 8 Neonatal intensive care unit admission
Study or subgroup Amniotomy Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmitz 2014 27/270 23/251 100.0 % 1.09 [ 0.64, 1.85 ]
Total (95% CI) 270 251 100.0 % 1.09 [ 0.64, 1.85 ]
Total events: 27 (Amniotomy), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 11.9. Comparison 11 Outpatient amniotomy for induction versus routine care, Outcome 9
Duration of birth (hours).
Review: Pharmacological and mechanical interventions for labour induction in outpatient settings
Comparison: 11 Outpatient amniotomy for induction versus routine care
Outcome: 9 Duration of birth (hours)
Study or subgroup Amniotomy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rijnders 2011 270 8.5 (6.9) 251 8.1 (6.1) 100.0 % 0.40 [ -0.72, 1.52 ]
Total (95% CI) 270 251 100.0 % 0.40 [ -0.72, 1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Uterine hyperstimulation with outpatient inductions
Uterine hyperstimulation
PGE (vaginal)
Hage 1993 1/18 PGE group (FHR status unknown), 0/18 in placebo group
Newman 1997 2/28 PGE group (FHR status unknown), 0/30 in control group (no treatment)
O’Brien 1995 1/50 PGE group (normal FHR), 0/50 in placebo group
Total 4/96 PGE, 0/98 in control group
PGE (intracervical)
Buttino 1990 1/23 PGE group (with FHR decelerations), 0/20 in placebo group
Lien 1998 2/43 PGE group, 1/47 placebo group with FHR deceleration in both
McKenna 1999 1/30 PGE group (fetal bradycardia), 0/31 placebo group
Rayburn 1999 1/143 PGE group, 0/151 control (no treatment) with hyperstimulation
11/143 FHR decelerations in PGE group, 12/151 in control
Total 5/239 PGE, 1/249 control with hyperstimulation
Intravaginal misoprostol
Stitely 2000 2/27 misoprostol group with FHR deceleration, 2/33 placebo group
1/27 misoprostol with tachysystole without FHR changes, 0/33 placebo group
Incerpi 2001 3/57 misoprostol with hyperstimulation (FHR unknown), 2/63 placebo group
2/57 misoprostol with hypertonus, 5/57 misoprostol with tachysystole, none control
McKenna 2004 1/33 misoprostol (FHR deceleration), 0/35 placebo group
Oral misoprostol
Lyons 2001 1/18 misoprostol, 2/22 placebo group (FHR unknown) with hyperstimulation
Gaffaney 2009 8/43misoprostol, 4/44 placebo group hyperstimulation syndrome (tachysystole or hypertonus, with FHR changes)
Total 9/61 misoprostol, 6/66 placebo group
Mifepristone
Giacalone 1998 4/41 mifepristone group, 0/42 placebo group with hypertonia (FHR unknown)
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Table 1. Uterine hyperstimulation with outpatient inductions (Continued)
Lelaidier 1994 0/16 in both groups
Total 4/57 mifepristone, 0/58 placebo with hypertonia
IMN
Habib 2008 0/51 IMN group, 2/51 placebo group with hyperstimulation (abnormal FHR)
1/51 IMN, 8/51 placebo group with tachysystolia (FHR normal)
Agarwal 2012 0/100 IMN group, 5/100 placebo group with hyperstimulation (FHR changes unclear)
Total 1/151 IMN group, 15/151 placebo group (hyperstimulation or tachysystolia, ±FHR changes)
IMN: isosorbide mononitrate; FHR: fetal heart rate
Table 2. Neonatal complications following induction in outpatient setting
Neonatal complications
PGE vaginal
Sawai 1991 0/24 in PGE group; 2/26 in placebo group to NICU
Sawai 1994 2/38 in PGE ; 4/42 in placebo group to NICU
O’Brien 1995 1/50 in PGE ; 5/50 in placebo group to NICU
Total 3/112 PGE, 11/118 control to NICU
PGE intracervical
Larmon 2002 6/41 PGE group, 8/43 placebo group with complication such as tachypnoea, meconium aspiration, meconium
or admission to NICU
Magann 1998 3/35 PGE versus 0/35 control NICU admission
McKenna 1999 1/30 PGE, 2/31 placebo group with complication
Total 10/106 PGE, 10/109 controls with neonatal complications/admitted to NICU
Vaginal misoprostol
Stitely 2000 1/27 misoprostol, 3/33 placebo group to NICU
Incerpi 2001 18/57 misoprostol, 20/63 placebo group to NICU
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Table 2. Neonatal complications following induction in outpatient setting (Continued)
McKenna 2004 0/33 misoprostol, 1/35 placebo group to NICU
Oboro 2005 1/38 misoprostol, 1/39 control (no treatment) to NICU
Gaffaney 2009 1/43 misoprostol, 1/44 placebo group to NICU
Total 21/198 misoprostol, 26/214 control to NICU
Misoprostol 25 µg versus 50 µg
Kipikasa 2005 1/23 25 µg, 2/26 50 µg misoprostol to NICU
Intracervical PGE versus intravaginal misoprostol
Meyer 2005 5/42 PGE, 4/42 misoprostol to NICU
Mifepristone
Elliott 1998 0/50 mifepristone, 1/30 placebo group to NICU
Giacalone 1998 5/41 mifepristone, 4/42 control to NICU
Total 5/91 mifepristone, 5/72 control to NICU
IMN
Bollapragada 2006a 18/177 IMN, 16/173 placebo group to NICU
Bullarbo 2007 13/100 IMN, 9/100 placebo group to NICU
Habib 2008 0/51 IMN, 1/51 placebo group to NICU
Agarwal 2012 5/100 IMN, 14/100 placebo group to nursery admission
Ghanaie 2013 0/36 IMN, 0/36 placebo group to NICU
Attanayake 2014 1/72 IMN, 1/72 placebo group to NICU
Total 37/536 IMN, 41/532 placebo group to NICU
Outpatient amniotomy for induction versus routine care
Rijnders 2011 27/270 IMN, 23/251 placebo group to NICU
NICU: neonatal intensive-care unit
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Table 3. Maternal complications following induction of labour in outpatient setting
Maternal complications
Intracervical PGE
Larmon 2002 4/41 PGE, 10/43 placebo group with complication such as endometritis, chorioamnionitis and pre-eclampsia
Lien 1998 6/43 PGE, 3/47 placebo group with complication such as endometritis and chorioamnionitis
McKenna 1999 1/30 PGE with PPH, 0/31 placebo group
2/30 PGE, 2/31 placebo group with infection
Rayburn 1999 8/143 PGE, 7/151 control (no treatment) with endometritis
Total 21/257 PGE , 22/272 control with maternal complications
Oral misoprostol
Gaffaney 2009 8/43 misoprostol group, 9/44 placebo group with chorioamnionitis
1/43 misoprostol group, 2/44 placebo group with endometritis
2/43 misoprostol group, 0/44 placebo group with PPH
Total 11/43 misoprostol group, 11/44 placebo group with maternal complications
IMN
Bollapragada 2006a Blood loss > 500 mL: 59/177 IMN, 47/173 placebo group
Bullarbo 2007 Blood loss > 1000 mL: 14/100 IMN, 12/100 placebo group
Habib 2008 PPH: 2/51 IMN, 3/51 placebo group
Agarwal 2012 2/100 IMN group, 3/100 placebo group with PPH
Ghanaie 2013 0/36 IMN group, 0/36 placebo group with need for blood transfusion
Schmitz 2014 0/678 IMN group, 0/684 placebo group for maternal death
124/678 IMN group, 112/684 placebo group for PPH
20/678 IMN group, 13/684 placebo group for severe PPH
1/678 IMN group, 0/684 placebo group for deep vein thrombosis
Total 202/1142 IMN group, 204/1148 placebo group with maternal complications
Outpatient amniotomy
Rijnders 2011 26/270 amniotomy group, 29/251 routine care group - mother treated with antibiotics
PPH: postpartum haemorrhage
193Pharmacological and mechanical interventions for labour induction in outpatient settings (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
WH A T ’ S N E W
Date Event Description
30 November 2016 New citation required but conclusions have not
changed
Six new studies have been included (Agarwal 2012;
Attanayake 2014; Gaffaney 2009; Ghanaie 2013;
Rijnders 2011; Schmitz 2014). Conclusions have not
changed.
30 November 2016 New search has been performed Search updated and 10 new reports identified. Three
GRADE ’Summary of findings’ tables have been added
C O N T R I B U T I O N S O F A U T H O R S
For the trials added to this review update, Joshua Vogel and Alfred Osoti assessed study eligibility, carried out data extraction and data
entry, analysed results and drafted text of the review. All authors reviewed and agreed on the final text of this review. Zarko Alfirevic is
guarantor for the review.
D E C L A R A T I O N S O F I N T E R E S T
Joshua P Vogel: none known.
Alfred O Osoti: none known.
Anthony J Kelly: none known.
Stefania Livio: none known.
Jane E Norman: Jane Norman was an investigator on two trials included in this review (Bollapragada 2006b; Osman 2006); the reports
from these trials were independently assessed by two other review authors. Jane Norman has received a grant of GBP 11,000 (paid to
her institution) from the Chief Scientist’s Office, Scottish Executive, for an epidemiological study entitled: “Ferguson EF, Norman JE,
Chalmers J, Shanks E, Finlayson A. Investigation of the beneficial and adverse effects of induction of labour.” Jane Norman has received
a number of research grants (paid to her institution) to support research into improving perinatal outcome - none specifically related
to immediate versus deferred delivery. Jane has also received small amounts of money for speaking at meetings about prematurity but
not immediate versus deferred delivery.
Zarko Alfirevic: none known.
S O U R C E S O F S U P P O R T
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Internal sources
• The University of Liverpool, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have added a number of additional (non-prespecified) outcomes focusing on proxymeasures of progress towards birth, and potential
adverse effects. These were added to capture additional outcome data that relate to the effectiveness and potential harms of the treatments
in outpatient settings.
Maternal and caregiver satisfaction were previously defined as “mother (or caregiver) not satisfied”, however these were revised during
this update.
Three GRADE ’Summary of findings’ tables have been added for this update (2017).
The title has changed from the 2010 version of the review from, Different methods for the induction of labour in outpatient settings, to
Pharmacological and mechanical interventions for labour induction in outpatient settings, in this 2017 update.
The objectives have been amended in this update (2017) to:
To examine pharmacological and mechanical interventions to induce labour or ripen the cervix in outpatient settings in terms of
effectiveness, maternal satisfaction, healthcare costs and, where information is available, safety.
In the previous version of this review,(2010), the objectives were:
To examine pharmacological and mechanical interventions to induce labour in outpatient settings in terms of feasibility, effectiveness,
maternal satisfaction, healthcare costs and, where information is available safety. The review complements existing reviews on labour
induction examining effectiveness and safety.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Ambulatory Care; Acupuncture Therapy [methods]; Feasibility Studies; Labor, Induced [∗methods]; Oxytocics; Randomized Con-
trolled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
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